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Abstract
Understanding the host immune response against Pseudomonas
aeruginosa to develop novel therapeutics and vaccines
Emel Sen Kilic

Pseudomonas aeruginosa is a Gram-negative opportunistic bacterium that causes a
broad range of acute and chronic infections. The high adaptability and emergence of
multidrug-resistant strains of this bacterium pose a significant threat to human health.
Particularly, pneumonia caused by this pathogen is associated with high morbidity and
mortality in immunocompromised patients. To prevent these infections, we aimed to
develop novel vaccine strategies by characterizing the host immune response against P.
aeruginosa. During respiratory infections, P. aeruginosa first contacts with epithelial cells
along the respiratory tract. Using RNA-sequencing, we were able to characterize
transcriptional changes of the epithelial cells in response to P. aeruginosa. We observed
that epithelial cells differentially upregulate immediate early response genes, that are
crucial to mediate downstream pro-inflammatory responses during P. aeruginosa
infection. To validate our in vitro observations, we performed acute infection studies using
a mouse model of pneumonia. We observed that P. aeruginosa challenged mice had lung
edema, high level of proinflammatory cytokines and neutrophils in their lungs. To prevent
acute pneumonia caused by P. aeruginosa, and develop a protective vaccine against this
pathogen, we characterized vaccine-mediated immune responses using the whole-cell P.
aeruginosa vaccine. We found that B cells and antigen-specific antibodies are required
for protection against this bacterium. Based on this work, we developed a novel intranasal
P. aeruginosa vaccine containing peptides from the ferripyoverdine receptor FpvA
conjugated with the carrier protein KLH. The FpvA-KLH vaccine decreased bacterial
burden and lung edema upon challenge. We observed that FpvA-KLH vaccinated mice
induced Th17 type immune response, tissue-resident memory T cells, and significant
antibody titers against P. aeruginosa. The antibodies elicited against this bacterium were
able to mediate opsonophagocytic killing. Together, these findings establish a foundation
for potential vaccine strategies and possible alternative therapeutics against this
bacterium and illuminate a better understanding of the host responses elicited against P.
aeruginosa.
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Chapter 1: Introduction

1

1.1 History and clinical significance of
Pseudomonas aeruginosa
Pseudomonas aeruginosa is a rod-shaped, motile, Gram-negative bacillus found
ubiquitously in nature. While this bacterium is a part of the human flora in some healthy
individuals,

it

causes

immunocompromised

severe

individuals

acute
and

and

chronic

patients

with

infections,

primarily

in

underlying

conditions1,2.

Pseudomonas aeruginosa was first isolated in pure culture by Carle Gessard in 1882 from
the patient's cutaneous wounds that had blue-green pus formation3. More thorough
information about acute and chronic infections caused by this bacterium came in 1916 by
Leonard Freeman4. This opportunistic pathogen received various names related to its
blue-green color during growth throughout its history, including "Bacillus pyocyaneus" 5.
The presence of blue-green pigmentation is due to the production of metabolites such as
pyoverdine and pyocyanin6. The first genome analysis of this bacterium was performed
for the strain PAO1 in 2000, which was isolated in 1950 from a patient's wound in
Australia7,8. The genome size of P. aeruginosa is 6.3 million base pairs, relatively large
compared to other bacteria. The large genome of this bacterium provides genetic
flexibility that leads to nutritional versatility and high adaptability, which is essential for its
persistence and colonization in many different environments, including medical
equipments9,10.
Infections caused by P. aeruginosa can lead to pneumonia, bacteremia, meningitis, otitis
media, burn wound infections, urinary tract infections, and keratitis2. Some of these
infections are caused by multidrug-resistant P. aeruginosa strains, which have increased
in prevalence in recent years11. Since there are no other alternative treatments, multidrugresistant strains of P. aeruginosa are a major health concern and can lead to lifethreatening infections11,12. According to the US Centers for Disease Control (CDC) and
Prevention 2019 Antibiotic Resistance Threats in the United States report, multidrugresistant P. aeruginosa infections led to the hospitalization of 32, 600 patients and 2, 700
mortalities in 201713.

2

Pneumonia caused by this organism is especially a problem in hospital and intensive care
units (ICU) since it can survive on respiratory ventilators and patient care equipments2.
Most nosocomial P. aeruginosa infections lead to acute pneumonia. According to the US
CDC 2015-2017 study, P. aeruginosa is the third most common Gram-negative pathogen
that causes healthcare-associated infections14.
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Figure 1: Prevalence of respiratory microorganisms by age cohort in CF
patients.
Figure modified from CF 2018 annual data report18.

The respiratory infections caused by this pathogen negatively impact patients with chronic
lung disorders such as cystic fibrosis (CF) and chronic obstructive pulmonary disease
(COPD)15–17. The presence of P. aeruginosa is associated with poor prognosis and higher
mortality in COPD patients17. Based on the 2018 Annual Data Report published by the
Cystic Fibrosis Foundation, by the time CF patients reach adulthood, more than 50%
become colonized and chronically infected with P. aeruginosa18 (Figure 1). Over the
years, it becomes the dominant bacterium found in the lungs of CF patients, which
contributes to pulmonary exacerbations associated with morbidity and mortality 18,19.
While there has been a decrease in overall P. aeruginosa positive CF patients based on
2018 reports, the infections caused by multidrug-resistant P. aeruginosa strains remained
3

constant18. P. aeruginosa infections are also prevalent in combat and burn wound
patients20. P. aeruginosa was one of the most common bacteria causing combat-related
infections in combat trauma patients in Iraq and Afghanistan, based on 2003-2009
records of Joint Theater Trauma Registry (JTTR). Based on surveillance in Lausanne
Burn Intensive Care Unit between 2001 and 2012, 26.2% of infection episodes were
caused by P. aeruginosa21. Epidemic outbreaks of multidrug-resistant P. aeruginosa
strains were previously reported in ICU units and CF centers of hospitals22–25. These
incidences and the emergence of multidrug-resistant P. aeruginosa strains are a serious
threat and raise concerns for general public health.

1.2 Pathogenesis of P. aeruginosa
P. aeruginosa can adapt and grow in diverse environments mediated by the versatility in
the carbon sources it can use and the capacity to grow in low nutrient and oxygen
conditions7,26,27. These features provide flexibility and capability to survive in harsh
conditions. P. aeruginosa normally can be found in aquatic environments and soil;
however, it can also survive in hospital equipment such as ventilators and catheters 28.
When P. aeruginosa is infecting the host, there is a dynamic interaction between the
host's defense mechanisms and bacterial virulence factors to evade host immunity.
Therefore, both host defense mechanisms and virulence factors of P. aeruginosa need
to be investigated to understand respiratory infections caused by this pathogen.

1.2.1 Major virulence factors
P. aeruginosa has a wide variety of virulence factors involved in the bacterial attachment
(pili, flagella), cell cytotoxicity (secretion systems, LPS), and evasion of the immune
response (biofilm formation). P. aeruginosa can orchestrate the expression of these
virulence factors to survive in the host and increase the bacterium's competitiveness
during acute or chronic infections (Figure 2). While most of these virulence factors have
been well studied in the field, we still need to better understand the role of individual
virulence factors on host immune response and respiratory infection caused by this
4

organism to develop novel therapeutic approaches and vaccines. The major virulence
factors of P. aeruginosa is further introduced in this chapter.

Figure 2: Major virulence factors produced by P. aeruginosa.
P. aeruginosa uses enzymes and toxins to degrade the protective barrier of epithelial cells
and damage the surrounding host cells. Pili and flagella mediate binding of P. aeruginosa to
epithelial cells. Once P. aeruginosa is in contact with epithelial cells, it uses its injectosomes
to secrete toxins directly into the epithelial cells to manipulate the host response and facilitate
cell invasion. Overtime, it becomes increasingly difficult to eradicate this pathogen due to
biofilm formation. This figure was created with BioRender.com
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1.2.1.1 Bacterial adhesion factors
P. aeruginosa has single polar flagellum and type IV pili, which are essential during the
initial contact with the host29,30. P. aeruginosa can approach the surfaces of epithelial cells
using its flagellum. Then, it can attach and spread further using twitching and swarming
motilities. Swarming motility depends on flagella and type IV pili31 while twitching motility
is flagella-independent crawling motility of bacteria on moist surfaces 32.
P. aeruginosa's flagellum and type IV pili are crucial for the acute stage of infection. Pilindeficient and flagellin-deficient mutant strains are less virulent in the acute pneumonia
model in mice29,33,34. Flagellum and type IV pili also play a role in activating the host's
immune system. In epithelial cells, asialo-GM1 and asialo-GM2 receptors are the main
cell surface receptors that bind to pili35. Flagella mediates pro-inflammatory signaling on
airway epithelial cells via asialo-GM1 and TLR5 receptor binding36,37. Recognition of
flagella and pili leads to activation of NF-KB signaling and the release of pro-inflammatory
cytokines38,39. Also, inflammasome complexes can be activated in response to pili and
flagellin of P. aeruginosa40,41.
Flagella and type IV pili are also important for biofilm formation. Flagella mediated motility
has a role in the formation of attachment into the surface, while type IV pili is important in
forming microcolonies42. After the establishment of biofilms, flagella and pili associated
genes are repressed during biofilm growth, partly due to the adaptation of P. aeruginosa
to its environmental conditions43.
1.2.1.2 Lipopolysaccharide (LPS)
LPS is found in the outer layer of the membrane of P. aeruginosa, and is composed of
lipid A, core oligosaccharide, and O antigen. Lipid A is the innermost domain that is
anchored to the outer membrane-associated with toxicity44. O antigen and lipid A domains
are connected via the core oligosaccharide domain of LPS. The O antigen is the outercore part of the LPS, which is hydrophilic and immunodominant45. O antigen can vary in
length and composition; in some instances, it might be absent (rough LPS)46. The most
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variance in P. aeruginosa LPS is observed in the O antigen between different strains,
leading to many different serotypes47.
Upon interaction with the host cell, LPS activates the host immune response via proinflammatory signal transduction complexes 48. LPS can signal mainly through the
TLR4/MD2 complex via interaction with lipid A and induce a pro-inflammatory immune
response49. Moreover, the core oligosaccharide of LPS can interact with cystic fibrosis
transmembrane conductance regulator (CFTR) which is an important mechanism for
internalization and removal of the P. aeruginosa50,51.
The smooth form of LPS is essential for virulence during acute infection 52. Most acute or
environmental P. aeruginosa strains have smooth LPS with long O-chains53. In contrast,
some of the P. aeruginosa strains isolated from CF patients are unable to produce long
O-chains54. The absence of O antigen decreases the immunogenicity of the bacteria, thus
helping bacteria evade immune recognition and potentially establish chronic infections.
1.2.1.3 Secretion Systems
P. aeruginosa secretes exotoxins, enzymes, and other proteins to increase its chances
of surviving in the host environment and evading the immune system. Some of these
secretion systems help transport these proteins through the bacterial membranes (type I,
type II, type V), while others play a role in directly injecting these toxins inside the host
cells (type III and type VI)55.
Type I secretion system resembles ABC transporters and can transport small molecules
outside the cell. In P. aeruginosa, the type I secretion system is important for the transport
of alkaline proteases, such as AprA. AprA prevents bacterial clearance by degrading host
response systems, including the complement system and mucin and helps nutrient
acquisition of bacteria56,57. HasA, a heme-binding protein essential for iron acquisition, is
also transported via type I secretion system58
The type II secretion system is a two-step secretion mechanism. P. aeruginosa secretes
many different extracellular virulence factors, such as exotoxin A, phospholipase C, and
elastases by using type II secretion system55. Exotoxin A ADP ribosylates elongation
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factor 2, leading to inhibition of protein synthesis and cell death59. Phospholipase C is
another important virulence factor of P. aeruginosa. Hemolytic phospholipase C can
cause tissue damage, change vascular permeability, and increase the inflammatory
response by mainly inducing granulocytes60–62. Elastases are especially crucial for
invasive P. aeruginosa infections. LasA and LasB elastases can breakdown the elastin in
lung tissue and blood vessels, which is very important for bacterial resilience63. They can
impair wound healing by altering the motility of the tissue. They can also enhance the
removal of apoptotic neutrophils, degrade immune defense systems such as surfactant
proteins and IgA, and activate the MAPK pathway leading to an increase in IL-8
production64–66.
Type V secretion system of P. aeruginosa also uses a two-step secretion mechanism. P.
aeruginosa can transport enzymes such as the exoprotease (LepA) and the esterase
(EstA)67,68. EstA is required for rhamnolipid production, a bacterial surfactant affecting
bacterial motility and biofilm formation67. LepA functions as a virulence factor which
contributes to nutrient acquisition and affects bacterial growth69
P. aeruginosa can inject its exotoxins directly into the host cell using a type III secretion
system (T3SS) upon direct cell to cell contact. Toxins secreted by T3SS increase the
virulence and severity of the disease70. ExoT and ExoY toxins are secreted by the majority
of P. aeruginosa strains, while ExoU and ExoS toxins are mutually exclusive71. ExoY is
an adenylate cyclase similar to adenylate cyclase toxin in Bordetella pertussis, that
increases host cyclic AMP concentrations72. ExoS and ExoT toxins, which have GTPaseactivating protein and ADP-ribotransferase activities, increase cytotoxicity in host cells73.
ExoU plays one of the major roles in disease pathogenesis73. ExoU toxin is a
phospholipase that leads to irreversible damage to the cell membrane and rapid necrotic
death of the host cells74,75. Also, the secretion of ExoU correlates with the poor prognosis
and high mortality in patients76. T3SS apparatus and secreted proteins are also
immunogenic. They can activate inflammasome pathways leading to activation of proinflammatory response and cell death77,78.T3SS is crucial during acute pneumonia for
bacterial survival79. However, the type III secretion system is downregulated in chronically
infected patients overtime80.
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There are three distinct type VI secretion system (T6SS) loci in P. aeruginosa, which are
called H1, H2, and H3. T6SS can directly deliver toxins to targeted cells. H1-T6SS is
important in competing with other bacterial species by direct delivery of toxins such as
Tse281,82. More recently, the delivery of T6SS effectors into eukaryotic cells has also been
identified83–86. Phospholipase D (PldB) an H3-T6SS effector of P. aeruginosa, contributes
to internalization in epithelial cells via PI3K-Akt pathway activation in host85. VgrG2b is an
effector of H2-T6SS, which is a metallopeptidase enzyme87. Vgr2b promotes
internalization of P. aeruginosa in microtubule-dependent manner86, while another
effector secreted by H2-T6SS, phospholipase TplE induces host autophagy in eukaryotic
cells84. The expression of genes encoding T6SS is significantly increased during acute
pneumonia in the mouse model88. However, T6SS also plays a role in the chronic
persistence of P. aeruginosa82,89.
1.2.1.4 Biofilm formation
Individual planktonic, free-swimming P. aeruginosa can form biofilms. The formation of
biofilm starts with the attachment of planktonic cells to a surface using pili and flagella 90.
This is followed by the growth of microcolonies embedded inside a matrix composed of
exopolysaccharides, lipids, nucleic acid, and proteins produced by the bacteria91–94. P.
aeruginosa can form biofilms on both abiotic or biotic surfaces such as medical devices95
and the lungs of CF patients91, respectively.
Alginate, Pel, and Psl are the main exopolysaccharides produced by P. aeruginosa to
form a biofilm96–98. Mucoid strains of P. aeruginosa, which are commonly overproducing
alginate, may contribute to the inability of bacterial clearance during chronic CF lung
infections. The overproduction of alginate is mostly related to mutation or regulation of
mucA gene of P. aeruginosa99. The secretion of alginate helps P. aeruginosa evade host
defenses such as phagocytosis100,101. In addition, biofilm formation helps bacteria
withstand antimicrobial agents102. Therefore, biofilm formation is crucial for colonization
and survival in the host.
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1.2.1.5 Other virulence factors
There are also some other mechanisms, such as quorum sensing and other compounds,
including rhamnolipids, leucocidin, and pyocyanin that participate in virulence of P.
aeruginosa. Rhamnolipids, which are rhamnose containing glycolipid biosurfactants, are
effective hemolysins103. Interestingly, one of the pigments of P. aeruginosa, pyocyanin,
also has a role in its pathogenesis. Pyocyanin modifies immune responses by interfering
with mitochondrial respiration inducing the release of reactive oxygen species, which
leads to neutrophil death104. Another essential mechanism of P. aeruginosa is quorum
sensing. It is a complex circuit of bacteria to communicate with each other, sense their
density, and respond to a stimulus as a population. Bacteria communicate by using small
"hormone-like" organic compounds known as auto-inducers. In the context of infection,
quorum sensing plays a role in persistent infections and severe outcomes in disease
phenotypes105.

1.2.2 Nutrient acquisition
Nutrient

acquisition, especially of biological metal ions,

is necessary for P.

aeruginosa and crucial for many biological processes. Among these metal ions, iron (Fe)
is one of the most abundant transition metals present in P. aeruginosa, which is essential
for its survival and growth106,107. During infection, regulation of the distribution of metal
ions is an important aspect of host-pathogen interactions. This phenomenon is called
"nutritional immunity"108
Most of the iron in the human host is not freely available since it is sequestered by host
factors such as transferrin and lactoferrin. Thus, the availability of iron is minimal for
microorganisms in the host. P. aeruginosa competes for iron with the host using its
siderophores and two other systems for heme uptake109. To obtain the required iron, the
iron acquisition systems are upregulated in P. aeruginosa during acute pneumonia88. It
has two siderophores pyoverdine (high affinity to iron) and pyochelin (low-affinity to iron),
which chelate iron (Fe3+) from the environment110. P. aeruginosa acquires iron bound to
pyoverdine and pyochelin by using specific receptors ferripyoverdine receptor (FpvA) and
pyochelin receptor (FptA), respectively111,112 (Figure 3). P. aeruginosa can also obtain
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iron from the heme produced by the host by using Phu and Has systems113 (Figure 3). It
can directly acquire the heme by using Pseudomonas heme uptake receptor (PhuR),
which is the main heme uptake mechanism114. On the other hand, the heme assimilation
system receptor (HasR) can receive heme captured by HasA113,115. The expression of
iron acquisition systems in P. aeruginosa is self-controlled, depending on the presence
or absence of iron and heme (Figure 3).

Figure 3: Main iron acquisition systems of P. aeruginosa.
When ferripyoverdine is bound to FpvA, it activates FpvI and PvdS sigma factors affecting
downstream signaling pathways in P. aeruginosa297. Iron-bound Ferripyochelin is transferred
into the cytoplasm via FptA receptor and inner membrane transporter FptX 379. Iron-bound
Ferripyochelin activates PchR, which positively regulates pyochelin synthesis genes379.
PhuR can directly bind to heme, while HasR binds to HasA, which acquires heme114. Upon
binding, the HasI is activated, which controls the expression of genes related to has and phu
systems114.
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P. aeruginosa can also obtain iron using its xenosiderophores. P. aeruginosa uses
ferrioxamine B secreted by Streptomyces species, ferrichrome produced by fungi, and
myobactin, and carboxymycobactin secreted by Mycobacterium species using Fox, Fiu,
and Fem systems of P. aeruginosa, respectively116,117
During acute pneumonia, iron acquisition receptors are highly upregulated88, and the
availability of iron correlates with P. aeruginosa persistence in the lungs of CF patients118.
The acquisition of iron is essential for the virulence of P. aeruginosa119. When P.
aeruginosa is starved for iron, it triggers the production of exotoxin A, endoprotease,
pyoverdine, and FpvA synthesis120. During acute pneumonia, iron acquisition via
siderophores is playing a critical role in the infectivity of P. aeruginosa compared to hemeuptake systems109. In the absence of pyoverdine, pyochelin, FpvA or HasR P. aeruginosa
strains are significantly attenuated, and the bacterial colonization during acute pneumonia
is diminished6,109.

1.3 Vaccine development against P. aeruginosa
P. aeruginosa has multiple mechanisms to evade the immune response and treatment of
infections caused by this pathogen. It is challenging to treat due to its adaptability and
presence of antibiotic-resistant strains. Once P. aeruginosa establishes chronic
infections, it can lead to severe outcomes in at-risk patients. One of the preventative
methods to avert these infections is vaccination. A vaccine is a biological preparation that
contains an agent that helps the immune system recognize and acquire immunity to a
disease-causing organism. Vaccines are often made from weakened/killed forms of a
pathogen or contain only a part of the pathogen, such as its toxin or surface protein,
known as subunit vaccines.
The development of a vaccine against P. aeruginosa has been an interest for many
researchers for over 50 years. Numerous vaccine candidates against this bacterium have
been developed and tested, including whole-cell, live attenuated, or subunit vaccines
strategies20,121. However, despite the efforts, there has never been a vaccine candidate
to succeed in Phase III clinical trials20.
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1.3.1 Whole-cell and live attenuated vaccines
One of the first vaccines developed against P. aeruginosa contained killed whole-cell
bacteria122. Over the years, the whole-cell P. aeruginosa vaccines were prepared in many
different ways, including formaldehyde-inactivation and heat-killing123,124. While the
preparations were slightly varied in different studies, whole-cell P. aeruginosa vaccines
have been shown to reduce the bacterial burden and provide protection against P.
aeruginosa in animal studies124,125. In clinical trials, oral administration of formaldehyde
inactivated P. aeruginosa whole-cell vaccine (Pseudostat) was shown to be safe and
immunogenic123,126.
One of the other approaches to generate P. aeruginosa vaccine was using live attenuated
strains. The deletion of aroA gene was one of the candidates for the live-attenuated P.
aeruginosa vaccine. Without aroA gene, P. aeruginosa cannot synthesize aromatic amino
acids, which limits bacterial dissemination and in vivo growth127. This strategy was wellstudied as a potential live attenuated vaccine127–130. Intranasal immunization with P.
aeruginosa PAO1 ΔaroA mutant was able to provide protection both in acute pneumonia
in healthy and neutropenic mice130,131. The same approach was performed to develop live
attenuated P. aeruginosa PA14 ΔaroA mutant and multivalent ΔaroA mutant
vaccines128,129. The live ΔmurI P. aeruginosa PAO1 vaccine was developed and shown
to be protective during acute pneumonia124,132. This mutant strain is auxotrophic and does
not have glutamate racemase (MurI), which has an essential role in the conversion of Lglutamate to D-Glutamate, and is required for peptidoglycan synthesis 124.
Live attenuated, or whole-cell P. aeruginosa vaccines are comprised of multiple bacterial
antigens, which may elicit a broader repertoire of immunological response against this
bacterium133. Over the years, both whole-cell and live attenuated P. aeruginosa vaccines
were shown to be protective in animal models124,127,129,130,134,135. However, despite the
earlier promising results, there are no whole-cell or live-attenuated P. aeruginosa
vaccines currently in clinical development in part due to the concerns about potential
toxicity and efficacy against different P. aeruginosa serotypes133,136.
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1.3.2 Subunit vaccines
Another approach to develop a vaccine against P. aeruginosa has been subunit vaccines.
Subunit vaccines based on virulence factors of P. aeruginosa, such as LPS137–139,
flagella140–143, alginate144,145, pili146–148, and components of type III secretion system149–152
have shown efficacy in preclinical animal models, and several of them tested in clinical
trials20,121.
In early efforts of developing a vaccine against P. aeruginosa, LPS had been identified
as highly immunogenic153, making it an ideal candidate for a vaccine antigen. Therefore,
one of the first subunit vaccines developed and tested in patients was the heptavalent
LPS O antigen vaccine made from seven different P. aeruginosa serotypes
(Pseudogen)154,155. Later on, vaccines with more O-antigen variants and LPS O antigen
exotoxin A conjugates were also developed121,156. While both of these strategies showed
early promising results, these vaccines were not very effective in trials involving cystic
fibrosis patients and have been suspended 133,157,158. One of the reasons for not pursuing
forward with LPS-based vaccines is the serotype variation of LPS and potential concern
on toxicity121. Similar to LPS, vaccines developed against flagella were immunogenic in
clinical trials but had similar concerns regarding serotype-specific responses133,159.
Another subunit vaccine strategy against P. aeruginosa involved using mucoid
exopolysaccharides (MEP, alginate), which are known to be produced during chronic
infections160. However, MEP is not highly immunogenic in humans, which is related to
pre-existing non-opsonic antibodies against alginate in patients161
More recent and promising studies have focused on various outer membrane proteins
(OMP) of P. aeruginosa, which are surface exposed and potentially more antigenically
conserved across serotypes162. The immune system can recognize these OMPs during
natural infection, which makes them potential vaccine candidates163. Among these OMPs,
OprF and OprI recombinant proteins have shown promising efficacy in preclinical murine
models164,165. OprF/I fusion protein vaccine IC43 has been used in clinical trials166–168.
This vaccine was well tolerated and immunogenic in phase II/III trial on ICU patients;
however, it did not increase the survival rate168. While this vaccine is discontinued, novel
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vaccine strategies based on OMPs are still under development. However, purification and
use of membrane proteins can be difficult due to insolubility and potential LPS
contamination. Instead, smaller peptides based on the outer-membrane regions of OMPs
can potentially be used as a substitute for the whole protein P. aeruginosa purification.
Over the years, there have been many vaccines developed against P. aeruginosa in
preclinical trials121. Several of these vaccines have been tested in clinical trials. One of
the main drawbacks of these vaccines were heterogeneity of P. aeruginosa strains,
potential toxicity and efficacy of these vaccines in susceptible human populations (Table
1). Unfortunately, there is no vaccine passed Phase III clinical trials yet 20. Therefore, it is
crucial to develop novel strategies and test potential vaccine candidates to be able to
generate a vaccine against this pathogen.
Table 1: P. aeruginosa vaccine candidates, clinical trials and major drawbacks

Vaccine Candidate

Clinical
Trial

Concerns/Limitations

References

Killed whole-cell

Phase I-II

Toxicity, strain variants

123,126

LPS/O antigen

Phase I-III

Toxicity, strain variants

133,157,158,169,170

Flagella

Phase I-III

Strain variants

159,171

Alginate

Phase I

Immunogenicity

121,161

Recombinant OprF/I

Phase I-III

Vaccine efficacy

166–168
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1.4 Host immune response
The host immune system has various mechanisms to combat infections caused by P.
aeruginosa. During acute pneumonia, the host uses both innate and adaptive immune
systems to detect and eliminate this pathogen. A better understanding of the immune
responses elicited to P. aeruginosa during infection and vaccination is crucial to develop
novel therapeutics and vaccines against this pathogen.

1.4.1 Epithelial cells
Respiratory defense upon contact with P. aeruginosa includes innate and adaptive
immune response strategies. The first line of defense against pathogens starts in the
airway surface and epithelial cells. Airway surface liquid layer (ASL) on the epithelial
surface is a layer of hydrated mucus. This layer helps mucociliary clearance of pathogens
and contains antimicrobial agents, secreted mucins, signaling molecules, and phagocytic
immune cells, which helps with the clearance of bacteria from the airways 172. Most of the
antimicrobial agents and cytokines are secreted to the ASL by epithelial cells. In addition,
epithelial cells can sense bacteria via pattern recognition receptors (PRRs) such as
membrane-bound Toll-like receptors and cytosolic NOD-like receptors. These receptors
can recognize P. aeruginosa pathogen-associated molecular patterns (PAMPs) such as
LPS and flagella173. The recognition of these PAMPs induces downstream signaling
cascades and result in the induction and transcription of pro-inflammatory signals such
as cytokines/chemokines. Those pro-inflammatory mediators recruit critical host defense
mechanisms such as neutrophils, macrophages, as well as T and B cells (Figure 4).

1.4.2 Innate immune responses
During lung infection, neutrophils, which are phagocytic leukocytes, play an essential role
in the clearance of P. aeruginosa174. Neutrophils recognize P. aeruginosa via the PRR's
expressed on their surface. Neutrophils kill P. aeruginosa primarily through phagocytosis.
The uptake of pathogens by neutrophils is increased via opsonization. To opsonize the
bacteria, humoral immune response and complement proteins play an important role. IgG
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and complement product C3b are classical opsonins of the immune system. In addition
to phagocytosis, neutrophils have other potential mechanisms to kill P. aeruginosa, such
as neutrophil extracellular trap (NET) formation175 (Figure 4). While neutrophils play an
essential role in clearing P. aeruginosa from the airways, neutrophils' presence also leads
to lung damage due to released bactericidal products176.
Similar to neutrophils, macrophages also have phagocytic activity on P. aeruginosa177.
One of the first encounters of P. aeruginosa after epithelial cells is resident macrophages
present in the lungs. During acute infection, these macrophages play a role in secreting
pro-inflammatory cytokines to recruit other immune cells, such as neutrophils178, and play
a role as professional antigen-presenting cells. During P. aeruginosa infection
macrophages are also recruited to the lungs via chemokines. The role of macrophages
during P. aeruginosa infection has been controversial. One study showed that the
depletion of macrophages before infection with P. aeruginosa increases the lung bacterial
burden in mice179. However, it was also reported that the depletion of alveolar
macrophages does not affect bacterial clearance174,180. Another study demonstrated that
depletion of alveolar macrophages decreases mortality in the early stage of infection,
leading to higher mortality in later time points178.
Dendritic cells are important antigen-presenting cells and are crucial for the formation of
an adaptive immune response against P. aeruginosa. Administration of dendritic cells
incubated with heat-inactivated P. aeruginosa into mice led to the activation of adaptive
immune responses and is protective against acute pneumonia181. Also, in the post-sepsis
model, dendritic cells did not affect bacterial burden but had a role in modulating elicited
cytokine response182. These findings suggest that dendritic cells may also play a role in
the modulation of immune responses to combat P. aeruginosa infections.
Overall, innate immune responses elicited during P. aeruginosa infection are crucial for
bacterial clearance, eliciting pro-inflammatory responses, and eliciting long term immunity
against this pathogen.
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Figure 4: Illustration of the host immune response during acute pneumonia.
(A) Upon entry of P. aeruginosa to the lungs, epithelial cells in the bronchi are the first
responders to infection. Once P. aeruginosa is in contact with epithelial cells, PAMP's of P.
aeruginosa are sensed by PRR's, which activates pro-inflammatory chemokines/cytokines.
These chemokines recruit innate and adaptive immune cells to the site of infection. (B)
Neutrophils and macrophages are recruited to the alveoli, where they eliminate bacteria and
provide additional inflammatory signals. (C) In addition to innate immune cells, antigenspecific B and T cells generated in secondary lymphoid organs are also transferred to the
blood vessel and recruited to the site of infection. This figure was adapted from "Cytokine
Storm" Biorender template created by Dr. Akiko Iwasaki (2020). Retrieved from
https://app.biorender.com/biorender-templates.
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1.4.2 Adaptive immune responses
Lymphocytes are important during acute pneumonia caused by P. aeruginosa. Mice
lacking functional lymphocytes are more susceptible to P. aeruginosa infection174,183,184.
Cytokines secreted by lymphocytes, such as IL-17 is important during acute pneumonia
caused by P. aeruginosa185. Th17 cells, γδ T cells, and B cells were identified as IL-17
secreting cells during P. aeruginosa infection184–186. Production of IL-17 leads to
neutrophil recruitment into the lungs 187. While IL-17 is crucial during acute and chronic
pneumonia to prevent infection185,186, it negatively affects the immunopathology during
chronic infections188. For vaccine-mediated protection, T cells play an important role.
(Table 2). In the absence of opsonic antibodies, CD4+ T cells and the IL-17 immune
response is critical for protection against LPS-heterologous strains during acute
pneumonia128,129. It is also shown that GM-CSF secretion by CD4+ T cells plays an
important role in the absence of neutrophils and opsonic antibodies 131.
Humoral immunity is comprised of B cells and antibodies, which are crucial against
extracellular pathogens like P. aeruginosa. The primary role of B cells is to produce
antibodies against the pathogen, but they can also act as professional antigen-presenting
cells and secrete cytokines such as IL-17186,189. Antibody production against P.
aeruginosa has been identified as a correlate of protection in various P. aeruginosa
vaccines (Table 2). Opsonic, anti-toxin, and anti-virulence antibodies have been shown
to play an important role in the clearance of P. aeruginosa121. The first antibody produced
during the primary immune response is IgM. Elicited IgM antibodies can activate the
complement system and lead to neutralization of the pathogens190,191. Upon
differentiation and class-switching of B cells, IgG and IgA antibodies are generated. IgG
antibodies can promote toxin neutralization, opsonization, and complement-mediated
killing of bacteria192,193. Passive immunization studies using monoclonal IgG antibodies
against specific virulence factors such as PcrV, flagella, and alginate alone have been
protective against P. aeruginosa194–196. On mucosal surfaces, IgA antibodies play an
important role in inhibiting the attachment of bacteria on epithelial cells, providing local
immunity4, 55. The presence of IgA antibodies was previously detected and shown as a
correlate of protection in mucosal P. aeruginosa vaccines (Table 2).
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Table 2: P. aeruginosa vaccines and their known correlates of protection
Vaccines

Route

Liveattenuated

Correlates of protection

Ref.

Opsonic antibodies, CD4+ T cells, GMIntranasal

ΔaroA

CSF, IL-17 immune response, anti-P.a.

127–131

IgG, macrophage recruitment

IL-17A producing CD4+ T cells, antiLiveauxotrophic

P.a. IgG, IgM and IgA antibodies,
Intranasal

ΔmurI

recruitment of neutrophils and

124,132

mononuclear phagocytes, memory
CD4+ T cells
Anti-P.a. IgG, IgM and IgA antibodies,

killed WCV

Intestinal

recruitment of PMN and macrophages,

125,197

TNFα
LPS O antigen
based*
Flagella/
flagellin
OMPs

Intranasal

Intranasal

Intranasal

Opsonic antibodies, anti-P.a. IgG and

137

IgA
Opsonic antibodies, anti-Pa IgG, IL-17

142,143

immune response
IL-17 immune response, antigen-

198,199

specific IgG

*P. aeruginosa serogroup O11 O antigen expressed in an attenuated strain of
Salmonella enterica serovar Typhimurium.
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Overall, both humoral and cell-mediated adaptive immune responses are shown to play
a role and provide defense against P. aeruginosa infections. To develop novel vaccination
strategies against this pathogen, the individual role of these immune responses during
infection and vaccination needs to be further determined.

1.5 Thesis Objective
This work aims to better understand the host immune responses against P. aeruginosa to
develop novel therapeutic approaches and vaccines. The first line of defense against P.
aeruginosa starts in epithelial cells. In chapter 2, we aimed to understand the elicited
response in epithelial cells upon contact with P. aeruginosa. We performed RNAsequencing on epithelial cells to observe transcriptional changes between P. aeruginosa
infected and non-infected control epithelial cells. We also characterized the role of
injectosomes and the viability of bacteria on the elicited response in epithelial cells. The
work in chapter 3 was performed to understand the vaccine-mediated immune responses
against P. aeruginosa. In chapter 3, we aimed to characterize mechanistic correlates of
protection against P. aeruginosa in a murine model of acute pneumonia using a wholecell P. aeruginosa vaccine. Defining these mechanistic correlates would be beneficial in
developing novel vaccine strategies against this bacterium. In chapter 4, we conducted a
study to test a novel peptide-based vaccination approach against P. aeruginosa. In this
study, we used FpvA, one of the main iron acquisition receptors of P. aeruginosa, as an
antigen, and developed FpvA-KLH vaccine. Intranasally administered FpvA-KLH vaccine
induced strong antibody response, decreased bacterial burden, and elicited systemic and
mucosal immune responses against P. aeruginosa. Chapter 5 discusses the implications
of this work and the future of novel therapeutics and vaccines against this pathogen. The
work performed in this dissertation enhances the current knowledge of host immune
responses elicited against P. aeruginosa and in response to vaccination. It offers a novel
vaccine strategy for subunit P. aeruginosa vaccines.
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Chapter 2: P. aeruginosa type III and type
VI secretion systems modulate early
response gene expression in type II
pneumocytes in vitro
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2.1 Abstract
Lung airway epithelial cells are part of innate immunity and the frontline defense against
bacterial infection. During infection, airway epithelial cells secrete proinflammatory
mediators that participate in the recruitment of immune cells. The pathogen can alter this
response through the use of numerous virulence factors. In this manuscript, we evaluated
the role of type III and type VI secretion systems, two major virulence factors of P.
aeruginosa, on the transcriptome response of epithelial cells, We observed that P.
aeruginosa differentially upregulates immediate-early response genes and transcription
factors that induce proinflammatory responses in type II pneumocytes. We observed that
infection with type III secretion system (T3SS) and type VI secretion system (T6SS)
mutants of P. aeruginosa led to changes in the expression of immediate-early response
genes and acute phase response signaling pathways in epithelial cells. We identified that
T3SS and T6SS modulate the expression of EGR1, FOS, and numerous genes that are
involved in proinflammatory response in epithelial cells during infection. Also, T3SS and
T6SS were associated with two distinct transcriptomic signatures. Our transcriptomic
analysis sheds light on the early host responses differentially regulated in epithelial cells
during infection with P. aeruginosa and the distinct role of T3SS and T6SS in this
response.
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2.2 Introduction
P. aeruginosa is an opportunistic Gram-negative bacterium responsible for a wide array
of infections in humans200. Respiratory infections caused by this organism can be lifethreatening in immunocompromised individuals and cystic fibrosis (CF) patients201. Based
on the 2018 Cystic Fibrosis Foundation report, almost 70% of cystic fibrosis patients
become infected with P. aeruginosa by the time they reach adulthood which negatively
affects their pulmonary function18,202. If the acute infections caused by P. aeruginosa are
not treated, this bacterium can acclimate to the lung environment, form biofilms, and
persist, resulting in chronic infections that are difficult to eradicate200. The emergence of
multidrug-resistant P. aeruginosa strains responsible for causing hard-to-treat infections
raises serious health concerns13,105. Thus, it is essential to generate novel therapeutic
strategies for this pathogen. Understanding the interactions of P. aeruginosa with its host
can be beneficial for the development of novel therapeutics targeting bacterial virulence
or host immune response mechanisms of bacterial clearance.
Airway epithelial cells constitute the first line of defense against pathogens during
respiratory infections and form a physical barrier 203. These cells participate in the innate
immune response through mechanical mucociliary clearance and secretion of
antimicrobial compounds in the airways172. During infection, P. aeruginosa directly
interacts with pathogen recognition receptors (PRRs) on airway epithelial cells and
triggers a series of cellular host signaling pathways, including expression of immediate
early response genes (IEGs)204. IEGs are controlled by constitutively active or posttranslationally activated transcription factors. As a result, IEGs expression is induced
rapidly after stimulation and does not require de novo protein synthesis205. Expression of
IEGs shapes the host response by regulating the secondary response genes and
downstream proinflammatory signaling cascades206. Infection with P. aeruginosa
upregulates several IEGs such as JUN, KLF2, and ZFP36 in epithelial cells207,208.
However, the molecular mechanisms involved in the induction of each of these IEGs are
unclear.
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P. aeruginosa uses numerous strategies to evade the host immune system and survive
in the host. P. aeruginosa manipulates host cells using a type III secretion system (T3SS)
that injects effector proteins directly into the cytoplasm209. In addition to T3SS, P.
aeruginosa can also use a type VI secretion system (T6SS) to inject effector proteins
inside eukaryotic cells210. While the role of effector proteins during infection has been
studied in-depth, T3SS, and T6SS systems’ role in mediating early host transcriptomic
responses is still poorly understood.
In this study, we aimed to characterize the initial early host transcriptomic response
produced by human epithelial cells to P. aeruginosa and to elucidate the role of two
injectosomes (T3SS and T6SS) in this process. We performed a transcriptomic analysis
of type II pulmonary epithelial cell line directly stimulated with live, heat-inactivated P.
aeruginosa, and T3SS and T6SS mutants. We showed that upon stimulation with P.
aeruginosa, most of the differentially upregulated transcription factors were immediateearly response genes in epithelial cells known to be involved in proinflammatory
responses. We identified that T3SS and T6SS affect EGR1 and FOS genes expression
in epithelial cells during infection. In addition, we observed that T3SS and T6SS led to
two distinct host response profiles upon infection. Overall, this study is beneficial to
understand the host response against P. aeruginosa during early phase of infection and
identify novel targets for the development of therapeutics against P. aeruginosa.
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2.3 Materials and methods
2.3.1 Bacterial strains
We used P. aeruginosa PA14211, PA14::pscC (PA14 transposon mutant ID: 29579)211
and PA14 ΔHSI-II : : III strains in this study212. All P. aeruginosa strains were grown in 3 ml
of Miller’s lysogeny broth (LB) overnight. Overnight cultures were diluted 1:100 in fresh
LB and grown until the cultures reached OD600 = 0.3.

2.3.2 Epithelial cell culture
Human alveolar basal epithelial adenocarcinoma A549 cells were obtained from the
American Type Culture Collection (ATCC). The cells were cultured using F-12K medium
supplemented with 10% v/v fetal bovine serum (FBS) (Corning, 10-025-CV), 50 IU/mL
penicillin, and 50 μg/mL streptomycin (Corning, 30001Cl) at 37°C in 5% CO2.

2.3.3 Infection of epithelial cells with P. aeruginosa mutants
Epithelial cells (9x106 cells/flask) were seeded in T-75 cell culture flasks (Greiner Bio-one.
658175) a day before the experiment. P. aeruginosa was grown as previously described.
The bacterial culture was diluted to a multiplicity of infection of 10 using F-12K medium
supplemented with 10% v/v FBS. The infection dose was validated by serially diluting and
plating the dose on Lysogeny Agar (LA) plates. Epithelial cells were washed three times,
with 10 ml of phosphate buffered saline (PBS) (Corning, 21-040-CV). The bacterial
suspension was added to epithelial cells and centrifuged at 167.8 x g for 5 minutes to
promote bacterial attachment. Flasks were then incubated for 1 h at 37°C in 5% CO2. For
the non-infected mock control, epithelial cells were treated as described above and
incubated with F-12K with 10% v/v FBS. Experiments were performed in independent
triplicates for each condition, and the same batch of serum was used throughout the study
to avoid batch-to-batch variability.
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2.3.4 RNA preparation
Epithelial cells were incubated with P. aeruginosa or medium alone for one-hour. Then
these cells were washed with 10 ml of PBS (Corning, 21-040-CV) three times. Cells were
scraped off using a cell scraper in 1 ml of PBS and centrifuged at 16,200 x g for 1 min.
The pellets were resuspended in 0.5 ml of RNAprotect cell reagent (Qiagen, 76526) and
stored at -80°C. Qiagen RNeasy Mini Kit (Qiagen, 74104) was used for RNA extraction.
The samples were thawed and centrifuged at 9,600 x g for 3 min. The pelleted cells were
resuspended in 400 µl of 1 mg/ml of TE lysozyme (1 mg lysozyme in 1ml of 10mM/1mM
Tris-EDTA buffer) and incubated for 10 min at room temperature. The RNA was extracted
using the RNeasy mini spin column based on the manufacturer’s instructions. Any
remaining DNA was degraded using the RNase-free DNase set (Qiagen, 79254)
according to the manufacturer’s instructions. The DNase was removed from the samples
using the RNeasy mini spin column (Qiagen, 74104) and purified RNA was eluted in 50
µl of RNAse-free water (Qiagen, 74104). The amount of RNA in samples was measured
using a Spectramax i3x (Molecular Devices), and the integrity of the samples was
characterized using an Agilent 2100 Bioanalyzer. The RNA integrity number of the
samples used for RNA-sequencing was greater than or equal to 8.

2.3.5 Library construction, RNA sequencing, and analysis
RNA samples were depleted of rRNA using the human RiboMinus kit (Thermo Fisher
Scientific). The samples were converted into Illumina sequencing libraries with the
ScriptSeq v2 Epi RNA-Seq Library Preparation Kit. The libraries passed standard quality
control PCR and were sequenced using an Illumina HiSeq1500 at Marshall University
(2x75bp reads). We sequenced three biological replicates in each group.
Resultant reads were trimmed and aligned onto the human UCSC hg38 reference
genome (GCA_000001405.27) using CLC Genomics Workbench, version 9.5.4 (Qiagen).
Reads were mapped against the reference genome with the following settings: mismatch
cost = 2, insertion cost = 3, deletion cost = 3, length fraction = 0.8, similarity fraction =
0.8. Fold changes in gene expression, and statistical analyses were performed using the
extraction of differential gene expression (EDGE) test as implemented in CLC Genomics,
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which is based on the Exact Test213,214. Differential gene expressions of infected A549
cells were determined by comparison to mock-infected cell controls. P-values calculated
by EDGE test without correction. Genes with differences in gene expression with a pvalue ≤ 0.05, fold change > 2, and average FPKM difference > 7. (Table S1, S5-7).
Immediate early response gene-set (IEG) used in this manuscript was generated using
previous literature (Table S4).

2.3.6 Functional analysis
We performed functional enrichment of differentially expressed genes using WebGestalt
to determine nonredundant biological processes215. Statistically enriched Gene Ontology
(GO) terms under “biological process” with Bonferroni correction p-value ≤ 0.05 were
identified. We then reduced the redundancy of functional GO terms using the affinity
propagation method implemented in WebGestalt. The upstream regulator analysis of
differentially regulated genes was performed by Ingenuity Pathway Analysis (IPA,
QIAGEN Inc.)216. R statistical software v3.5.2 was used to visualize data using volcano
plots and enriched GO Term comparisons for multiple groups 217. Heatmaps were
generated using Heatmapper218.

2.3.7 Network analysis
The protein-protein interaction network information of differentially expressed genes
during PA14 infection was retrieved from STRING V11.0219. The generated protein
interaction network was reconstructed using Cytoscape software version 3.8220. The
protein nodes with a high degree of connectivity were calculated by Cytoscape network
analysis. KEGG pathway enrichment analysis was made using STRING V11.0219.

2.3.8 Transcription factor activating profiling array
The epithelial cells were infected with P. aeruginosa mutants, as described above. At 1 h
post-infection, the nuclear extracts were obtained using a nuclear extraction kit (Signosis,
SK-0001) following the manufacturer’s instructions. Triplicates for each condition were
obtained by completing three independent experiments. The amount of protein in each
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extract was measured using both the NanoDrop Protein quantification instrument
(Thermo Fisher Scientific) and using a bicinchoninic acid assay (BCA) total protein kit
(Thermo Fisher Scientific, 23225). The activation level of 48 different transcription factors
in each condition was measured using the Transcription Factor Activation Profiling Plate
Array I (Signosis, FA1001) according to the manufacturer’s instructions. Briefly, 10 µg
nuclear extracts were incubated with biotin-labeled probes encoding TF DNA-binding site
consensus sequences from 30 minutes at room temperature. The unbound probes were
washed away using the provided isolation column. The remaining probes were eluted and
hybridized to complementary sequences in provided 96-well hybridization plate at 42°C
overnight. The plates were washed, blocked, and the luminescence signal measured on
Synergy™ HTX Multi-Mode Microplate Reader (BioTek). The values were normalized to
(ER Estrogen Receptor).
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2.4 Results
2.4.1 Differentially regulated genes and molecular pathways in lung
epithelial cells post-infection with P. aeruginosa
To gain insight into the response of lung epithelial cells to P. aeruginosa at the early stage
of infection, we analyzed the transcriptomic response of human type II pneumocytes
(A549 cells) after 1 h infection with P. aeruginosa PA14. We identified 143 differentially
expressed genes with P. aeruginosa in epithelial cells compared to mock-treated control.
Among these genes, 73% of the genes (105 genes) were upregulated, and 27% of the
genes were down-regulated (38 genes) compared to mock-treated control (Figure 5A,
Table S1). The top 10 differentially upregulated and down-regulated protein-encoding
genes are shown in Table 3 and Table 4, respectively.
To understand the biological processes associated with the products from the genes
differentially regulated during P. aeruginosa infection, we performed GO term and KEGG
pathway analysis (Figure 5B-C, Table S2-S3). We also generated a protein-protein
interaction network with differentially expressed protein-encoding genes during P.
aeruginosa infection using STRING V11.0219 to identify what molecular networks are
activated upon P. aeruginosa infection (Figure 5C). We identified that molecular networks
and pathways associated with a pro-inflammatory response and external stimulus are
differentially regulated in epithelial cells upon infection with P. aeruginosa (Figure 5B-C).
In particular, MAPK, TNF, and IL-17 signaling pathways were upregulated in response to
P. aeruginosa in airway epithelial cells.
Among the genes significantly upregulated in response to P. aeruginosa infection, we
observed that 17.5% of the genes were encoding transcription factors and proteins
previously identified as IEGs (Figure 6A, Table S4). The top 3 IEGs upregulated in
epithelial cells after infection with P. aeruginosa included EGR1, KLF6, and c-Fos
encoding genes which are all involved in response to the extracellular stimulus (Table S2)
and play a role in regulating expression of genes with diverse functions including
regulating inflammation, cell proliferation, and signal transduction221–225.
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Figure 5: Characterization of epithelial cells transcriptomic response to P.
aeruginosa at one-hour post-infection.
(A) The number of differentially regulated genes in P. aeruginosa PA14 infected epithelial
cells compared to non-infected control. (B) GO term analysis of “biological processes”
enriched in P. aeruginosa PA14 infected A549 cells compared to non-infected control. (p ≤
0.05). (C) Protein-protein interaction network of differentially regulated genes in A549 cells
during P. aeruginosa infection compared to non-infected control. The node size positively
correlates with the degree of connectivity. The color of the nodes correlates with the fold
change of the corresponding genes. Genes associated with KEGG “MAPK signaling
pathway”, “IL-17 signaling pathway” and “TNF signaling pathway” are circled in blue, green
and red, respectively. Only nodes with connection are shown.
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Table 3: Top 10 differentially up-regulated protein-encoding genes in epithelial
cells at one-hour post-P. aeruginosa infection.
Gene symbol

Official full name

Fold change

EGR1

Early growth response 1

28.41

FOS

Fos proto-oncogene, AP-1 transcription factor subunit

17.47

FOSB

FosB proto-oncogene, AP-1 transcription factor subunit

7.39

TET3

Tet methylcytosine dioxygenase 3

7.17

SCG2

Secretogranin II

6.17

SLC6A15

Solute carrier family 6 member 15

4.59

NR4A2

Nuclear receptor subfamily 4 group A member 2

4.39

CCL20

C-C motif chemokine ligand 20

4.15

CRABP2

Cellular retinoic acid binding protein 2

4.10

ATF3

Activating transcription factor 3

3.51

Table 4: Top 10 differentially down-regulated protein-encoding genes in epithelial
cells at one-hour post-P. aeruginosa infection.
Gene symbol

Official full name

Fold change

FAM25C

Family with sequence similarity 25 member C

-4.36

TC2N

Tandem C2 domains, nuclear

-3.32

FRMD3

FERM domain containing 3

-2.65

ASS1

Argininosuccinate synthase 1

-2.48

TM4SF4

Transmembrane 4 L six family member 4

-2.41

CRELD2

Cysteine rich with EGF like domains 2

-2.35

FICD

FIC domain protein adenylyltransferase

-2.34

ANXA8

Annexin A8

-2.32

VCAN

Versican

-2.3

IGFBP3

Insulin like growth factor binding protein 3

-2.27
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Figure 6: Immediate-early response genes in epithelial cells are upregulated
upon P. aeruginosa infection.
(A) Volcano plot of differentially expressed genes. Upregulated genes in response to PA14
compared to non-infected control are shown in red and down-regulated genes are shown in
blue. Immediate early response genes are outlined in black. Black proportion on the pie charts
shows the percentage of immediate early response genes in total differentially up or
downregulate genes (B) Differentially regulated immediate-early response genes in P.

aeruginosa PA14 infected epithelial cells with predicted upstream regulator function.
Activation z-scores were calculated using IPA216. Only upstream transcriptional regulators
with z-score > 2.0 or z-score < -2.0, and p-value < 0.01 are shown.

The products of IEGs play a major role in the activation of downstream signaling pathways
essential for stimulating an immune response206. The expression of IEGs is controlled by
transcriptional regulators already present in the cell waiting for signal-mediated activation
such as phosphorylation. As a result, the induction of IEG expression happens rapidly
upon stimulation and does not require de novo protein synthesis226. To identify the
upstream regulators likely involved in regulating gene expression in response to P.
aeruginosa, we used ingenuity pathway analysis (IPA)216. The upstream regulator
analysis predicts the transcriptional regulators that are activated/inhibited based on the
differential expression of downstream genes. We identified 184 upstream transcriptional
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regulators predicted to be activated or repressed in P. aeruginosa infected epithelial cells.
Among these genes, we identified upstream regulators that also are IEGs differentially
regulated in response to P. aeruginosa infection (Figure 6B). The analyses predicted that
transcription factors encoded by EGR1 and FOS were activated, acted as upstream
regulators, and were important hub proteins in the protein interaction network (Figure 6B,
Figure 5C). In addition, IL-6 encoding gene had the highest positive activation z-score
and IL-6 had the most interactions in the protein interaction network (Figure 6B, Figure
5C). ZFP36 encoding gene was predicted to be inhibited even though it was upregulated
in epithelial cells after infection with P. aeruginosa (Figure 6B). Overall, these data show
that during early interaction with P. aeruginosa, IEGs are one of the main classes of genes
upregulated and products of these IEGs participate in the regulation of gene expression
during P. aeruginosa infection.

2.4.2 Effect of P. aeruginosa type III and type VI secretion systems on
the transcriptomic response of epithelial cells
P. aeruginosa manipulates the host responses by directly injecting its effectors into
epithelial cells using its injectosomes T3SS and T6SS209,210. We hypothesized that the
changes in the transcriptomic response to P. aeruginosa are in part due to the action of
T3SS and T6SS effector proteins. To test this hypothesis, we infected lung epithelial cells
for 1 h with P. aeruginosa mutants with defective T3SS and T6SS. We used the P.
aeruginosa PA14::pscC transposon mutant to study the effect of T3SS on the response
of the epithelial cells to P. aeruginosa. This mutant has a transposon insertion in the pscC
gene, an outer-membrane secretion component of P. aeruginosa T3SS211,227. P.
aeruginosa PA14ΔHSI-II : : III mutant was used to study the effect of defective T6SS on
epithelial cell response. This mutant harbors deletion of HSI-II and HSI-III gene loci of P.
aeruginosa, which are essential for the formation of the T6SS needle and its secreted
effector proteins212. As controls, we used heat-killed P. aeruginosa, as inactivated bacteria
cannot use its injectosomes and secrete effector proteins directly into the epithelial cells.
Cluster analysis of differentially expressed genes in epithelial cells in response to live,
heat-killed, or P. aeruginosa mutants defective of T3SS or T6SS showed the gene
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expression patterns common or specific for each group (Figure 7A. Figure S5-S7). We
observed that 13 genes were differentially regulated in all groups compared to the noninfected mock control, which included the cytokines/chemokines CXCL8, CXCL2,
CXCL3, CCL20, and immediate-early response genes EGR1, FOS, KLF6, NR4A1, and
IER2 (Table 5). While the expression levels of these genes varied in each group, all were
differentially expressed in response to P. aeruginosa independently of bacterial viability
and presence of T3SS or T6SS.
Table 5: Common genes differentially regulated in epithelial cells in response to
parental strain, heat-killed, T3SS, or T6SS mutant P. aeruginosa.
For each group, fold-change compared to mock-infected control epithelial cells are
shown.
Gene symbol

PA14

HK

T3SS

T6SS

EGR1

28.41

9.08

16.64

31.27

FOS

17.47

7.23

8.93

36.46

NR4A1

3.38

2.36

2.42

3.16

KLF6

3.22

2.05

2.43

2.73

IER2

2.68

2.05

2.03

2.78

U1_8

83.98

41.99

60.44

57.08

RNVU1-18

14.23

3.36

8.22

13.02

CCL20

4.15

2.64

2.92

3.86

CRABP2

4.1

2.11

4.61

2.09

CXCL3

3.2

3.49

2.04

3.17

PRDM1

3.1

2.38

3.23

2.77

CXCL2

3.01

3.12

2.83

3.99

CXCL8

2.57

2.26

2.06

3.24
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Figure 7: Comparison of transcriptomic and functional response of epithelial
cells in response to type III or Type VI secretion system defected P. aeruginosa.
(A) Venn diagram of differentially expressed epithelial genes, (B) Comparison of GO term
analysis of “biological processes” of epithelial cells positively enriched in response to P.
aeruginosa PA14 (PA14), heat-killed P. aeruginosa PA14 (HK), P. aeruginosa PA14::pscC
(T3SS), and P. aeruginosa PA14 ΔHSI-II : : III (T6SS). Only GO terms with p ≤ 0.05 and
number of genes associated with GO term > 5 is shown. The node color indicates the
significance of functionally enriched GO terms in each group. The node size correlates with
number of genes associated with functionally enriched GO terms.
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Interestingly, most of the genes differentially regulated in each condition were unique to
that condition (Figure 7A). To better understand those unique transcriptomic signatures,
we performed GO term analysis on the genes upregulated in response to each group.
We observed that only genes associated with the cytokine-mediated signaling pathway
were enriched in heat-killed P. aeruginosa infected epithelial cells compared to mock
control (Figure 7B). The biological GO terms shared in response to P. aeruginosa parental
strain, T3SS, and T6SS mutants were associated with cell motility, proliferation,
endogenous stimulus, cytokine response, and regulation of developmental processes
compared to non-infected cells (Figure 7B). We observed that the regulation of the
apoptotic process was only enriched in epithelial cells in response to P. aeruginosa
parental strain PA14 and the T3SS mutant, but not with the heat-killed PA14 nor the T6SS
mutant (Figure 7B). This result may suggest the potential effect of T6SS on the cellular
apoptosis process inside the host. T3SS of P. aeruginosa secretes exotoxins related to
the modulation of the cytoskeleton 209. Accordingly, we observed that GO terms
associated with cell localization were only enriched in genes differentially expressed in
epithelial cells infected with the parental P. aeruginosa strain and the T6SS mutant, but
not with the heat-killed PA14 or T3SS mutant (Figure 7B).
The immediate-early response genes in the host can be stimulated by variety of internal
and external signals206. To understand whether injectosomes of P. aeruginosa have a
specific role in the upregulation of immediate-early response genes, we compared
differentially regulated IEGs in each group (Figure 8A). We observed that epithelial cells
incubated with the PA14 parental strain P. aeruginosa had the highest, and heat-killed P.
aeruginosa had the lowest number of differentially upregulated IEGs (Figure 8A).
Epithelial cells infected with P. aeruginosa deficient of T3SS or T6SS still led to the
differential regulation of IEGs. However, the expression level of several IEGs varied
compared to the PA14 parental strain (Figure 8B). We observed that in the absence of
T3SS, the induction of EGR1, FOS, KLF6, NR4A1, and IER2 expression was lower than
the induction triggered by the parental strain (Figure 8B, Table 3). Interestingly, during
infection with the T6SS mutant of P. aeruginosa, the expression of the FOS and EGR1
genes increased in epithelial cells compared to infection with the parental strain (Figure
8B, 9A-B, Table 3). These results show that in the absence of T3SS, the modulation of
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the expression of IEGs that are crucial for the overall response elicited by epithelial cells,
such as EGR1 and FOS, are impaired.

Figure 8: Differential expression of immediate-early response genes in epithelial
cells during contact with type III, or Type VI secretion system defected P.
aeruginosa strains.
(A) Total number of differentially regulated immediate-early response genes (B) Heatmap of
differentially regulated early response genes in epithelial cells incubated with P. aeruginosa
PA14 (PA14), heat-killed P. aeruginosa PA14 (HK), P. aeruginosa PA14::pscC (T3SS), and
P. aeruginosa PA14 ΔHSI-II : : III (T6SS) compared to non-infected mock control.
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2.4.3 Effect of T3SS and T6SS on transcription factors activation during
P. aeruginosa infection.
The expression of IEGs is controlled by transcriptional regulators, which are activated by
cell-intrinsic and extrinsic signals upon infection206. To understand the effect of P.
aeruginosa injectosomes on the activation of transcription factors, we performed
transcription factor activation assay. To do that, we specifically analyzed the activation of
transcription factors in nuclear extracts of epithelial cells that were predicted to be
upstream regulators of EGR1 and FOS genes (Table 6). We observed that the AP1
transcription factor was activated in the parental strain, while this activation was lower in
T3SS and T6SS mutants (Figure 9C). We observed that STAT3 was only activated during
infection with the parental P. aeruginosa strain. Interestingly, STAT1 and SP1 activation
increased in the T6SS mutant compared to the parental strain and the T3SS mutant
(Figure 9C). While EGR1 encoding gene was the most differentially upregulated gene in
epithelial cells upon infection with P. aeruginosa, we did not observe the activation of
EGR transcription factor at the protein level (Figure 9C). Overall, these data indicate that
T3SS and T6SS affect the activation levels of transcription factors that are important for
induction and control of IEG expression during infection with P. aeruginosa in epithelial
cells.
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.
Figure 9: Activation of transcription factors in epithelial cells stimulated with
type III or type VI secretion system mutants or parental strain of P. aeruginosa.
RPKM values of (A) EGR1 and (B) FOS genes. (C) Transcription factor activation of nuclear
extracts of epithelial cells incubated with P. aeruginosa PA14 (PA14), P. aeruginosa
PA14::pscC (T3SS), and P. aeruginosa PA14 ΔHSI-II : : III (T6SS) and mock control. The
values were normalized to (ER Estrogen Receptor)
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Table 6: Predicted upstream regulators of EGR1 and FOS genes in epithelial cells
after one-hour infection with P. aeruginosa.
Selected upstream regulators were identified based on genes that were differentially
regulated in epithelial cells after P. aeruginosa infection. Activation z-score shows
predicted activation states of upstream regulators. The further the activation z-score from
zero, the more likely that observed directionality of the target genes are consistent with
the upstream regulator. Only upstream transcriptional regulators with z-score> 2.0 or zscore < -2.0, and p-value of < 0.01 are shown.

Upstream
regulator

Activation
z-score

p-value

Target genes in the dataset

FOS

2.33

6.33E-13

ATF3, BDNF, CCL20, CRABP2, CXCL3, CXCL8,
EGR1, EREG, FASN, FOS

JUN

2.555

2.73E-15

APOE, ATF3, BDNF, CCL20, CD274, CXCL3, CXCL8,
CYP1B1, DUSP5, DUSP6

STAT3

3.553

1.71E-14

CCL20, CD274, CXCL2, CXCL3, CXCL8, EGR1,
FASN, FOS, HAS2, IL18R1

STAT1

2.207

6.38E-07

APOE, CCL20, CD274, CXCL2, CXCL3, CXCL8,
EGR1, FOS, IL6, KLF4

SP1

2.530

3.79E-23

APOE, ASS1, ATF3, BDNF, CCL20, CITED2,
CRABP2, CXCL3, CXCL8, CYP1B1

CREB

2.953

1.25E-11

HIF1A

2.521

4.63E-13

ATF3, BDNF, CXCL8, EGR1, FOS, FOSB, FOSL1,
HAS2, IER3, IL6
APOE, CD274, CITED2, CXCL2, CXCL3, CXCL8,
EREG, FOS, IGF2, IGFBP3

EGR1

3.093

3.98E-11

ATF3, CXCL2, CXCL3, CXCL8, EGR1, EREG,
FOSL1, GDF15, IGF2, LDLR
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2.5 Discussion
Airway epithelial cells are the first barrier against pathogens and responders during
respiratory infections. In this study, we performed RNA-sequencing to study the response
of epithelial cells during the early stages of infection with P. aeruginosa and to understand
the role of the pathogen’s injectosomes in this response. After one-hour infection with P.
aeruginosa, 17.5% of upregulated genes consisted of immediate-early response genes
in A549 cells. Some of these IEGs were also predicted to have a role as an upstream
regulators of the differentially expressed genes. We observed that infection with T3SS
and T6SS mutants led to differences in the induction of IEGs, suggesting that each
system induces a unique transcriptomic signature.
The biological GO terms associated with response to a stimulus, cell motility, proliferation,
cytokine response, and regulation of developmental processes were enriched in epithelial
cells in response to infection with P. aeruginosa regardless of the presence of T3SS and
T6SS (Figure 7B). We identified that the infection of epithelial cells with P. aeruginosa
leads to the induction of genes associated with MAPK, IL-17, and TNF signaling pathways
(Figure 5C). Induction of MAPK pathway and proinflammatory cytokines such as TNFα,
IL-6, and IL-17 was previously observed during in vitro P. aeruginosa infection228–231.
Supporting these findings, the expression of IL-6, TNFα and IL-17 encoding genes was
also increased during in vivo infection with P. aeruginosa88,232,233 Among the
proinflammatory cytokines/chemokines, the expression of CXCL8, CXCL2, CXCL3, and
CCL20 encoding genes were upregulated in epithelial cells in response to P. aeruginosa
(Table 5). The induction of these proinflammatory cytokines/chemokines might be
mediated by the immunogenic components of P. aeruginosa, such as LPS and flagella
that induce TLR4 and TLR5 signaling in epithelial cells, respectively. It was previously
demonstrated that P. aeruginosa flagellin alone could stimulate CXCL8, CXCL2, and
CCL20 production by human airway epithelial cells38,234. In addition, P. aeruginosa LPS
can induce CXCL3 and CCL20 in human leukocytes and cause induction of CXCL2 in
mouse corneas235,236. Among the differentially expressed cytokines, the expression of IL6 encoding gene in epithelial cells was lower in the absence of T3SS relative to the
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parental P. aeruginosa strain (Figure 8B). IL-6 was identified as one of the hub proteins
and as upstream regulator of differentially expressed genes during P. aeruginosa
infection (Figure 5C, 6B). While multiple bacterial components of P. aeruginosa contribute
to the induction of IL-6 response in epithelial cells38,173, it was previously reported that the
T3SS and its effector toxins could induce IL-6 secretion in human epithelial cells237.
Overall, the data obtained in this study supports prior observations in the field on the
induction of proinflammatory cytokines, and in particular, IL-6 in response to P.
aeruginosa.
IEGs are associated with the activation of proinflammatory response genes and
pathways238. Among IEGs, EGR1 was the most differentially regulated IEGs upon
infection with P. aeruginosa (Figure 6A, Table S1). Elevation in expression of EGR1 gene
was previously reported in pulmonary diseases and bacterial infections, including P.
aeruginosa. Increase in its expression is linked to the induction of various inflammatory
mediators such as IL-6, IL-8, IL-1β, and TNF-α239–244. Recently, its role in host defense
against P. aeruginosa was shown using the Egr-1 deficient mouse model245. Egr-1deficiency was associated with bacterial clearance and reduced mortality, which might be
linked to a reduced systemic inflammation245. It was previously shown that its induction in
epithelial cells depends on bacterial viability and contact with the cells241. In line with this
study, we showed that EGR1 gene expression was decreased in response to heat-killed
P. aeruginosa compare to live bacteria (Figure 8, Table 5). Furthermore, the expression
of the EGR1 gene was lower in the T3SS mutant strain of P. aeruginosa compared to the
parental strain (Figure 8, Table 5). These results suggest that EGR1 encoding gene
induction during the early phase of infection with P. aeruginosa depends on bacterial
viability and the T3SS. Similar observations have been made in other Gram-negative
bacteria in which T3SS was shown to play a role in the induction of EGR1 expression in
epithelial cells246–248. The second most differentially upregulated IEG upon P. aeruginosa
infection was the FOS gene (Figure 6A, Table S1). C-Fos is part of the AP-1 transcription
factor complex that is associated with inflammatory pathways crucial for initial hostresponse against pathogens249,250. The FOS gene was shown to be upregulated upon P.
aeruginosa infection207,231. In line with these studies, we observed that upon infection with
P. aeruginosa, the FOS gene was upregulated compared to the non-infected mock45

control (Table 5, Figure 8-9). We observed that bacterial viability and the absence of the
T3SS in P. aeruginosa negatively affected the expression of the FOS gene and activation
of the AP-1 transcription factor in epithelial cells. These results are in line with evidence
that the T3SS effector ExoU is essential in the upregulation of the FOS gene expression
in epithelial cells231. Both EGR1 and FOS genes expression were increased in the T6SS
mutant compared to parental P. aeruginosa infected epithelial cells. These results might
be in part due to effect of the regulation of the upstream activators of EGR1 and FOS
genes (Figure 9C). However, the exact mechanism of EGR1 and FOS gene upregulation
during the early phase of P. aeruginosa infection and the role of secreted effectors of
T3SS and T6SS needs to be further examined. Interestingly, the activation profiles of
transcription factor complexes associated with proteins encoded by EGR1 and FOS
genes were different than what we observed in gene expression levels of epithelial cells
upon infection with T3SS and T6SS mutants (Figure 9C). In future studies, we need to
examine the expression of genes as well as proteins and their activation state overtime
to better understand the epithelial cell response during P. aeruginosa infection.
This study sheds light on the transcriptomic response elicited in epithelial cells during the
early stages of P. aeruginosa infection and on the role of T3SS and T6SS. P. aeruginosa
infection upregulated immediate-early response genes, which play a key role in the
induction of proinflammatory responses by epithelial cells. We identified that EGR1 and
FOS genes are the most differentially upregulated protein encoding genes and key upstream regulators upon infection with P. aeruginosa in epithelial cells. The induction of
these genes was negatively affected by the loss of T3SS but positively affected by the
loss of T6SS. Further mechanistic studies will help identify the molecular mechanisms of
EGR1 and FOS gene expression in response to P. aeruginosa and potentially lead to the
development of novel therapeutic strategies for this organism.
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3.1 Abstract
Pseudomonas aeruginosa is a Gram-negative pathogen that causes severe pulmonary
infections associated with high morbidity and mortality in immunocompromised patients.
The development of a vaccine against P. aeruginosa could help prevent infections
caused by this highly antibiotic-resistant microorganism. We propose that identifying the
vaccine-induced correlates of protection against P. aeruginosa will facilitate the
development of a vaccine against this pathogen. In this study, we studied the mechanistic
correlates of protection of a curdlan-adjuvanted P. aeruginosa whole-cell vaccine (WCV)
delivered intranasally. WCV significantly decreased bacterial loads in the respiratory tract
after intranasal P. aeruginosa challenge and raised antigen-specific antibody titers. To
study the role of B and T cells during vaccination, anti–CD4, –CD8, and –CD20 depletions
were performed prior to WCV vaccination and boost. The depletion of CD4+, CD8+, or
CD20+ cells had no impact on the bacterial burden in mock vaccinated animals. However,
depletion of CD20+ B cells, but not CD8+ or CD4+ T cells, led to the loss of vaccinemediated bacterial clearance. Also, passive immunization with serum from WCV mice
alone protected naive mice against P. aeruginosa, supporting the role of antibodies in
clearing P. aeruginosa. We observed that in the absence of T-cell dependent antibody
production, mice vaccinated with WCV were still able to reduce bacterial loads. Our
results collectively highlight the importance of the humoral immune response for
protection against P. aeruginosa and suggest that the production of T cell-independent
antibodies may be sufficient for bacterial clearance induced by whole-cell P.
aeruginosa vaccination.
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3.2 Introduction
Pseudomonas aeruginosa is a Gram-negative pathogen that causes acute and chronic
severe pulmonary infections associated with high morbidity and mortality201.The
treatment of P. aeruginosa infections is often difficult due to the prevalence of antibioticresistant strains and the adaptability of this pathogen. P. aeruginosa infections are
particularly problematic in hospitalized, immunocompromised, elderly, and cystic fibrosis
(CF) patients121. Based on the 2018 Cystic Fibrosis Foundation report, by the time CF
patients reach adulthood, almost 70% are infected with P. aeruginosa18. Early eradication
of P. aeruginosa in life before colonization may help prevent infections caused by this
bacterium251. Therefore, numerous researchers have proposed over the years that
developing a protective immune response against P. aeruginosa early in life through
vaccination can help prevent infections caused by this bacterium. This preventative
strategy could increase the quality and longevity of life in susceptible patients and provide
solutions where antibiotic treatments are failing.
The development of novel immunotherapies and vaccines against P. aeruginosa has
been extensively studied, and numerous experimental vaccine candidates have been
evaluated20,121. Among them, whole-cell and live-attenuated P. aeruginosa mucosal
vaccines were shown to be protective in animal models127,129,130,132,134,135,233.
Unfortunately, while early clinical trials using whole-cell P. aeruginosa vaccines were
promising123,126,252, there were concerns about efficacy against different P. aeruginosa
serotypes and potential toxicity133,136. Subunit vaccines based on virulence factors of P.
aeruginosa, such as flagella159,171,253,254, LPS158,169,255,256, and outer-membrane proteins
OprF-OprI166,167,257–260 have also been developed and tested in clinical trials, but to this
day, none have been approved for human use. To generate novel treatment options and
vaccine strategies against P. aeruginosa and increase their chances of clinical success,
it is essential to first thoroughly understand vaccine-induced immunity against P.
aeruginosa in pre-clinical models.
During acute P. aeruginosa infections, innate immune responses play an important role
in bacterial clearance
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. Neutrophils are recruited to infected lungs during pneumonia
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and are considered the main effector cell population of the innate response against P.
aeruginosa174. In the context of vaccine-induced protection, P. aeruginosa-specific
antibodies are an important component of the adaptive immune response20. Passively
acquired polyclonal or monoclonal antibodies generated to various outer-membrane
proteins and virulence factors protect against P. aeruginosa20,121,133. In addition, CD4+ T
cells especially play a role against P. aeruginosa in animals vaccinated with bivalent
flagellin and live-attenuated strains in the absence of lipopolysaccharide (LPS) O antigenspecific opsonophagocytic antibodies129,131,135,143. These studies have shed light on the
importance of the various individual mechanisms involved in the innate and adaptive
immune response against P. aeruginosa. However, their relative contribution to protection
against P. aeruginosa during vaccination remains to be determined.
In this study, we identified the relative role of vaccine-induced humoral and T cellmediated immunity against P. aeruginosa during acute murine pneumonia by using a
heat-inactivated whole-cell P. aeruginosa vaccine. To generate immunity at the site of
infection, we administered the vaccine intranasally137,262. We used curdlan as an adjuvant
to induce a Th1/Th17 immune response198,263. We observed that depletion of CD20+ B
cells, but not CD8+ or CD4+ T cells prior to WCV priming resulted in the loss of bacterial
clearance and that the whole-cell vaccine-mediated humoral immune response was the
most critical component of immunity. We expect that this work will provide valuable
insights into the mechanisms underlying whole-cell vaccine-mediated protection and
inform the development of future vaccines against P. aeruginosa.

3.3 Materials and methods
3.3.1 Bacterial strains and growth conditions
P. aeruginosa PAO1 (Dr. Michael L. Vasil, University of Colorado) strain was used for
vaccination and challenge experiments. For challenge experiments, P. aeruginosa was
grown from a frozen stock on Lysogeny Agar (LA, Miller formulation) overnight at 37°C.
A single colony from the LA plate was grown in Lysogeny Broth (LB, Miller formulation)
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overnight and diluted 1:100 in 3 ml of fresh LB for exponential growth for 4 h unless
otherwise specified.

3.3.2 Vaccine preparation and murine immunization
To prepare the whole-cell P. aeruginosa vaccine used in this study, P. aeruginosa PAO1
strain was grown overnight at 37°C on Pseudomonas Isolation Agar (PIA) (Becton
Dickinson, 292710). Bacteria were resuspended in endotoxin-free Dulbecco’s phosphatebuffered saline (PBS) (Thermo Fisher, TMS012A) and inactivated for 1 h at 60°C. The
heat-treated bacteria were plated to confirm the bacteria were killed. Each dose of WCV
contained 1-2x108 CFU and 200 µg of curdlan (Invivogen, 54724-00-4) in PBS. The
adjuvant-only control (mock) contained 200 µg of curdlan in PBS. Mice were anesthetized
prior to vaccination by intraperitoneal injection (IP) of 200 µl of ketamine (77 mg/kg) and
xylazine (7.7 mg/kg). Six-week-old CD-1 female mice were vaccinated intranasally with
40 µl of adjuvant only (mock) or whole-cell vaccine (WCV) at day 0 and day 21.

3.3.3 Cell depletion procedures
Anti-mouse CD20 mAb (IgG2a, clone 5D2, Genentech, 250 μg/mouse/dose), CD4 mAb
(IgG2b, clone GK1.5, Bio X cell, BE0003-1, 300 μg/mouse/dose) and CD8 mAb (IgG2b,
clone 2.43, Bio X cell, BE0061, 300 μg/mouse/dose) were used for cell depletion trials.
Anti-mouse IgG2a (clone C1.18.4, Bio X Cell, BE0086, 250 µg/mouse/dose) and IgG2b
(clone Mpc11, Bio X cell, BE0085, 300 µg/mouse/dose) were used as isotype controls.
Antibodies were injected IP two days before initial vaccination and day 19 postvaccination (Figure 10A). Cell depletions were confirmed using flow cytometry (Figure 10
and 12).

3.3.4 Bacterial challenge
To challenge mice, P. aeruginosa PAO1 was grown as described above. Following
exponential growth, bacteria were resuspended in PBS (Thermo Fisher, TMS012A), and
20 µl of the challenge dose was administered intranasally at day 35 (2-8 x107 CFU/dose)
(Figure 10A). In this model, this dose corresponds approximately to the LD50 (data not
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shown). The endpoint for the infection studies was set at 14 hours post-challenge to
optimize the collection of samples and biological variables while minimizing animal
distress. Mice were anesthetized prior to challenge by IP injection of 200 µl of ketamine
(Patterson Veterinary, 07-803-6637, 77 mg/kg of body mass) and xylazine (Patterson
Veterinary, 07-808-1947, 7.7 mg/kg of body mass). Before euthanasia, the surface body
temperature of the mice was measured using a non-contact infrared thermometer with a
laser sight (Kent Scientific, CODA-IRT) aimed at their abdomen from a distance of two
inches. Mice were euthanized by IP injection of pentobarbital (390 mg/kg of body weight)
(Patterson Veterinary, 07-805-9296) in sterile 0.9% w/v sodium chloride (Baxter, 2F124)
at 14 h p.c. Cardiac puncture was performed as a secondary method of euthanasia and
for blood collection. The lungs of each mouse were weighed and homogenized using
Dounce tissue homogenizers with type A pestles (Corning, 7722-7) in 1 ml of sterile PBS.
Nasal lavages were collected by flushing the nares of each mouse with 1 ml of sterile
PBS. Serial dilutions of nasal lavages and lung homogenates were plated on PIA plates.
Animal experiments were performed according to National Institutes of Health Guide for
the Care and Use of Laboratory animals. The animal protocols used in this study were
approved by the West Virginia University Institutional Animal Care and Use Committee
(WVU-ACUC protocol 1606003173).

3.3.5 Blood collection and tissue preparation for flow cytometry
Blood samples were collected from the submandibular vein one day prior to vaccination
and at days 7, 14, 20, and 30 post-vaccination. After euthanasia at day 36 postvaccination, blood was collected via cardiac puncture (Figure 10A). For flow cytometry
analysis, blood collection tubes with dipotassium EDTA (BD, 365974) were used to
prevent blood coagulation. Red blood cells from the blood samples were lysed using 5 ml
red blood cell lysis buffer (BD, 555899) for 30 min at room temperature. The cells were
centrifuged at 1,000 x g for 5 min at room temperature and resuspended in 1 ml Roswell
Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher Scientific, A1049101) with
10% v/v fetal bovine serum (FBS) (Gemini Bio, 100-500) twice. The cells were centrifuged
again and resuspended in 150 µl PBS with 1% v/v FBS.
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Spleen and cervical lymph nodes were collected and homogenized using disposable
pestles (USA Scientific, 1405-4390) in 500 µl of Dulbecco’s Modified Eagle Media
(DMEM) (Corning Incorporated, 10-013-CV) with 10% v/v FBS (Gemini Bio, 100-500).
Homogenized samples were centrifuged at 1,000 x g for 5 min at room temperature. The
cell pellets were resuspended with 1 ml PBS 1% v/v FBS and 5 mM EDTA. The cell
suspensions were then strained using a 70 µm pore nylon mesh (Elko Filtering Co, 0370/33) with 4 ml of PBS with 1% v/v FBS and 5 mM EDTA. The samples were centrifuged
at 1,000 x g for 5 min at room temperature. Red blood cells were lysed in splenocytes
using 1 ml red blood cell lysis buffer and incubated at 37°C for 2 min. The samples were
centrifuged at 1,000 x g for 5 min and resuspended in 1 ml of PBS with 1% v/v FBS and
5 mM EDTA.
Single-cell suspensions from blood, cervical lymph nodes, and spleen were incubated
with 5 µg/ml anti-mouse CD16/CD32 Fc block (clone 2.4G2, BD, 553142) for 15 min at
4°C. Samples were then centrifuged at 1,000 x g for 5 min at room temperature and
resuspended in PBS. Single-cell suspensions were incubated with specific cell surface
markers for 1 h at 4°C in the dark. After staining, blood samples were centrifuged at 1,000
x g for 5 min at room temperature and washed with PBS twice. The spleen and cervical
lymph node samples were fixed with 0.4% w/v paraformaldehyde overnight. After fixation,
the samples were pelleted and washed twice and resuspended in PBS for flow cytometry
analysis.

3.3.6 Flow cytometry
Lymphocyte populations within the blood, spleen, and cervical lymph nodes were
identified using the following anti-mouse antibodies: 1:500 v/v phycoerythrin (PE)-CF594
conjugated CD45 (Clone 30-F11, BD, 562420), fluorescein isothiocyanate (FITC)
conjugated B220 (Clone RA3-6B2, eBioscience, 14-0452-82), BV510 conjugated CD3e
(Clone 145-2C11, BD, 563024), allophycocyanin (APC)-Cy7 conjugated CD4 (Clone
GK1.5, BD, 552051), peridinin chlorophyll protein (PerCP)-Cy5.5 conjugated CD8α
(Clone 53-6.7, BD, 551162), and PE conjugated CD19 (Clone 1D3, BD, 553786). Cells
were counted using Sphero AccuCount 5-5.9 µm beads (Spherotech, ACBP-50-10).
56

Samples were processed using an LSR Fortessa (BD) and analyzed using FlowJo v10
(FlowJo).

3.3.7 Serological testing by ELISA
P. aeruginosa specific antibodies were quantified using enzyme-linked immunosorbent
assay (ELISA). Blood was obtained as described above and collected in capillary blood
collection tubes (BD, 355967) that were centrifuged for 2 min. at 16200 x g. The serum
from each mouse was saved in a microcentrifuge tube and stored at -80°C. The lungs
were processed as described above, and 360 µl of homogenized lung tissue from each
mouse were centrifuged at 16,200 x g for 4 min. The lung supernatants were saved in
microcentrifuge tubes and stored at -80°C. High protein binding 96-well plates (Thermo
Fisher Scientific, 15041) were coated with 50 µl/well 2x107 CFU P. aeruginosa PAO1 in
PBS overnight at 4°C. The plates were washed (3 times) with PBS with 0.05% v/v Tween
20 (Thermo Fisher Scientific, AAJ20605AP) and blocked using 2% w/v Bovine Serum
Albumin (Research Products International, A30075-250.0) (BSA) in PBS overnight at
4°C. The plates were rewashed with PBS with 0.05% v/v Tween 20 (3 times). The serum
and lung supernatant samples were serially diluted in plates 1:50 to 1:25, 600 and 1:5 to
1:640 using 2% w/v BSA in PBS, respectively. The serially diluted plates were incubated
overnight at 4°C. The antibody titers were detected using goat anti-mouse IgG
(SouthernBiotech, 1030-04), IgG1 (SouthernBiotech, 1071-04), IgG2b (SouthernBiotech,
1091-04), IgG2a (SouthernBiotech, 1081-04), IgG3 (SouthernBiotech, 1100-04), IgM
(SouthernBiotech, 1021-04), and IgA (SouthernBiotech, 1040-04) conjugated to alkaline
phosphatase. The secondary antibodies were diluted in 2% w/v BSA in PBS. The sampletreated plates were washed (4 times) and incubated with secondary antibodies for 1 h at
37°C. The plates were washed (5 times) and incubated with p-nitrophenyl phosphate
(PNPP) (Thermo Fisher Scientific, 37620) for 30 min in the dark at room temperature.
The plates’ signal (optical density at 405 nm [OD405]) was detected using a Synergy HTX
Multi-Mode Reader (BioTek). The antibody titers were defined as the highest dilution that
yielded an absorbance value two times above the average of blanks.
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3.3.8 Infection with pre-opsonized P. aeruginosa
Pools of sera from mice intranasally vaccinated with WCV or curdlan only (mock) were
used for the pre-opsonization experiment. Pooled sera from each group (150 µl) were
heat-inactivated at 56°C for 30 min and incubated with 2x108 CFU of P. aeruginosa PAO1
in 150 µl of PBS in microcentrifuge tubes by tumbling in an end-over-end rotator at 37°C
for 30 min. As a non-opsonized control, 108 CFU of P. aeruginosa in 300 µl of PBS were
incubated while tumbling in an end-over-end rotator at 37°C for 30 min. After incubation,
30 µl of 107 CFU of P. aeruginosa PAO1 WCV pre-opsonized, mock pre-opsonized, or
non-opsonized control were administered intranasally to 5-week-old CD1 mice. The dose
for each group was serially diluted in PBS and plated on PIA plates. At 16 h p.c., mice
were euthanized as described above. Bacterial burden in the lungs and nasal lavage was
determined by plating serial dilutions of the samples on PIA plates.

3.3.9 Passive immunization with serum
For passive immunization experiments; the WCV was prepared with Freund’s Adjuvant.
Mice were vaccinated and boosted with 1-2x108 CFU heat-killed P. aeruginosa PAO1 and
100 µg of Complete Freund’s adjuvant (Invivogen, vac-cfa-10) (WCV-CFA, prime) or 100
µg Incomplete Freund’s Adjuvant (Invivogen, vac-ifa-10) (WCV-IFA, boost) prepared in
PBS. The vaccine was adsorbed to the adjuvant by incubation in microcentrifuge tubes
by tumbling in an end-over-end rotator for 30 min at room temperature prior to vaccination.
Groups of 6-week-old CD1 mice were vaccinated IP (200 µl) with WCV-CFA at day 0. On
day 21, mice were boosted IP (200 µl) with WCV-IFA. As a control, mice were vaccinated
with 200 µl PBS (Naive) at day 0 and 21. At day 35 post-vaccination, mice were
euthanized as described above. Serum was collected by cardiac puncture from a total of
10 mice, and sera from the mice in each group were pooled together. A total of 500 µl of
pooled WCV or naive mouse sera was administered to 5-week-old CD1 mice via IP
injection. One hour after serum administration, blood was drawn from the submandibular
vein to determine circulating antibody titer and intranasally challenged with a 107
CFU/dose of P. aeruginosa PAO1. At 16 h post-infection, mice were euthanized as
described above, and blood was collected by cardiac puncture. Nasal lavage and lung
58

homogenates, along with their serial dilutions were plated on PIA plates to quantify viable
bacterial burden.

3.3.10 Statistical analysis
Prism version 8 (GraphPad) was used for all statistical analyses performed. Data
comparisons of more than two groups were performed using one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test for normally distributed data and
Kruskal-Wallis test with Dunn’s multiple comparison test for non-parametric data. One
sample t-test was used to compare the data to the value of the limit of detection. We
performed unpaired two-tailed student’s t-test (normally distributed) and Mann-Whitney U
test (non-parametric) to compare two groups. When calculating the averages of technical
and biological replicates, values below the detection limit were recorded as 0.
Correlations between two parameters were calculated using linear regression analysis.
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3.4 Results
3.4.1 Depletion of CD4+ and CD8+ T cells during WCV priming does not
affect bacterial burden and lung edema during acute pneumonia
CD4+ T cells induce specific cytokines to coordinate innate and adaptive immune
responses that promote bacterial clearance131,264 and provide support for antigen-specific
B cell maturation, proliferation, and class-switching265. On the other hand, CD8+ T cells
also play a role in bacterial clearance by secreting cytokines, producing cytotoxic
granules, and direct killing of infected cells266,267. To understand the role of CD4+ and
CD8+ T cells in vaccine-mediated protection against P. aeruginosa, we depleted CD4+
and CD8+ T cells using monoclonal antibodies (mAbs) prior to WCV priming (Figure 10A).
We hypothesized that depletion of either CD4+ or CD8+ T cells would impair the murine
immune response to P. aeruginosa in both naïve and vaccinated animals. Using flow
cytometry, cell depletions were confirmed in blood during vaccination and challenge, as
well as in secondary lymphoid organs after-challenge. At day 1 post-depletion, >98% of
CD4+ T cells and CD8+ T cells were depleted in mice receiving anti-CD4 and anti-CD8
mAbs, respectively (Figure 10C-D). Throughout the course of vaccination, both CD8+ or
CD4+ T cell populations remained depleted from blood in mice that received anti-CD8 or
anti-CD4 treatment (Figure 10B-D). After challenge, we observed significant reductions
in frequencies of CD4+ or CD8+ T cell populations in the blood, spleen and cervical lymph
nodes of anti-CD4 or anti-CD8 treated mice, compared to isotype control mice (Figure
10E-J). To evaluate the effect of cell depletion on the response to infection, we measured
the bacterial burden in the lung and nares 14 h post-challenge (p.c.). We did not observe
significant differences in the bacterial burden in the nares and the lungs of mockvaccinated mice, which received anti-CD4, anti-CD8, or anti-IgG2b isotype control
treatments (Figure 11A-B). In mice that received the isotype control, we observed that
vaccination with the WCV led to a significant decrease in bacterial burden in the nares
and lung compared to the mock vaccinated group, which demonstrates that the intranasal
WCV is protective against P. aeruginosa acute pneumonia in this model (Figure 11A-B).
Interestingly, mice vaccinated with WCV in which CD4+ or CD8+ T cells
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Figure 10: CD4+ and CD8+ T cell depletion during vaccination and challenge.
(A) Schematic representation of the vaccination/challenge timeline (B) Representative
contour plots showing the proportion of CD4+ and CD8+ T cell populations in CD3e+CD45+
leukocytes at day 20 post-vaccination. (C) The proportion of CD3e+CD4+ T cells (n = 4 to 5
per group) and (D) CD3e+CD8+ T cells in CD45+ cells during vaccination in the blood (n = 3
to 5 per group). (E, G, and H) The proportions of CD3e+CD4+ T cells in blood (E), cervical
lymph nodes (CLN) (G), and spleen (H) CD45+ leukocytes in mock vaccinated or whole-cellvaccinated (WCV) mice treated with IgG2b isotype control or anti-CD4 antibodies at 14 h p.c.
(n = 8 to 10 per group). (F, I, and J) The proportions of CD3e+CD8+ T cells in blood (F),
cervical lymph nodes (I), and spleen (J) CD45+ leukocytes in mock vaccinated or WCV mice

treated with IgG2b isotype control or anti-CD8 at 14 h p.c. (n = 5 to 9 per group). Data
represent four independent experiments. ANOVA followed by Tukey’s multiple comparison
test was used for statistical analysis. Error bars indicate SEMs. The asterisks show the
statistical significance: **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.
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were depleted also had a significantly lower number of bacteria in the nares and the lungs
14 h p.c. compared to CD4+ or CD8+ T cell-depleted mock vaccinated mice (Figure 11AB). These results suggest that neither CD4+ T cell nor CD8+ T cell depletion prior to
vaccination and boost affect bacterial clearance in WCV mice.
Acute pneumonia caused by P. aeruginosa is associated with lung injury and pulmonary
edema268. As an indicator of lung edema, lung weights were measured in each group.
We observed that lung weights increased in response to challenge in mock vaccinated
mice compared to non-infected mock vaccinated mice (adjuvant only), regardless of the
presence of circulating CD4+ or CD8+ T cells (Figure 11C). We did not observe an
increase in the weight of the lung in mice vaccinated with WCV, regardless of the
depletion of CD4+ or CD8+ T cells (Figure 11C). These results demonstrate that neither
CD4+ T cell nor CD8+ T cell depletion affected the degree of lung edema in mock
vaccinated or WCV mice.
Mouse body temperature is another physiological parameter associated with lung
infection caused by P. aeruginosa269. We observed a significant decrease in mock
vaccinated challenged mice surface body temperature compared to non-infected mock
vaccinated control (Figure 11D). In contrast, the temperature of the WCV group of mice
treated with isotype control or anti-CD4 antibodies and challenged remained similar to the
temperature of non-infected mock-vaccinated control mice. (Figure 11D). Surprisingly,
the body temperature of CD8+ T cell-depleted WCV mice decreased compared to noninfected mock vaccinated animals (Figure 11D). Overall, the bacterial burden, lung
weight, and body temperature data indicate that mice vaccinated with WCV were
protected against P. aeruginosa infection. In addition, the protection conferred by wholecell vaccination did not depend on the presence of circulating CD4+ or CD8+ T cells.

62

Figure 11: CD4+ or CD8+ T cell depletion does not affect the bacterial burden
and lung edema during acute pneumonia in WCV mice.
(A and B) Nasal lavage (A) and lung (B) bacterial loads of vaccinated and challenged groups
at 14 h p.c. (n = 6 to 17 per group). (C and D) (C) Lung weights and (D) body temperatures
of mice groups at 14 h p.c. (n = 5 to 17 per group). Data represent four independent
experiments. Dashed lines represent the lower limit of detection. ANOVA followed by Tukey’s
multiple comparison test was used for statistical analysis. Error bars indicate SEMs. The
asterisks show the statistical significance: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤
0.0001.

3.4.2 Depletion of B cells abrogates WCV-mediated protection
To understand the role of B cells in whole-cell vaccine-mediated immunity against P.
aeruginosa, we performed B cell depletion experiments prior to WCV priming using an
anti-CD20 mAb (Figure 10A). CD20 is expressed on immature, mature, germinal center,
and memory B cells, but not on plasma cells, plasmablasts, and pro-B cells270–272. We
depleted B cells prior to vaccination and boost and monitored the presence of circulating
B cells over-time. At day 1 post-CD20 depletion, we observed that the proportion of
CD19+B220+ B cells in blood was reduced from average of 28% to 1%, which
corresponds to a depletion of >96% (Figure 12A). B cell depletion was sustained
throughout the duration of the experiment in the blood (Figure 12A-C). B cells were also
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depleted in the cervical lymph nodes (CLN) and the spleen of anti-CD20 treated groups
after-challenge (Figure 12D-E). To evaluate whether depletion of B cells during
vaccination plays a role in protection during acute pneumonia caused by P. aeruginosa,
the WCV and mock vaccinated mice that received anti-CD20 or IgG2a isotype control
mAbs were challenged at day 35.

Figure 12: CD20+ cell depletion during vaccination and challenge.
(A) The proportion of B220+CD19+ B cells in CD45+ leukocytes during vaccination in the
blood (n = 4 to 5 per group). (B) Representative contour plots of B220+CD19+ B cells
showing the proportion of these cells in CD45+ leukocytes at day 20 post-vaccination. (C to
E) The proportions of B220+CD19+ B cells in blood (C), cervical lymph nodes (CLN) (D),
and spleen (E) CD45+ leukocytes in mock vaccinated or whole-cell-vaccinated (WCV) mice
treated with IgG2a isotype control or anti-CD20 antibodies at 14 h p.c. (n = 9 to 10 per group).
Data represent those from two independent experiments. ANOVA followed by Tukey’s
multiple comparison test was used for statistical analysis. Error bars indicate SEMs. The
asterisks show the statistical significance as follows: *, p ≤ 0.05; **, p ≤ 0.01; ****, p ≤ 0.0001.
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At 14 h p.c., the bacterial burden in the nasal lavage and lung homogenates was
determined. We did not observe changes in the bacterial loads of nasal lavage and lung
homogenates of mock vaccinated mice, that received anti-CD20 or isotype control mAbs
(Figure 13A-B). These data indicate that the depletion of B cells does not impact the
murine response to challenge in mock vaccinated animals. WCV mice that received
isotype control mAb had a significantly lower number of bacteria in the lung and nasal
lavage compared to isotype control-treated mock vaccinated mice (Figure 13A-B).
However, B cell-depleted WCV mice had a significantly higher number of bacteria in the
lung and nasal lavage compared to isotype control-treated WCV mice (Figure 13A-B).

Figure 13: B cell depletion prior to WCV priming abrogates the protection
against P. aeruginosa during acute pneumonia.
(A and B) Nasal lavage (A) and lung (B) bacterial loads of vaccinated and challenged groups
at 14 h p.c. (n = 9 or 10 per group). (C and D) Lung weights (C) and body temperatures (D)
of mice groups at 14 h p.c. (n = 5 to 10 per group). Dashed lines represent the lower limit of

detection. Data represent those from two independent experiments. ANOVA followed by
Tukey’s multiple-comparison test was used for statistical analysis. Error bars indicate SEMs.
The asterisks show the statistical significance as follows: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤
0.001; ****, p ≤ 0.0001.
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As expected, we observed that the lung weights of mock vaccinated mice increased in
response to challenge compared to the non-infected control, regardless of the presence
of circulating B cells (Figure 13C). However, depletion of B cells in WCV mice also
resulted in a significant increase in lung weight compared to the non-infected control
(Figure 13C). While the body surface temperature decreased in response to challenge in
all groups, the decrease observed in B cell-depleted mice vaccinated with WCV was more
modest (Figure 13D). Overall, these results indicate that WCV mice with depleted B cells
have a more severe P. aeruginosa infection compared to isotype control-treated WCV
mice.

3.4.3 B cell depletion results in decrease in antigen-specific antibodies
which negatively correlates to bacterial loads in WCV group mice
The primary role of B cells during vaccination is to produce antigen-specific antibodies
273.

To observe the effect of anti-CD20 mAb treatment on vaccine-induced P. aeruginosa-

specific antibody production, we measured serum and lung supernatant antibody titers
using ELISA. The isotype-control-treated WCV mice elicited significant anti-P. aeruginosa
serum IgM, IgG, and IgA lung supernatant titers compared to isotype control-treated mock
vaccinated mice (Figure 14A-C). Anti-P. aeruginosa serum IgM, IgG, and IgA lung
supernatant titers were significantly lower in B cell-depleted WCV mice compared to
isotype control-treated WCV mice (Figure 14A-C). To understand whether the loss of the
antigen-specific immune response correlates with bacterial clearance, we compared the
lung bacterial burden to antibody titers. We observed a negative correlation between
serum IgM and bacterial loads in the nasal lavage but not in lung homogenates (Figure
14D, G). Both anti-P. aeruginosa serum IgG and lung supernatant IgA titers negatively
correlated with bacterial loads in the lung and nasal lavage (Figure 14E, F, H, I). The
results obtained demonstrate that depletion of B cells prior to WCV priming negatively
affects the production of P. aeruginosa specific antibodies which are correlated to
bacterial clearance.
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Figure 14: Depletion of B cells during P. aeruginosa whole-cell vaccination
reduces antigen-specific antibody titers.
(A to C) P. aeruginosa-specific IgM (A) and IgG (B) serum antibody titers and IgA lung
supernatant antibody titers (C) of vaccinated and challenged mouse groups (n = 9 or 10 per
group). Dashed lines represent the limit of detection. Kruskal-Wallis test with Dunn’s multiple
comparison was used for statistical analysis. (D to F) Correlation of lung CFU per milliliter with
serum IgM (D), serum IgG (E), and lung supernatant IgA (F) titers in whole-cell-vaccinated
animals. (G to I) Correlation of nasal lavage CFU per milliliter with serum IgM (G), serum IgG
(H), and lung supernatant IgA (I) titers in whole-cell-vaccinated animals. Gray dots represent
whole-cell-vaccinated IgG2a isotype control-treated mice, and red dots represent WCV antiCD20-treated mice. Each dot represents data from one individual mouse. The R2 and p values
for each correlation were calculated using linear regression analyses. Error bars indicate
SEMs. The asterisks show the statistical significance as follows: **, p ≤ 0.01; ***, p ≤ 0.001;
****, p ≤ 0.0001.
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3.4.4 Polyclonal serum from WCV group mice is sufficient for bacterial
clearance of P. aeruginosa.
To determine if antibodies generated in response to WCV participate in bacterial
clearance during P. aeruginosa acute pneumonia, we performed pre-opsonization and
passive immunization experiments. We observed that the bacterial burden in the nares
and lungs of mice infected with P. aeruginosa pre-opsonized with WCV sera were
significantly decreased compared to mice infected with P. aeruginosa PBS control or preopsonized with the mock sera (Figure 15).

Figure 15: Pre-opsonization of P. aeruginosa with WCV sera decreases
bacterial burden in lungs and nasal lavage samples.
Shown are bacterial burdens in nasal lavage (A) and lung samples (B) of mice infected with
107 CFU/dose of P. aeruginosa pre-opsonized with mock sera, WCV mouse group sera, or
non-opsonized PBS control at 16 h p.c. (n = 5 per group). ANOVA followed by Tukey’s
multiple comparison test was used for statistical analysis. Error bars indicate SEMs. The
asterisks show the statistical significance as follows: **, p ≤ 0.001; ***, p ≤ 0.001; ****, p ≤
0.0001.

To determine if a similar effect could be observed using circulating antibodies, we
performed passive immunization. We collected the sera from WCV and naive immunized
mice at day 35. Pooled sera were administered to 5-week-old CD1 mice intraperitoneally
for passive immunization one-hour prior to challenge with P. aeruginosa. Control mice
received serum from naive mice that did not contain anti-P. aeruginosa antibodies (data
not shown). The presence of anti-P. aeruginosa IgM and IgG in mice passively immunized
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with WCV sera were detected both at 0 h and 16 h p.c. (Figure 16A). We observed that
passive immunization with WCV sera significantly decreased bacterial burden, and lung
edema compared to the naive sera control group (Figure 16B-D). These data show that
serum antibodies from WCV mice alone contribute to bacterial clearance during acute P.
aeruginosa infection.

Figure 16: Passive immunization alone is sufficient to decrease bacterial loads
during P. aeruginosa acute pneumonia.
(A) P. aeruginosa-specific serum IgG and IgM titers at 0 h and 16 h p.c. of animals passively
immunized with WCV. For statistical analysis, a one-sample t test comparing the data to the
value of the detection was performed. (B to D) The bacterial burdens of nasal lavage (B) and
lung samples (C) and lung weights (D) of mice passively immunized with sera from WCV
group and naïve mice at 16 h p.c. (n = 10 per group). Data represent those from two

independent experiments. Dashed lines represent the limit of detection. For comparisons,
unpaired two-tailed Student’s t test was used. Error bars indicate SEMs. The asterisks show
the statistical significance as follows: **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.
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3.4.5 Depletion of CD4+ T cells is associated with changes in antigenspecific antibody isotype switching
CD4+ T cells play a critical role in immunoglobulin class-switching by providing critical
help to germinal center B cells during vaccination265. While we observed that antibodies
participate in bacterial clearance, depletion of CD4+ T cells during WCV priming did not
affect bacterial burden during acute pneumonia. As a result, we hypothesized that B cell
isotype class-switching triggered by CD4+ T cells is not required for protection against P.
aeruginosa. To test this hypothesis, we compared the anti-P. aeruginosa serum IgG and
IgM, and lung supernatant IgA titers in mice that received anti-CD20, anti-CD4, and
isotype controls. We observed that depletion of CD4+ T cells did not affect the production
of antigen-specific IgM, while the depletion of B cells significantly reduced the antigenspecific IgM titers in WCV mice (Figure 17A). As expected, depletion of CD4+ T cells prior
to WCV priming significantly decreased antigen-specific serum IgG and lung supernatant
IgA compared to titers in mice given IgG2b isotype control (Figure 17B-C). The anti-P.
aeruginosa serum IgG and lung supernatant IgA titers were similar in B cell-depleted and
CD4+ T cell-depleted WCV mice (Figure 17B-C). We did not observe any differences in
anti-P. aeruginosa specific antibody titers in CD8+ T cell-depleted WCV mice compared
to WCV control (data not shown). P. aeruginosa-specific serum IgG and lung supernatant
IgA titers significantly correlated with the number of CD4+ T cells present in the serum,
but this was not the case for serum IgM titers (Figure 17D-F). The depletion of CD4+ T
cells also significantly reduced anti-P. aeruginosa IgG1, IgG2a, IgG2b, and IgG3 serum
responses relative to the isotype-control-treated WCV mice (Figure 17G). We observed
that only 20% of anti-CD4 treated WCV mice were able to produce anti-P. aeruginosa
specific IgG2a and IgG1 response above the limit of detection, while 100% and 90% of
mice were able to elicit anti-P. aeruginosa IgG2b and IgG3 response in serum (Figure
17G-H). These results show that the depletion of CD4+ T cells decreased class switching
of P. aeruginosa specific antibodies to IgA, IgG2a, and IgG1. Overall, the results obtained
demonstrate that the depletion of B cells diminished the production of P. aeruginosa
specific antibodies, while the depletion of CD4+ T cells mainly had an impact on T celldependent P. aeruginosa specific antibody production in WCV mice.
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Figure 17: CD4+ T cell depletion prior to WCV priming affects T cell-dependent
isotype class switching in WCV.
(A to C) P. aeruginosa-specific IgM (A) and IgG (B) serum antibody titers and IgA lung
supernatant antibody titers (C) of vaccinated and challenged mice (n = 5 to 19 per group).
Data represent those from six independent experiments. Kruskal-Wallis test with Dunn’s
multiple-comparison test for statistical analysis was used. (D to F) Correlation of CD4+ T
cells blood counts with P. aeruginosa-specific serum IgM (D) and serum IgG (E) and lung
supernatant IgA titers (F) in whole-cell-vaccinated animals. Yellow filled dots represent
whole-cell-vaccinated IgG2b isotype control mice (WCV mIgG2b). Yellow circles represent
whole-cell-vaccinated anti-CD4-treated mice (WCV α-CD4). Each circle/dot represents
values from one individual mouse. The R2 and p values for each correlation were calculated
using linear regression analyses. (G) P. aeruginosa-specific serum IgG2a, IgG2b, IgG1, and
IgG3 antibody titers (n = 10 per group). Mann-Whitney U test was used for comparisons.

Error bars indicate SEMs. Limits of detection are shown with dashed lines. The asterisks
show the statistical significance as follows: *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001. (H)
Percentage of anti-P. aeruginosa IgG subtype response above the limit of detection in wholecell vaccinated α-CD4 treated mice (WCV α-CD4).
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3.4 Discussion
Vaccine development against P. aeruginosa has been challenging due to the complex
pathogenesis of the bacterium and the lack of a complete understanding of host immune
responses required for protection133,136. To characterize the host immune response
required for bacterial clearance, we used a protective intranasal heat-inactivated wholecell vaccine as a model233. By performing systematic depletion of CD4+ and CD8+ T cells,
and B cells, we demonstrated that the humoral immune response elicited by this vaccine
is one of the main vaccine-induced mechanistic correlates of protection against P.
aeruginosa.
In this study, we observed that the depletion of CD4+ T cells and CD8+ T cells does not
impact bacterial burden and lung edema in whole-cell vaccinated animals at 14 h p.c.
(Figure 11). These data are in line with the work of others showing that depletion of CD8+
T cells does not affect the protective immunity acquired by X-ray irradiated live-attenuated
P. aeruginosa vaccination135. At first glance, the results obtained on the role of CD4+ T
cells on vaccine-mediated protection against P. aeruginosa seem to contradict previous
studies. Various authors have identified the importance of CD4+ T cells in live-attenuated
or killed whole-cell P. aeruginosa vaccines either by transferring CD4+ T cells from killed
whole-cell P. aeruginosa immunized rats to naïve rats274, or by depleting CD4+ T cells
and challenging with LPS heterologous strains in live-attenuated P. aeruginosa
vaccinated mice129,135. However, these published observations suggest that CD4+ T cells
primarily play a role in models in which the challenged animals do not have opsonic
antibodies against the serotype of the strain used for challenge129,135. In this study,
preparation of the WCV and challenge were only performed with an LPS homologous
strain, which is a major difference from previously published works. The role of CD4+ T
cells for protection against LPS heterologous strains in WCV mice needs to be further
determined in future studies.
While there is extensive evidence supporting the role of antibodies in protection against
P. aeruginosa acute pneumonia, the role of B cells is not clearly defined. We observed
that depleting B cells during vaccination and boost led to an increase in bacterial burden
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in whole-cell vaccinated and challenged mice (Figure 13A-B). One of the primary roles of
B cells is to generate antigen-specific antibodies. Antigen-specific antibodies raised in
response to vaccination can help prevent infection and are a correlate of protection for
many commercially available vaccines against pathogenic bacteria275. Production of IgM
is often followed by class switching and production of IgG antibodies 191, which play an
essential role in bacterial clearance by promoting toxin neutralization, opsonization, and
complement-mediated killing of bacteria192,193. On mucosal surfaces, in addition to IgG,
secretion of IgA antibodies serve as one of the first lines of defense against these
pathogens, providing local immunity and inhibiting the adherence of pathogens on
mucosal epithelial cells193,276. During respiratory infections, P. aeruginosa colonizes the
respiratory tract2, and both mucosal and systemic vaccine-induced immune responses
have been shown to be elicited against this pathogen in pre-clinical studies

133.

Mucosal

immunization with killed P. aeruginosa whole-cell vaccine induces anti-P. aeruginosa IgG,
IgM, and IgA antibody titers274. Similarly, we observed that intranasal vaccination with
heat-inactivated whole-cell P. aeruginosa elicits anti-P. aeruginosa specific serum IgM,
IgG, and lung supernatant IgA antibody titers that participate in both mucosal and
systemic humoral immune responses against P. aeruginosa (Figure 14A-C). Depleting B
cells during whole-cell vaccination lead to a significant decrease in anti-P. aeruginosa
specific serum IgM, IgG, and lung supernatant IgA antibody titers and negatively
correlated with bacterial loads in the nares (Figure 14). IgM, IgG, and IgA antibodies
participate in bacterial clearance through various mechanisms, including phagocytosis
and complement deposition. Further studies are required to identify the exact mechanism
of clearance provided by these immunoglobulins in this model of vaccination and
challenge. Interestingly, only serum IgG and lung supernatant IgA titers were significantly
correlated with the bacterial loads in the lungs (Figure 14E-F). Passive immunization and
pre-opsonization experiments using sera from whole-cell vaccinated mice significantly
decreased the bacterial burden and lung edema, suggesting that serum antibodies alone
are sufficient to protect against this pathogen (Figure 15-16). These results support the
findings of previous studies describing that passive immunization with serum antibodies
or monoclonal antibody therapies specific to virulence factors such as PcrV, LPS O
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antigen, Psl, flagella, alginate and outer-membrane proteins such as OprF and OprI can
protect against P. aeruginosa in pre-clinical studies121,143,149,196,277–282.
The opsonic antibodies generated by live-attenuated or whole-cell P. aeruginosa
vaccinations are shown to be directed in part against lipopolysaccharide (LPS)123,129. AntiLPS antibodies can assist with bacterial clearance280. However, the serotype variability
of clinically relevant P. aeruginosa isolates47, as well as the selection of mutants with a
truncation of the O-antigen during chronic respiratory infections such as those observed
in CF patients47,54,283 raise concern regarding their potential use for clinical vaccine
applications. It is important to note that the production of IgM, IgG2b, and IgG3 antibodies
can be elicited in response to highly repetitive structures, such as LPS, in a T cellindependent manner190,284,285. In CD4+ T cell-depleted whole-cell vaccinated mice, P.
aeruginosa specific circulating IgG antibodies were significantly reduced, while the levels
of P. aeruginosa specific IgM antibodies were unchanged (Figure 17A-B). Interestingly,
we observed that these mice were still protected against P. aeruginosa, which suggests
that T cell-dependent isotype-switching is not required for bacterial clearance during
challenge with a homologous LPS strain (Figure 11A-B). IgM antibodies can efficiently
activate the complement system and play a role in neutralizing the pathogen190,191. In line
with our findings, patients with selective IgM deficiency (SIGMD) or splenectomy are
prone to infections caused by microbial organisms including P. aeruginosa286,287. Our data
suggest that IgM antibodies play an important role in WCV-induced protection against P.
aeruginosa and that the use of IgM anti-P. aeruginosa antibody therapy such as the antiLPS O antigen IgM monoclonal antibody (KBPA101, panobacumab)280,288,289 can be a
potential treatment against P. aeruginosa. In addition, while anti-P. aeruginosa IgG
antibodies were significantly reduced in CD4+ T cell-depleted whole-cell vaccinated mice,
we observed that IgG2b and IgG3 serotypes were still present, albeit reduced in CD4+ T
cell-depleted WCV mice. These results suggest that T cell-independent antibody
production elicited by whole-cell vaccination may be sufficient to facilitate the clearance
of P. aeruginosa during acute pneumonia when mice are challenged with an LPS
homologous strain.

74

This work focused on identifying the mechanistic correlates of protection provided by an
intranasal heat-killed whole-cell vaccine. We observed that depletion of B cells but not
CD8+ or CD4+ T cells during whole-cell vaccine priming resulted in the loss of protection
against P. aeruginosa challenge with an LPS homologous strain. We also observed that
T cell-independent IgG and IgM antibody production by B cells may potentially be
sufficient for whole-cell vaccine-induced protection. Our data suggest that the vaccinemediated humoral immune response is a critical component of whole-cell vaccineinduced immunity against P. aeruginosa challenge with an LPS homologous strain in the
acute murine pneumonia model. We anticipate that this study will establish a blueprint of
vaccine-mediated protection against P. aeruginosa and facilitate the development of
future subunit vaccines.
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4.1 Abstract
Pseudomonas aeruginosa is an opportunistic pathogen causing acute and chronic
respiratory infections associated with morbidity and mortality, especially in patients with
cystic fibrosis. Vaccination against P. aeruginosa before colonization may be a solution
against these infections and improve the quality of life of at-risk patients. To develop a
vaccine against P. aeruginosa, we formulated a novel peptide-based P. aeruginosa
subunit vaccine based on the extracellular regions of one of its major siderophore
receptors, FpvA. We evaluated the effectiveness and immunogenicity of the FpvA
peptides conjugated to keyhole limpet hemocyanin (KLH) with the adjuvant curdlan in a
murine vaccination and challenge model. Immunization with the FpvA-KLH vaccine
decreased the bacterial burden and lung edema after P. aeruginosa challenge.
Vaccination with FpvA-KLH lead to antigen-specific IgG and IgM antibodies in sera, and
IgA antibodies in lung supernatant. FpvA-KLH immunized mice had an increase in
recruitment of CD11b+ dendritic cells as well as resident memory CD4+ T cells in the lungs
compared to non-vaccinated challenged mice. Splenocytes isolated from vaccinated
animals showed that the FpvA-KLH vaccine with the adjuvant curdlan induces antigenspecific IL-17 production and leads to a Th17 type of immune response. These results
indicate that the intranasal FpvA-KLH conjugate vaccine can elicit both mucosal and
systemic immune responses. These observations suggest that the intranasal peptidebased FpvA-KLH conjugate vaccine with curdlan is a potential vaccine candidate against
P. aeruginosa pneumonia.
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4.2 Introduction
Pseudomonas aeruginosa is one of the leading opportunistic Gram-negative pathogen
responsible for life-threatening respiratory infections290. High adaptability and increasing
prevalence of multidrug-resistant P. aeruginosa poses a significant threat for at-risk
patients291. People with compromised immunity, chronic obstructive pulmonary disease,
cystic fibrosis (CF), or those who receive immunosuppressive therapies are particularly
susceptible to P. aeruginosa infections290. P. aeruginosa-associated chronic lung
infections are one of the main contributors to loss of pulmonary function, which is the
primary cause of death in patients with CF292,293. Based on the Cystic Fibrosis Foundation
2017 annual report, the median age at first detection of P. aeruginosa infection is 5.2
years in CF patients292. Although eradication is possible early in life, once the airway of a
CF patient becomes chronically colonized, it is difficult to treat P. aeruginosa infections251.
Therefore, therapies that prevent or delay the colonization of P. aeruginosa in CF airways
have the potential to increase pulmonary function, and thus improve the longevity and
quality of a CF patient’s life. An effective vaccine against P. aeruginosa could provide a
solution against infections caused by this bacterium in CF patients, as well as in other atrisk populations.
Recent efforts in P. aeruginosa vaccine development have focused on subunit vaccines
based on virulence mechanisms of P. aeruginosa, such as lipopolysaccharide (LPS),
flagella, alginate, and outer-membrane proteins (OMPs)121. While a number of these
vaccines showed promising results in clinical studies, no vaccine against P. aeruginosa
has been approved for human use20. Lack of efficacy has been attributed to serotype
variation of LPS and flagella, as well as to the difficulty of performing clinical trials in P.
aeruginosa at-risk populations121. Although there is no vaccine available for clinical use,
research efforts focused on the use of OMPs as vaccine antigens are highly promising.
OMPs are surface-exposed, often more conserved across strains with varying LPS
serotypes, and can be recognized by the immune system during natural infection, which
makes them potential vaccine candidates162,163. In addition, we propose that these
proteins need to be expressed during infection to be relevant as antigens. In previous
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studies performed by our laboratory, we identified P. aeruginosa genes expressed during
acute murine pneumonia294. From this study, we observed that genes associated with
iron acquisition were significantly upregulated in P. aeruginosa during in vivo acute lung
infection and decided to further examine their potential use as vaccine antigens.
Iron is an essential nutrient for P. aeruginosa virulence and survival in the host107. During
infection, P. aeruginosa competes for iron with the host using its siderophores and two
other systems for heme uptake109. Iron availability is correlated with P. aeruginosa
persistence in the lungs of CF patients295, and iron acquisition systems are expressed
within CF sputum296. Each iron acquisition system of P. aeruginosa includes an outermembrane receptor located on the surface of the organism. Therefore, we hypothesize
that these receptors involved in iron acquisition in P. aeruginosa can be used as antigens
to generate a subunit P. aeruginosa vaccine. Among these receptors, the ferripyoverdine
receptor FpvA is involved in siderophore-mediated iron uptake297. In addition, our
laboratory observed that the gene encoding this receptor is highly expressed in vivo
during acute murine pneumonia294. P. aeruginosa uses FpvA to bind the high-affinity
siderophore pyoverdine to capture iron from the host environment and translocate it to
the cell cytoplasm through a TonB-dependent system 297. Studies from Wu et al. and Liu
et al. have previously identified and tested FpvA as a potential antigen against P.
aeruginosa6,198. FpvA displays numerous characteristics often associated with protective
antigens: 1) FpvA is present on the surface of the bacterium 298, 2) is expressed during
infection6,294,299, 3) is important for bacterial homeostasis and virulence6,109,300,301, and 4)
is present in the majority of P. aeruginosa strains including isolates from CF patients302,303.
In addition, iron acquisition receptor-based vaccines are protective against E. coli,
Klebsiella spp., Salmonella enterica serovar Enteritidis, Neisseria gonorrhoeae, Neisseria
meningitidis, Staphylococcus aureus, and Haemophilus parasuis in different animal
models304–311. Therefore, the iron acquisition receptor FpvA has the potential to be used
as an antigen against P. aeruginosa. However, purification of FpvA and maintenance of
the proper folding of the protein during the purification process is challenging because
FpvA is an OMP6,312. To circumvent this problem, smaller peptides based on the outermembrane regions of this protein are more soluble and may be used as a substitute for
the whole protein. We hypothesize that a peptide-based vaccine containing outer81

membrane regions of FpvA can provide protection against P. aeruginosa respiratory
infections.
In this study, we generated a vaccine containing a cocktail of peptide antigens based on
the outer-membrane regions of FpvA. These peptides were covalently attached to the
carrier molecule keyhole limpet hemocyanin (KLH) to increase immunogenicity. Previous
studies showed that both Th1 and Th17 associated immune responses are important to
reduce the severity of P. aeruginosa lung infections313,314. Therefore, the vaccine was
formulated with the β-glucan adjuvant curdlan, a known inducer of Th1/Th17 immune
responses263. In addition, numerous pathogens, including P. aeruginosa, use mucosal
surfaces as the initial site of entry into the human body 315,316. Therefore, having both
systemic and mucosal immune responses against P. aeruginosa is often thought to be
crucial for protection. Intranasal vaccination induces both systemic and mucosal immune
responses in the respiratory tract317. Thus, the vaccine was administered intranasally. By
performing vaccination and challenge studies in a murine model of acute pneumonia, we
evaluated the vaccine’s immunogenicity and protective potential. We determined that
intranasal peptide-based FpvA-KLH conjugate vaccination is effective to decrease the
bacterial burden in the airways and lung edema following intranasal challenge. We
showed that intranasal vaccination with FpvA-KLH peptides and curdlan as an adjuvant
elicits both systemic and mucosal humoral and cellular immune responses. Overall, this
study supports that in a murine model, the intranasal administration of a peptide-based
FpvA conjugate vaccine is an efficient vaccine strategy against acute pneumonia caused
by P. aeruginosa and could be pursued as a potential human vaccine candidate.
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4.3 Materials and methods
4.3.1 Bioinformatic design and selection of FpvA peptide antigens
Peptides were designed using a multi-step approach: 1) The crystal structure of the FpvA
protein was obtained from the RCSB Protein Data Bank (PDB) ID:2IAH

318.

The

extracellular regions of FpvA were determined from deposited transmembrane regions in
the Orientations of Proteins in Membranes (OPM) database319. 2) The protein sequence
of FpvA was analyzed to identify hydrophilic regions based on the Kyte-Doolittle scale
using CLC Genomics Workbench 7.5.1320 and to predict linear B cell epitopes using the
BepiPred algorithm321. Based on the hydrophilicity and B cell linear epitope prediction,
candidate peptides overlapping with FpvA extracellular regions and with a length
comprised between 20 and 30 amino acids were selected. 3) The candidate peptides
were screened for homology to other proteins using NCBI-BLAST-P (protein-protein
BLAST)
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Peptides with a percentage of identity higher than 50%, when compared to

non-pathogenic commensal bacteria or human protein sequences, were excluded from
the study to avoid any undesired cross-species reactivity. 4) Four peptides were selected
and synthesized by Biomatik USA with >85% w/w purity. A cysteine residue was added
on the N-terminus of the peptide sequence to allow for conjugation to a carrier protein. 5)
Each peptide was conjugated to Keyhole Limpet Hemocyanin (KLH). The peptides and
conjugates were validated using mass spectrometry and HPLC by the manufacturer.
Chimera 1.10.2323 was used to visualize selected peptides and FpvA protein.

4.3.2 Bacterial strains
The following strains were used: P. aeruginosa PAO1 “Vasil” (Dr. Michael L. Vasil,
University of Colorado), PAO1 “Washington” (Dr. Colin Manoil, University of Washington),
PAO1 “Spain” (Dr. Sebastian Alberti, University of the Balearic Islands), PA14 (Dr.
Frederick M. Ausubel, Harvard University), and CF clinical isolates
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(Dr. Robert Ernst,

University of Maryland). P. aeruginosa PAO1 “Vasil” strain was used for vaccination and
challenge. P. aeruginosa was grown for 16 h at 37°C on Pseudomonas Isolation Agar
(PIA) (Becton Dickinson) unless otherwise specified.
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4.3.3 Vaccine formulation
FpvA and FpvA-KLH peptides were resuspended in 125mM NaOH (Fisher Scientific).
The unconjugated FpvA peptide vaccine was prepared using a mix of 35 μg of each FpvA
peptide in PBS. The FpvA-KLH conjugate vaccine dose consisted of a mix of 35 μg of
each FpvA-KLH peptide in PBS. The whole-cell vaccine (WCV) was prepared using P.
aeruginosa PAO1 “Vasil”. The strain was grown as described above. Swabbed bacteria
were resuspended in Phosphate Buffered Saline (PBS), and heat-killed at 60°C for 1 h.
The efficiency of heat-killing was verified by plating on PIA. Each WCV dose consisted of
4-5x107 heat-killed colony-forming unit (CFU) of P. aeruginosa in PBS. All vaccines were
prepared in a final volume of 20 μl and contained 100 μg of curdlan (Sigma Aldrich) as
an adjuvant unless otherwise specified. The curdlan-only control consisted of 100 μg of
curdlan in PBS.

4.3.4 Murine immunization
Groups of 6-week-old outbred female CD-1 mice (Strain code:022, Charles River) were
anesthetized by intraperitoneal (IP) injection of a total of 0.2 ml of ketamine (7.7 mg/kg)
(Patterson Veterinary) and xylazine (0.77 mg/kg) (Patterson Veterinary) in 0.9% saline
according to the Institutional Animal Care and Use Committee guidelines. Mice were
immunized intranasally with adjuvant only, unconjugated FpvA peptides, FpvA-KLH
conjugates, or WCV at day 0 followed by a booster at day 21. The experiments were
performed in accordance with the National Institutes of Health Guide for the care and use
of laboratory animals. The protocols used were approved by West Virginia University
Institutional Animal Care and Use Committees (WVU-ACUC protocol 1606003173).

4.3.5 Blood sample collection
Blood samples were collected from the tail vein or submandibular vein of each mouse at
days 0, 7, 14, and 20 post-vaccination. The samples were left at ambient temperature for
30 min to allow the blood to coagulate and centrifuged for 2 min at 17, 900 x g. Serum
was collected and stored at -80°C.
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4.3.6 ELISA
The antibody titers were assayed by ELISA in Costar® 96 well high-binding microtiter
plates (Corning Incorporated). The microtiter plates were coated with a volume of 50
μl/well of 2x107 CFU of heat-killed P. aeruginosa PAO1, 500 ng of individual FpvA
peptides, or a mix of all peptides (125 ng of each peptide; 500 ng total) overnight at 4°C.
After coating, the plates were washed 3 times with PBS with 0.05% Tween 20 (Fisher
Scientific) (PBS-T) and blocked with 2% Bovine Serum Albumin (BSA) (Bioworld) in PBS
overnight at 4°C. Blocked plates were washed 3 times with PBS-T. The samples were
prepared in 2% BSA in PBS. The serum samples were serially diluted from 1:50 to 1:25,
600, and the lung supernatants were serially diluted from 1:1 to 1:25, 600. After 1 h of
incubation at 37°C, the plates were washed 4 times with PBS-T and incubated with antiIgG, -IgM, -IgG1, -IgG2a or -IgG2b, -IgA alkaline-phosphatase conjugated goat antimouse antibodies (SouthernBiotech) at 1:2, 000 per well for 1 h at 37°C. Plates were then
washed five times with PBS-T and incubated with Pierce p-Nitrophenyl Phosphate
(PNPP) (Thermo Fisher Scientific) for 30 min following the manufacturer’s instructions.
The absorbance of the plates was read at 405 nm using SpectraMax i3 (Molecular
Devices LLC). Antibody titers were determined as the highest dilution of the serum with
a signal two times above the average of blanks. To measure the serum IgG response,
eleven CF clinical isolates described by Burns et al., 2001324, different P. aeruginosa
PAO1 strains, and the PA14 strain211 were grown at 37°C on minimal growth medium M9
(Teknova) overnight. The following day, the isolates were diluted 1:20 and grown
exponentially on M9 media until they reached OD600=0.25. The Costar® 96 well highbinding microtiter plates (Corning Incorporated) were coated with 50 μl/well of 2x107 CFU
of these cultures. Plates were then incubated with pooled sera from NVC and FpvA-KLH
vaccinated challenged mice (1:50 diluted in PBS). Anti-P. aeruginosa antibodies present
in these samples were then detected using the procedure as described above. To
characterize the lung IgA response, PAO1 and CF clinical isolates were grown and
CorningTM 96-well white high-binding microtiter plates (Corning Incorporated) were
coated as described above. Plates were then incubated with pooled lung supernatants
from NVC and FpvA-KLH vaccinated challenged mice (1:16 diluted in PBS). For
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detection, an anti-IgA horseradish peroxidase conjugated goat anti-mouse secondary
antibody (SouthernBiotech) (1:4, 000 per well) and the SuperSignal™ ELISA Femto
Substrate (Thermo Fisher Scientific) were used. The chemiluminescence signal of the
plates was detected using Synergy HTX Multi-Mode Reader (BioTek).

4.3.7 Bacterial challenge and respiratory tissue processing at 16 h
post-challenge
The bacterial challenge was performed at day 34, and mice were dissected at 16 h postchallenge. Anesthetized mice were challenged intranasally with 20 µl of the PAO1 strain
(6x107 CFU in PBS unless otherwise specified) grown as described above. As a vehicle
control, 20 µl of PBS was administered to the adjuvant-only group (non-vaccinated nonchallenged, NVNC). Mice were euthanized by IP injection of 390 mg pentobarbital/kg
(Patterson Veterinary) in 0.9% NaCl. The blood was collected by cardiac puncture after
euthanasia. The lungs of each mouse were aseptically removed and weighed. Nares
were flushed with 1 ml of sterile PBS to collect the nasal washes (NW). Lungs were
homogenized in 1 ml of PBS using a glass Dounce homogenizer. One hundred microliters
of homogenized lung samples and NW from each mouse were then serially diluted and
plated on PIA plates to determine viable CFU counts. To measure the cytokine response,
200 µl of lung homogenate from each mouse were pelleted by centrifugation. The lung
supernatant was collected and stored at -80°C until cytokine analysis. The remaining lung
homogenates were further analyzed by flow cytometry.

4.3.8 Purification of FpvA protein
The gene fpvA was amplified by PCR from PAO1 “Vasil” genomic DNA. Primers were
designed to include a SacI restriction site on the forward primer, and a His6 tag and a
HindIII restriction site on the reverse primer to facilitate cloning and purification. The PCR
primers used to amplify fpvA gene were 5’-AGTCGAGCTCATGGCAGCACCACACGGTCTCAG-3’
and

5’-AGTCAAGCTTTTAATGATGATGATGATGATGGAAGTCCCAGCGAGTGCT-3’.

The

PCR

fragment was first cloned into pCR4-TOPO (Invitrogen) to generate pCR4-TOPO-fpvA,
and resulting clones were confirmed using Sanger sequencing. pCR4-TOPO-fpvA was
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then digested with SacI and HindIII and ligated into pHERD20T 325 digested with the same
enzymes. Resulting plasmids were transformed into Escherichia coli strain Clear Coli
(Lucigen), and correct insertion of fpvA in pHERD20T was confirmed by Sanger
sequencing. For protein purification, pHERD20T and pHERD20TfpvA were grown
overnight in Lysogeny Broth (LB, Miller formulation) supplemented with 100 µg/ml
carbenicillin (Fisher Scientific) at 37°C. Cultures were then diluted 1:100 in fresh LB and
grown for 6 h at 37°C. Protein expression was then induced by addition of 0.1% w/v Larabinose (Sigma-Aldrich) for 18 to 24 h at 37°C. Cells were harvested by centrifugation
at 5,000 x g for 10 min at 4°C. Cell pellets were washed with PBS and centrifuged at 5,
000 x g 10 min 4°C. Cells were lysed for 30 min on ice with PBS containing 1mM MgCl2,
protease inhibitors (Halt protease cocktail EDTA free) (Thermo Fisher Scientific) and 160
µg/ml lysozyme (Sigma-Aldrich). Lysates were then sonicated twice for 30 seconds on
ice and centrifuged at 20, 000 x g for 15 min at 4°C. Pellets were solubilized with 1.5%
w/v dodecyl-beta-D-maltoside (MP Biochemicals) in PBS. Samples were centrifuged
20,000 x g for 15 min at 4°C and supernatants transferred to HisPur Cobalt columns
(Thermo Fisher Scientific). Elutions were pooled and dialyzed with 10 K molecular weight
cut-off SnakeSkin Dialysis Tubing (Thermo Fisher Scientific) in water overnight at 4°C.
Samples were then concentrated using an Amicon 50kDa Nominal Molecular Weight
Limit (Millipore). Protein concentrations were measured using bicinchoninic acid assay
(BCA) total protein kit (Thermo Fisher Scientific).

4.3.9 Western blot detection of FpvA-specific antibodies
Five µg of purified FpvA protein was resuspended in Laemmli buffer (Bio-Rad), boiled for
5 min, loaded into each well, and resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Separated proteins were transferred to a previously
rehydrated PVDF membrane (Bio-Rad). After the transfer, the membrane was blocked
with 5% w/v skim milk (BD Diagnostic Systems) in PBS-T at 4°C overnight. The following
day, the membrane was incubated with pooled murine sera from the FpvA-KLH (n = 5)
and NVC (n = 5) groups at a dilution of 1:2,000, or with anti-His antibodies (Proteintech
Group) at 1:5,000 in 5% w/v skim milk in PBS-T for 16 h. The membrane was washed 3
times with PBS-T and incubated with anti-mouse IgG antibodies conjugated with HRP
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(Immunoreagents) at 1:5,000 in 5% w/v skim milk in PBS-T for 1 h. The membrane was
rewashed 3 times with PBS-T and finally developed using SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Fisher Scientific). Chemiluminescence signal
was detected using a Chemidoc Touch Imaging System (Bio-Rad).

4.3.10 Opsonophagocytic killing assay
P. aeruginosa PAO1 was grown in 5 ml of LB overnight. The following day, the suspension
was diluted at 1:100 dilution in fresh LB and exponentially grown to OD600= 0.3. The cells
were pelleted and re-suspended in 5 ml of minimal essential medium (MEM) (Corning
Incorporated) with 1% BSA (MEM-BSA) (Bioworld). The suspension was diluted in MEMBSA to obtain a final concentration. J774A.1 macrophages (ATCC) were grown in DMEM
medium (Corning Incorporated), harvested and resuspended in MEM-BSA. Mice sera
from NVNC, WCV, and FpvA-KLH groups were used for opsonophagocytic assays at a
concentration of 2x the titer for anti-P. aeruginosa antibodies for each serum. Sera of
each group were incubated for 30 minutes at 56°C to inactivate complement activity. P.
aeruginosa PAO1 (2.5x105 CFU/ml), macrophages (2.5x105 cells/ml), and serum sample
were incubated together in microcentrifuge tubes by tumbling end-over-end on a rotator
at 37°C for 1.5 hours. As control, the same amount of NVNC control serum was used for
each WCV and FpvA-KLH serum sample. After the incubation period, samples were
serially diluted and plated on PIA. The percentage of bacterial killing was calculated by
comparing the number of bacteria killed in samples incubated with WCV or FpvA-KLH
sera to the NVNC control serum. The percent killing was calculated relative to NVNC
control serum. Percent Kill = [{(CFU counts from the same amount of NVNC serum) (CFU counts from vaccinated challenged serum)} / (CFU counts from the same amount
of NVNC serum) x 100]. Serum from each mouse was evaluated using technical
duplicates.
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4.3.11 Hematologic analysis
To measure the number of white blood cells in blood upon challenge, 200 μl of blood were
collected into BD Microtainer® Blood Collection Tubes (BD Biosciences). Blood samples
were analyzed immediately using an Hemavet 950 FS (Drew Scientific). The results were
compared to a mouse blood standard (Drew Scientific).

4.3.12 Flow cytometry sample preparation and analysis
Flow cytometry was performed on lung and spleen samples. Lung samples were
prepared as described above. Lung homogenates were diluted with 4 ml of PBS and the
suspension was strained using a 100 µm pore cell strainer (VWR International). The
spleens from mice challenged with 107 CFU were collected at day 7 post-challenge,
diluted with 4 ml RPMI 1640 medium (Thermo Fisher Scientific) with 10% v/v fetal bovine
serum (FBS) and 0.5% w/v penicillin-streptomycin (Corning) (RPMI complete medium),
and homogenized gently through a disposable 100 µm pore cell strainer. Samples were
centrifuged at 1,000 x g for 5 min, and supernatants were removed. Red blood cells were
lysed using Pharm Lyse (BD Biosciences) for 2 min at 37°C. The remaining cells were
centrifuged at 1, 000 x g for 5 min. The pellets were resuspended in PBS with 1% v/v FBS
for Fc receptor blocking and incubated on ice for 15 min. Lung cells were stained with
myeloid and resident memory cell surface markers (Table 7). Each cell suspension
sample was incubated with the antibody cocktails for 1 h at 4°C in the dark. Cell
suspension samples were pelleted and resuspended in PBS. Spleen cells were stained
with specific T cell surface markers and intracellular transcription factor markers using
Pharmingen™ Transcription Factor Buffer (BD Biosciences) (Table 7). The cell surface
staining was performed as described above. The cells were then pelleted, fixed, and
permeabilized with 1 ml of Fix/Perm buffer (BD Biosciences) for 50 min at 4°C. The fixed
and permeabilized cells were washed with 1 ml of Perm/Wash buffer (BD Biosciences)
twice before intracellular staining for 50 min at 4°C in the dark. Cell suspension samples
were pelleted, washed with Perm/Wash buffer and resuspended in PBS. Samples were
processed using an LSR Fortessa flow cytometer (BD Biosciences) and analyzed using
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FlowJo v10 (FlowJo, LLC). The flow cytometry gating strategy for myeloid cells was
adapted from Misharin et al., 2013326 (Figure 18).
Table 7: List of used flow cytometry antibodies
Antibody

Fluorophore

Company

Catalog Number

CD45

PE-CF594

BD Biosciences

562420

CD11b

BV510

BD Biosciences

562950

CD11c

APC-Cy7

Biolegend

117324

CD24

BV421

BD Biosciences

562563

CD64

APC

Biolegend

139306

GR-1

PE

BD Biosciences

553128

MHCII

FITC

Thermo Fisher

MA1-10403

Siglec-F

APC-R700

BD Biosciences

565183

CD8

PerCP-Cy5.5

BD Biosciences

551162

GATA3

APC

Miltenyi Biotec

130-100-650

RoRγT

PE-CF594

BD Biosciences

562684

T-bet

PE

BD Biosciences

561265

CD4

APC-Cy7

Biolegend

100526

CD44

BB515

BD Biosciences

564587

CD62L

APC

BD Biosciences

553152

CD69

BV421

BD Biosciences

562920

CD103

APC-R700

BD Biosciences

565529
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Supplementary Figures:
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Figure 18: Gating strategy for flow cytometry analysis of myeloid cells
Single
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first

gated

for

CD45 +

cells.

Alveolar

macrophages

(CD45+SiglecF+CD11c+) were gated out from CD45+ cells, and remaining cells were gated for
CD11b and GR1 markers. The neutrophil (CD45 +CD11b+GR1hi) population was then gated
out, and the remaining cells were gated for eosinophils (CD45+SiglecF+CD11c-). After
exclusion of neutrophils, alveolar macrophages and eosinophils, the remaining population was

gated for CD11b+MHCII+ cells. These cells were further gated for interstitial macrophages
(CD45+

CD11b+SiglecF+/-GR-1lo/-MHCII+CD64+CD24-)

(CD45+Cd11b+ SiglecF+/-GR1lo/-MHCII+CD64-CD24+).
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4.3.13 Cytokine analysis
To measure the cytokine response, the concentration of IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL6, KC/GRO, IL-10, IL-12p70, TNF-α and IL-17 in the lung were determined by quantitative
sandwich

immunoassays

using

the

Meso

Scale

Diagnostics

V-PLEX

Plus

Proinflammatory Panel 1 Mouse Kit (K15048G-1) and Mouse IL-17 Ultra-Sensitive kits
(K152ATC-1), following the manufacturer’s instructions. The electrochemiluminescence
signal was detected using the MSD Multi-Array Imaging Platform (Meso Scale
Diagnostics). Lung supernatants from NVNC, NVC, and FpvA-KLH groups were diluted
1:5 and 1:300 to avoid saturation of the signal.

4.3.14 ELISpot
ELISpot assays were performed to determine the number of antigen-specific splenocytes
in vaccinated animals secreting IL-17 and IFN-γ in response to antigen stimulation. For
these experiments, a FpvA-KLH vaccine was also formulated with a mixture of 35 μg of
each FpvA-KLH peptide and 62.5 µg of alhydrogel (Invivogen) in PBS. EMD Millipore
Multiscreen 96-well assay (Thermo Fisher Scientific) plates were pre-wetted with 15 µl of
35% v/v ethanol for 1 min. The plates were washed 5 times with 200 μl of sterile water
and coated with anti-IL-17 (5µg/ml) (Mabtech) and anti-IFN-γ (5µg/ml) (BD Biosciences)
antibodies overnight at 4°C. Splenocytes were isolated from immunized and boosted CD1 mice as described above. The spleen of each mouse was collected at day 34 and
homogenized using a 100 µm sterile cell strainer (VWR International). The splenocytes
were counted using trypan blue (Life Technologies) with a Countess II FL Automated Cell
Counter (Invitrogen). The cells were diluted to 106 cells/ml using RPMI complete medium.
The splenocytes were then aliquoted in duplicate and incubated with RPMI complete
medium only, or RPMI complete medium containing 107 heat-killed P. aeruginosa using
pre-wetted, antibody-coated plates. The splenocytes from non-vaccinated control mice
were also incubated with RPMI complete medium containing 50 ng/ml Phorbol 12myristate 13-acetate (PMA) (Fisher Scientific) as a positive stimulant control. IL-17
antibody-coated plates were incubated for 72 h and IFN-γ antibody-coated plates were
incubated for 16 h at 37°C with 5% CO2. After the incubation, the wells were washed and
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incubated with biotinylated anti-IL-17 (0.25 µg/ml), or anti-IFN-γ (2 µg/ml) secondary
antibodies for 2 h at room temperature according to the manufacturer’s instructions. The
wells were then rewashed, incubated with streptavidin-alkaline phosphatase (Mabtech)
for 1 h at room temperature, and developed using a filtered substrate solution of
BCIP/NBT (Mabtech). ELISpot plates were imaged using an Olympus MVX10
Microscope. The images were processed with FFT Bandpass filter, converted to binary
images and counted automatically for particles bigger than 10 pixel2 using Image J
software v.1.52a 327.

4.3.15 Histological analysis
For these experiments, mice were vaccinated as described above and challenged with
2x108 CFU of P. aeruginosa PAO1. The lungs were collected from vaccinated mice at 16
h post-challenge, perfused, and fixed with 4% v/v formalin (Fisher Scientific). The
samples were sectioned and stained with hematoxylin and eosin (H&E) by the WVU
Pathology Department. A total of 10 images per 2 slides in each group were imaged at
10x and 40x magnification on an EVOS XL Cell Imaging System (Thermo Fisher
Scientific).

4.3.16 Statistical analysis
All statistical analyses were performed using the software Prism version 7 (GraphPad).
Comparisons between two groups were performed using an unpaired Student’s t-test.
Comparisons between three or more groups were analyzed by one-way analysis of
variance (ANOVA) followed by a Tukey’s multiple comparison test for data that follows a
normal distribution. Statistical analysis for non-parametrical data was performed using the
Kruskal-Wallis test with Dunn’s multiple comparison test. For statistical analysis of nonparametric samples for which no signal was detected (i.e. NVNC and NVC serum titers),
comparisons were made to the hypothetical value of 1 using a Wilcoxon signed-ranked
test to compare the antibody titer responses. One sample t-test was used for comparison
of opsonophagocytic killing assays.
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4.4 Results
4.4.1 FpvA-KLH peptide vaccination leads to FpvA-specific antibody
production in a murine model of vaccination
To develop a vaccine against P. aeruginosa using the OMP FpvA, we designed and
selected peptides based on the outer-membrane regions of the protein. The workflow of
peptide design is shown in Figure 19A. The selected peptides were synthesized and
conjugated to the carrier protein, keyhole limpet hemocyanin (KLH), to increase their
immunogenicity. Peptide position and sequence information are shown in Figure 19B-C.

Figure 19: Vaccine design and selection of the FpvA peptides.
(A) Schematic representation of the FpvA peptide design process. (B) Structure of FpvA
protein (gray) bound to pyoverdine (ocean green) (PDB ID: 2IAH). The peptides used in this
study are highlighted in yellow. (C) Peptide sequences and amino acid residue numbers of the
selected FpvA peptides.
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To determine the immunogenicity of the peptides, we formulated them as vaccines with
the adjuvant curdlan198. We used P. aeruginosa heat-inactivated whole cell vaccine
(WCV) with curdlan as a positive control. Curdlan alone (non-vaccinated challenged,
NVC) was used as vehicle control. Cocktails of unconjugated FpvA peptides, FpvA-KLH
peptide conjugates, and control groups were intranasally administered to 6-week-old
female CD-1 mice (Figure 19A).

.

Figure 20: Experimental design and antibody responses over time.
(A) Schematic diagram of the vaccination timeline and overall experimental design. Mice were
vaccinated with FpvA peptides, FpvA-KLH conjugates, WCV or adjuvant only (NVNC) and

received a booster of the same vaccine at day 21. Mice were challenged with P. aeruginosa
PAO1 by intranasal instillation at day 34. IgG and IgM anti-PAO1 antibodies in WCV
vaccinated mice (n = 14) (B), anti-unconjugated FpvA peptide antibodies in FpvA-vaccinated
mice (n = 13) (C), or in FpvA-KLH vaccinated mice (n = 14) (D) collected at day 7, day 14, day
20 and day 35. No antibody response was detected in NVNC animals, the comparisons were

made to the hypothetical value of 1 using Wilcoxon signed-ranked test. The asterisks refer to
statistical significance: **p ≤ 0.01; ***p ≤ 0.001, ****p ≤ 0.001. Error bars are mean ± SEM
values
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The immunogenicity of each vaccine was determined by measuring IgG and IgM levels
over time. Using this experimental design, we observed as expected that our positive
control WCV led to an increase in the production of anti-P. aeruginosa IgM, followed by
a class-switch to IgG over time (Figure 20B). The unconjugated FpvA peptides elicited
low anti-FpvA peptide-specific IgM antibody titers that did not result in significant isotype
switching to IgG (Figure 20C). This suggests that the unconjugated FpvA peptides are
poorly immunogenic and fail to induce a significant IgG antibody response over time. In
the FpvA-KLH vaccinated mice, we observed a significant production of anti-FpvA
peptide-specific IgM antibodies. In addition, we observed isotype switching to IgG in the
FpvA-KLH group (Figure 20D). We also observed that mice immunized with the FpvAKLH vaccine resulted in significant increase in anti-FpvA peptide-specific IgG compared
to unconjugated FpvA peptides at day 35 post-vaccination (1,000-fold) (Figure 21A).
Compared to the NVC group, immunization with FpvA-KLH lead to the significant
production of anti-FpvA peptide-specific IgG and IgM (Figure 21A). While the mice were
immunized with a mix of four FpvA peptides conjugated to KLH, anti-peptide 2 antibodies
accounted for most of the IgG serum titers, and anti-peptide 4 antibodies were detected
in 3 out of 9 mice (Figure S1).
We observed that vaccination with FpvA-KLH could induce an antibody response that
recognizes the FpvA peptides. However, this response is unlikely to be protective if these
antibodies do not recognize the FpvA protein or the whole bacterium. To determine if
antibodies generated by vaccination with FpvA-KLH could recognize the full-length
protein, we performed Western blot analysis with the purified recombinant FpvA protein.
The results indicate that the serum from FpvA-KLH vaccinated mice, but not NVC mice,
recognizes the purified recombinant FpvA protein (Figure 21B). Finally, we tested whether
the antibodies elicited by FpvA-KLH vaccination could recognize the whole bacteria. We
detected a significant amount of IgG and IgM against P. aeruginosa PAO1 in the FpvAKLH vaccinated mice compared to NVC (Figure 21C). Conjugation of the peptides with
KLH resulted in significant increase in IgG (100-fold) and in IgM antibody response (10
fold) compared to the unconjugated FpvA peptides (Figure 21C). Immunization with the
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unconjugated FpvA peptides did not produce a significant antibody response against P.
aeruginosa PAO1 compared to NVC (Figure 21C).

Figure 21: Antibodies elicited by FpvA-KLH peptide vaccination can recognize
the FpvA peptides, FpvA protein, and P. aeruginosa.
(A) IgG and IgM antibody titers of NVC, FpvA peptides only, and FpvA-KLH vaccinated and

challenged mice groups. Unconjugated FpvA peptides were used as antigen. (B) Western blot
analysis of pooled NVC and FpvA-KLH (n = 5) sera against purified FpvA protein expressed
in E. coli using the vector pHERD20TfpvA-His6. pHERD20T is used as a vehicle control. (C)
IgG and IgM antibody titers of vaccinated and challenged mice groups. Heat-killed whole-cell
P. aeruginosa PAO1 was used as antigen. In panels A and C, each circle represents data
from one mouse of NVC (n = 14), WCV (n = 14), FpvA (n = 13), and FpvA-KLH (n=14) vaccine
groups. The p-values were calculated using a Kruskal Wallis test with Dunn’s multiple
comparison test. (D) IgG response of pooled sera from NVC and FpvA-KLH vaccinated
challenged mice using P. aeruginosa cystic fibrosis isolates (n = 11) and lab strains (PAO1
and PA14) (n = 4) as antigens. Each circle represents different P. aeruginosa strains, triangles
show the PAO1 strain used for infection. The p-values were calculated using unpaired

Student’s t-test. (E) Percentage of opsonophagocytic killing activity of FpvA-KLH and WCV
sera against P. aeruginosa PAO1. Percentage was calculated relative to NVNC control. The
p-values were calculated using a one-sample t-test. *p ≤ 0.05; **p≤ 0.01; ***p ≤ 0.001;
****p ≤ 0.0001. Error bars: mean ± SEM values.
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To characterize whether sera from FpvA-KLH vaccinated mice could recognize other P.
aeruginosa strains, we performed ELISA experiments with 11 P. aeruginosa clinical
isolates from the sputum and bronchoalveolar lavage of CF patients324. We compared the
serum IgG response to various P. aeruginosa laboratory-adapted strains, including
different P. aeruginosa PAO1 and PA14 strains211. The data obtained indicate that the
serum from FpvA-KLH peptide-vaccinated mice can bind to CF isolates as well as the lab
strains above the background threshold, suggesting that these antibodies can also
recognize clinical P. aeruginosa isolates (Figure 21D). These data indicate that
vaccination with FpvA-KLH peptides triggers the production of antibodies that recognize
the unconjugated FpvA peptides, purified recombinant FpvA protein, as well as different
P. aeruginosa strains.
Finally, to determine the role of these antibodies in bacterial killing, we performed
opsonophagocytosis assays using murine macrophage J774A.1 cells. Both FpvA-KLH
(33.9% killing) and WCV (72.7% killing) sera significantly increased opsonophagocytosis
of P. aeruginosa PAO1 compared to sera from naïve animals (Figure 21E). These data
show that antibodies generated by FpvA-KLH can mediate opsonophagocytosis in vitro
and could potentially participate in bacterial clearance during infection.

4.4.2 FpvA-KLH vaccination reduces the bacterial burden and
pulmonary edema during acute pneumonia caused by P. aeruginosa
To evaluate whether FpvA-KLH vaccination conferred protection against P. aeruginosa,
mice were challenged on day 34 (Figure 20A). The bacterial burden in the nares and the
lung were determined by plating the serial dilutions and counting viable bacteria at 16 h
post-challenge. As expected, the bacterial load in the airways of the WCV mice was
significantly lower than in NVC. Vaccination with FpvA-KLH resulted in decreased
bacterial burden in nasal cavities and lung compared to the NVC control group (p = 0.0028
and p = 0.0061, respectively) (Figure 22A- B). This decrease was not significantly different
between FpvA-KLH and WCV vaccinated mice, indicating that these mice are similarly
protected against colonization in the lungs and nares. When the mice were vaccinated
KLH alone, we did not observe any decrease in bacterial burden (data not shown). These
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results suggest that protection is conferred by the conjugation of the FpvA peptides to
KLH and not KLH alone. Overall, vaccination with FpvA-KLH peptides leads to a
significant decrease in the bacterial burden during acute P. aeruginosa pneumonia.

Figure 22: FpvA-KLH vaccination decreases bacterial burden and pulmonary
edema in mice challenged with P. aeruginosa.
The bacterial burden of NVC (n = 8), WCV (n = 10), and FpvA-KLH (n = 8) vaccinated mice
in the nasal wash (A) and lung (B). (C) Lung weight of vaccinated and challenged mice. The
NVNC (n = 10) group was used as a control. Each circle represents data from one mouse.
Data represent two independent experiments. The p-values were calculated using ANOVA
followed by a Tukey’s multiple-comparison test. Error bars are mean ± SEM values. The
asterisks refer to statistical significance: **p≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. (D) H&E
staining of lungs from immunized and adjuvant only control mice. Representative
histopathological sections are shown (magnification = 10x and 40x).
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P. aeruginosa causes pneumonia associated with acute lung injury, inflammation, and
pulmonary edema during infection

328,329.

We hypothesized that FpvA-KLH could help

alleviate these pathologies. As an indicator of lung edema, we measured the wet weights
of the lung from the infected mice. To observe pulmonary damage and inflammation, we
performed lung histopathological analysis. The lung weight of mice vaccinated with FpvAKLH was significantly decreased compared to the NVC mice after challenge. There were
no significant differences in the lung weight between the FpvA-KLH vaccinated, NVNC,
and WCV groups (Figure 22C). The body weight of mice was not significantly different in
any of the groups (Figure S2), which suggests that the differences observed in lung
weights are not associated with differences in overall body mass. In addition, the FpvAKLH and WCV vaccinated mice had a lower recruitment of polymorphonucleated cells
compared to NVC (Figure 22D). These data indicate that FpvA-KLH vaccination prevents
the increase in pulmonary edema and recruitment of polymorphonucleated cells
associated with P. aeruginosa infection. Altogether, these results show that FpvA-KLH
vaccination reduces the bacterial burden in the lung and nares as well as lung damage
and inflammation.

4.4.3 Effect of FpvA-KLH vaccination on the cytokine and myeloid cell
response
Myeloid cells are crucial in the initial phase of infection. These cells participate in
phagocytosis, antigen presentation, recruitment of other immune cells to the site of
infection through cytokine secretion, and assist in inducing an adaptive immune response
330,331.

To understand how the FpvA-KLH vaccination mediates protection against P.

aeruginosa, we characterized the immune response at 16 h post-challenge. We first
measured the cytokines present in the lung. We observed that the amount of IL-17, IL12, IL-5, IFN-γ, TNF-α, IL-1β, and IL-10 in the lung supernatant significantly increased in
all challenged groups compared to non-challenged control mice (Figure 23, Table S8).
However, there was no significant difference in cytokine secretion between the
challenged groups, regardless of the vaccine they received (Figure 23, 24A, Table S8).
From these experiments, we concluded that cytokine measurement during acute P.
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aeruginosa lung infection is insufficient to identify differences in the immune response of
vaccinated and non-vaccinated mice in this model.

Figure 23: Analysis of cytokines in lung homogenates after challenge.
Cytokines IL-17, IL-6, IL-1β, KC and IL-10 (A) IFN-γ, IL-2, TNF-α, IL-12, IL4 and IL-5 (B)

were quantified using electrochemiluminescence immunoassays. Group comparisons were
performed using the Kruskal Wallis test. The asterisks refer to the level of significance:
*p ≤ 0.05; **p ≤ 0.01. Error bars are mean ± SEM values.

To gain further insights into the type of immune response mounted upon FpvA-KLH
vaccination, we measured the number of circulating white blood cells and performed flow
cytometry on lung single cell suspensions. We did not observe any differences in total
white blood cells counts, or in the proportion of monocytes and neutrophils in blood
(Figure S3A-C). However, we observed a significant increase in the percentage of
eosinophils in the blood samples of the NVC group compared to NVNC and FpvA-KLH
groups (Figure S3D). Interestingly, we detected opposite trends in the lung. First, we
observed that the number of both CD11b+GR-1hi (neutrophils) and CD11b+GR-1lo myeloid
cells increased in NVC and FpvA-KLH groups compared to the NVNC mice group (Figure
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24B-C). However, we did not observe any significant changes between NVC and FpvAKLH vaccinated groups (Figure 24C). In addition, while the proportion of eosinophils was
increased in blood of NVC group, it was not significantly different in the lung samples of
NVC, NVC and FpvA-KLH (Figure S3D, S4A). Also, there were no significant differences
in the proportion of lung alveolar macrophages between any of the challenged groups
(Figure S4B).

Figure 24: Innate immune responses in lungs at 16 hours post-challenge.
(A) Logarithmic average of overall cytokine responses in lung supernatant represented
using a spider graph. The vertical axis shows the log scale increase of averaged cytokine
response (pg/ml). (B) Representative contour plots of the NVNC (n=5), NVC (n=6) and
FpvA-KLH (n=4) groups showing the gating strategy for CD11b+GR-1hi (neutrophils) and
CD11b +GR-1lo cell populations in lung leukocytes. (C) Proportion of CD11b +GR-1hi and

CD11b +GR-1lo in lung leukocytes from panel 5B. Group comparisons were analyzed by
ANOVA followed by a Tukey’s multiple-comparison test. (D) Representative histograms
show proportion of MHCII+ cells in CD45 + SiglecF +/-GR-1lo/-CD11b+ cell populations. (E)
MHCII+CD45+SiglecF +/-GR-1lo/-CD11b +

cell proportions

of

lung

leukocytes.

Group

comparisons were analyzed by ANOVA followed by a Tukey’s multiple-comparison test for
MHCII+CD45+SiglecF +/-GR-1lo/-CD11b + cell population. The asterisks refer to statistical
significance: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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4.4.4 FpvA-KLH vaccine stimulates the recruitment of antigenpresenting cells to the site of infection
CD11b+ cells are of particular interest during vaccination and challenge as they include
professional antigen presenting cells (APCs), which are crucial in the establishment of an
adaptive immune response. To further determine the effect of the FpvA-KLH vaccination
on MHCII+ CD11b+ cell population in the lungs, we used the gating strategy shown in
Figure 18. We observed that MHCII+ cells in the CD45+ SiglecF+/-GR-1lo/- CD11b+
myeloid cell population were increased more than two-fold in the FpvA-KLH vaccinated
and challenged mice compared to NVC and NVNC (Figure 24D-E). Within this
population, CD11b+ dendritic cells (CD45+SiglecF+/-GR-1lo/-CD11b+CD64-CD24+) were
the major cell type increased in the FpvA-KLH vaccinated group compared to NVNC and
NVC (Figure 24E and S4C). There were no significant differences in the proportion of
interstitial macrophages (CD45+SiglecF+/-GR-1lo/-CD11b+CD64+CD24-) between any of
the challenged groups (Figure S4D). Overall, these results suggest that FpvA-KLH
vaccination increases the recruitment of CD45+SiglecF +/-GR-1lo/-CD11b+MHCII+ myeloid
cells to the lung upon challenge, and the majority of these cells are CD11b+ dendritic
cells.

4.4.5 Intranasal FpvA-KLH vaccine with curdlan induces a Th17
immune response
Th1 and Th17 specific immune responses were previously shown to decrease the
severity of pneumonia caused by P. aeruginosa and are required to mount an adaptive
immune response against this pathogen

313,314.

To characterize the type of CD4+ T cell

response elicited by FpvA-KLH vaccination, we first identified the presence of IgG2 and
IgG1 isotypes as surrogate markers of Th1 and Th2 immune responses, respectively. We
observed the presence of FpvA peptide-specific IgG1 and IgG2 antibodies in the serum
(Figure 23A). FpvA peptide-specific IgG2b antibodies were detected in all sera of FpvAKLH vaccinated mice, while we detected IgG2a only in some of them (8/14) (Figure 25A).
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Figure 25: Quantification of the T cell immune response.
(A) Elicited IgG subtypes (IgG1, IgG2b, and IgG2a) of FpvA-KLH vaccinated sera using the

unconjugated FpvA peptides as antigen. Each circle represents data from one mouse. Data
represent three independent experiments combined. P-values were calculated by comparing
data to hypothetical value of 1, using a Wilcoxon signed-ranked test. Error bars are mean ±
SEM values. In panel B and C, splenocytes were isolated from NVNC (n = 5), NVC (n = 8)
and FpvA-KLH (n = 5) vaccinated groups 7 days post-challenge. (B) CD4+T-bet+ (Th1) and

CD4+GATA3+ (Th2) cell proportions in the spleen. (C) Proportion of CD4+RORγT+ (Th17)
cells in the spleen. (D) ELISpot assay with splenocytes to identify IL-17 specific response of
each group in the presence or absence of heat-killed P. aeruginosa at day 34 (n=5 in each
group). Phorbol 12-myristate 13-acetate (PMA) was used as a positive stimulant control.
Group comparisons were analyzed by ANOVA followed by a Tukey’s multiple-comparison
test. The asterisks refer to statistical significance: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001;
****p ≤ 0.0001. Error bars are mean ± SEM values.
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Interestingly, we did not observe any increase in the percentage of Th1 (CD4+Tbet+) or
Th2 cells (CD4+GATA3+) in the splenocytes of FpvA-KLH vaccinated and challenge
groups compared to NVNC or NVC at day 7 post-challenge (Figure 25B). However, we
observed a significant increase in the Th17 (CD4 +RORγT+) cell population in the FpvAKLH vaccinated mice compared to both NVC and NVNC mice groups (Figure 25C). These
data suggest that FpvA-KLH vaccination with curdlan leads to a Th17 cellular immune
response.
To evaluate whether the elicited cellular immune response is antigen-specific, we
performed IFN-γ and IL-17 ELISpot assays using splenocytes. In the mice vaccinated
with curdlan alone or FpvA-KLH with curdlan, we did not observe any difference in IFN-γ
secreting cells in response to stimulation with P. aeruginosa (Figure S5). On the other
hand, splenocytes from FpvA-KLH vaccinated mice had a significantly higher number of
IL-17 secreting cells than those immunized with curdlan alone in response to stimulation
with P. aeruginosa (Figure 25D). Previous studies have shown that the adjuvant curdlan
is an inducer of Th17 immune responses263,332. To determine whether the increase in the
Th17 response is due to the inclusion of the FpvA-KLH peptides or the adjuvant, we reformulated the FpvA-KLH vaccine with alum adjuvant. We observed that the FpvA-KLH
vaccine adjuvanted with alum was not able to induce a significant increase in IL-17
producing cells in response to heat-killed P. aeruginosa compared to unstimulated control
(Figure 25D). These results may indicate that both the adjuvant curdlan combined with
the FpvA-KLH antigen are necessary to induce IL-17 secretion in splenocytes.

4.4.6 Induction of mucosal memory immune response by intranasal
FpvA-KLH vaccination
Previous studies have shown that upon intranasal vaccine administration, IgA317 and
tissue-resident memory response can be elicited333. These responses play an essential
role in protecting against respiratory bacterial pathogens. Therefore, we hypothesized
that intranasal vaccination with FpvA-KLH could induce a humoral mucosal immune
response via IgA secretion as well as a tissue-resident memory response in upper
airways. Mice vaccinated intranasally with FpvA-KLH had significant IgA titers against
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FpvA peptides compared to NVC mice in lung supernatants (Figure 26A). In addition,
these IgA antibodies were able to bind significantly to different lab-adapted and CF P.
aeruginosa isolates (Figure 26B).

Figure 26: FpvA-KLH vaccination elicits antigen-specific IgA antibodies in the
lungs.
(A) Lung supernatant IgA antibody titers of NVC (n = 9), and FpvA-KLH (n = 9) vaccinated
and challenged mice using unconjugated FpvA peptides as antigen. (B) Detection of IgA
binding from lung supernatants to P. aeruginosa lab-adapted (n = 3) and CF (n = 10) isolates.
Each circle represents different strain of P. aeruginosa. Triangles show the PAO1 strain used
for infection.

To determine whether FpvA-KLH vaccination also increased the recruitment of memory
T cells to the lung, we performed flow cytometry. The contour plots show the gating
strategy in NVNC, NVC and FpvA-KLH groups to identify naïve CD4+ T cells (TN)
(CD4+CD44-CD62L+), T effector memory-like cells (TEM) (CD4+CD44+CD62L-) and T
central memory cells (TCM) (CD4+CD44+CD62L+) within CD4+ T cell population (Figure
27A). We observed that the proportion of naïve CD4+ T cells was decreased in FpvA-KLH
vaccinated mice compared to NVNC (Figure 27B). While there are fewer naïve CD4+ T
cells, we observed that the proportion of T effector memory-like cells (TEM) but not T
central memory cells (TCM) (CD4+CD44+CD62L+) was significantly increased in the FpvAKLH group compared to NVC and NVNC (Figure 27C). Among the T-effector memorylike cell population, the percentage of CD103+CD69+ cells (Figure 27D), which are known
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to have a tissue-resident memory phenotype (TRM)333, was significantly increased in the
FpvA-KLH vaccinated mice compared to NVNC and NVC (Figure 27E). Overall,
intranasal the FpvA-KLH vaccine can induce mucosal IgA, as well as a tissue-resident
memory T cell response in the lung. These results suggest that intranasal vaccination
with FpvA-KLH elicits both humoral and cellular mucosal immune responses.
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Figure 27: FpvA-KLH vaccine leads to an increase in CD4+ tissue-resident

memory cells in the lung.
(A) Representative contour plots show the gating strategy for central memory (TCM), T
effector memory-like (TEM), and naïve T cells (TN). (B) Proportion of naïve T cell population.
(C) Proportion of central memory T cells and effector memory-like T cells. (D) Representative
gating strategy for tissue-resident memory T cells (TRM). (E) Proportion of tissue-resident
memory cells. Comparisons in A and B were performed using an unpaired student t-test.
Group comparisons in D, E, and G were analyzed by ANOVA followed by a Tukey’s multiplecomparison test. The asterisks refer to statistical significance: *p ≤ 0.05; **p ≤ 0.01;
***p ≤ 0.001; ****p ≤ 0.0001. Error bars are mean ± SEM values.
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4.5 Discussion
The ferripyoverdine receptor FpvA, is one of the main iron acquisition receptors of P.
aeruginosa297. It is essential for virulence and homeostasis, is expressed during infection,
and is known to be antigenic 6,109,294,299–301. In this study, we explored if a vaccine
containing peptides based on the outer-membrane regions of FpvA could be protective
against acute P. aeruginosa pneumonia in mice. We demonstrated that the FpvA peptides
conjugated to the carrier protein KLH can induce both cellular and humoral immune
responses and can provide protection against P. aeruginosa acute pneumonia in mice.
Peptide-based vaccines have been shown to be protective against both bacterial and viral
pathogens in animal models334. They can provide solutions with minimal cross-reactivity
or reactogenicity in patients, as the type of response they trigger can be more finely
controlled335. Due to their small size, peptides are usually weakly immunogenic without
carrier molecules to induce a robust immune response334,336. As expected, we observed
that the FpvA peptides used in this study were more immunogenic when conjugated to
the carrier protein KLH (Figure 20B-C). Overall, antibodies secreted in response to the
FpvA peptides conjugated to KLH were able to recognize the unconjugated FpvA
peptides, the full-length FpvA protein, as well as whole bacteria in vitro (Figure 21). These
data suggest that while we used short and linear antigen sequences for vaccination, the
FpvA-KLH peptides were sufficient to provide a response that would also recognize the
full protein and the bacteria.
Previous studies have identified the FpvA protein as a potential protective vaccine antigen
for P. aeruginosa6,198. In an earlier study, purified FpvA protein adjuvanted with curdlan
administered intranasally could produce antigen-specific antibody responses but failed to
protect against P. aeruginosa6. In this study, while we expressed and purified the FpvA
protein in E. coli, we chose not to pursue its use as an antigen due to difficulties in
purification and low solubility. Smaller peptides based on the outer-membrane regions of
OMPs are more soluble and can be used as a substitute for the whole protein. In addition,
biological impurities from purified OMPs, such as endotoxin, are another challenge to
formulate clinically safe vaccines336. Instead, we used extracellular peptides based on
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FpvA conjugated to KLH. We observed that vaccination with FpvA-KLH was as protective
as WCV. Differences between the protection provided by FpvA-KLH peptides and the
whole FpvA protein could be associated with protein conformation, folding, stability, and
solubility. Interestingly, among the four selected FpvA peptides, FpvA peptide 2 was the
most immunogenic peptide (Figure S1). The efficacy of using FpvA peptide 2 conjugated
to KLH alone or other carrier proteins remains to be further examined.
Vaccine-mediated protection is often conferred by the production of antigen-specific
antibodies that neutralize bacteria and their toxins to facilitate clearance 275. Vaccination
with FpvA-KLH led to the production of IgM, IgG in serum, and mucosal IgA in the lung.
Both IgG from serum and IgA from lung supernatants were able to recognize lab-adapted
strains as well as CF clinical P. aeruginosa isolates (Figure 26). We also showed that the
antibodies present in serum were able to mediate opsonophagocytosis and participate in
bacterial clearance in vitro suggesting a potential role for these antibodies during infection
(Figure 21E). Similar experiments could not be performed with lung IgA due to the low
concentration of these antibodies in the samples. Interestingly, we did not find a
correlation between antibody titers (IgM, IgG, or IgA) and bacterial CFU counts in
vaccinated and challenged animals (data not shown). This may indicate that
immunoglobulins alone are not sufficient to promote the clearance of P. aeruginosa, and
that other components of the immune system have a role in protection. Additional studies
are required to determine the exact role of antibodies, and in particular IgA, in the
mechanism of protection of this mucosal vaccine.
In this study, we observed a strong cytokine response in mice challenged with P.
aeruginosa (Figure 23, 24A), which is characteristic of infections caused by this
bacterium337,338. Bacterial products drive inflammation in the lungs by interacting with
pattern recognition receptors (PRR’s) such as Toll-like receptors or NOD-like
receptors339,340. In addition, the generation of additional bacterial products resulting from
bacterial clearance also promote a pro-inflammatory response338. Therefore, even though
we observed a decrease in bacterial burden in the FpvA-KLH vaccinated mice, we still
detected a strong acute inflammatory cytokine response in the lungs. Future studies
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monitoring the cytokine response and cellular recruitment of cells over-time from bacterial
challenge to clearance could help assess the differences in between the groups.
During our histopathology analysis, we observed a strong recruitment of immune cells to
the lung of NVC mice, accompanied by an increase in lung weight. While this increase
was in part due to the recruitment of neutrophils, no significant differences were observed
in myeloperoxidase levels by ELISA or immunohistochemistry (data not shown).
Interestingly, the only innate immune cell population that increased in the lung of FpvAKLH vaccinated mice was MHCII+CD45+ SiglecF +/-GR-1lo/- CD11b+ (Figure 24D-E).
Among this population, CD11b+ dendritic cells were the main cell type increased in
FpvA-KLH vaccinated and challenged mice compared to NVC (Figure 24E, S4C). One
caveat of the flow cytometry analyses in this study is that mice were not perfused prior
to organ harvest. As a result, there might be low remaining amounts of circulating blood
in the tissue analyzed. To control for this, we measured the changes in white blood
cells in the blood in response to challenge in vaccinate animals. We did not observe
any significant changes in the proportion of neutrophil or monocyte in the blood in any
of the vaccinated groups compared to control (Figure S3). For this reason, while we did
not perform perfusions prior to lung single cell analysis, we do not anticipate that the
presence of residual blood in the lung affected the proportion of cell measured in the lung.
Murine lung CD11b+ dendritic cells are potent stimulators of Th17 immunity 341,342. IL-17
production in acute pulmonary P. aeruginosa infections plays a protective role in the
innate immune response to P. aeruginosa and is critical in vaccine-induced
protection198,313. We observed that vaccination with FpvA-KLH leads to a significant
increase in Th17 T cells and antigen-specific IL-17 secreting cells in the spleen (Figure
25). This result is not surprising as we used curdlan, which is known to promote a Th17
immune response263,332. Curdlan alone or alum-adjuvanted FpvA-KLH did not lead to
production of an antigen-specific IL-17 response (Figure 25D). This suggests that the
combination of the FpvA-KLH peptides with the adjuvant curdlan is necessary to produce
IL-17 secreting splenocytes. However, the exact mechanism of the IL-17 response
elicited by FpvA-KLH vaccination and the effect of the adjuvants used requires further
examination.
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Intranasal vaccination induces protective systemic and mucosal humoral and cellular
responses in the respiratory tract317. After intranasal FpvA-KLH vaccination, we detected
a significant increase in IgA response in the lung supernatant. This suggests that
intranasal FpvA-KLH leads to humoral mucosal immunity. Previous studies indicate the
importance of a CD4+ tissue-resident memory response for naturally-acquired immunity
against bacterial infections333. To access whether tissue-resident memory cells were
present in the lung of vaccinated animals, we performed flow cytometry to determine the
proportion of TN, TCM, TEM, and TRM cells. We observed a significant decrease in the
proportion of TN cells while the proportion of TEM increased in FpvA-KLH vaccinated
animals compared to NVNC and NVC controls (Figure 27C). These changes might not
be tissue specific and could be in part attributed to residual blood in the tissue. In addition,
we observed that vaccination with FpvA-KLH leads to a significant increase in CD4 +
tissue-resident memory T cells (Figure 27E). Since the markers used in this study to
identify tissue-resident memory T cells are not expressed in circulating T cells but only in
tissue-resident memory T cells, we do not anticipate that the presence of residual blood
in the tissue influenced the data presented here. Overall, this study shows the recruitment
of tissue-resident memory T cells to the lung in response to intranasal vaccination;
however, the role of these cells in protection against P. aeruginosa has not yet been
demonstrated.
In this study, we examined the efficacy of FpvA-KLH vaccination in a murine model of
acute pneumonia. The efficacy of the FpvA-KLH vaccine in the context of CF remains to
be further examined. Unfortunately, the currently available CFTR mutant CF mice models
do not recapitulate CF lung disease343. However, the β-ENaC mouse model, which
overexpress the β-subunit of the epithelial sodium channel (ENaC), displays CF-like
clinical lung phenotype344. In future studies, FpvA-KLH vaccination will be studied using
the β-ENaC mouse model to evaluate vaccine efficacy on P. aeruginosa-induced lung
disease.
Overall, we developed an intranasal peptide-based subunit P. aeruginosa vaccine using
the main iron acquisition receptor of P. aeruginosa, FpvA, as a vaccine antigen. We
observed that FpvA-KLH vaccination decreased the bacterial burden as well as lung
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edema. The FpvA-KLH vaccine was able to induce antigen-specific humoral and IL-17
immune response as well as a mucosal adaptive immune response in acute pneumonia.
Taken as a whole, this study demonstrates that the peptide-based FpvA conjugate
vaccine is an effective strategy in mice that could be used to prevent lung infections
caused by P. aeruginosa in at-risk patients.
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Chapter 5: Discussion
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P. aeruginosa is a pathogen that utilizes a variety of mechanisms to evade the immune
system and survive in the host. Upon host entry, P. aeruginosa adapts to its environment
and changes the production of its virulence factors to escape host immunity 345. These
adaptations are a consequence of host-pathogen interactions. Therefore, understanding
these interactions is essential for the development of therapeutics and vaccines. In this
work, we aimed to characterize the host immune response during infection and in
response to vaccination. We performed in-vitro and in-vivo infection studies to understand
the acute response against this pathogen. We characterized the vaccine-mediated
immune responses against P. aeruginosa using intranasal whole-cell and subunit vaccine
strategies. We also generated a new vaccine platform and identified peptides based on
the sequence of the protein FpvA that can serve as a potential vaccine candidate against
this pathogen.
This chapter selectively discusses the implications of this work resulting in understanding
the host immune response in the context of infection and vaccination. The primary longterm goal of the conducted studies was to develop a vaccine against P. aeruginosa and
identify therapeutic targets to alleviate the disease burden in at-risk patients.

5.1 Host response to Pseudomonas aeruginosa infection
Airway epithelial cells establish the first line of defense against many pathogens, including
P. aeruginosa346. During infection, P. aeruginosa directly interacts with epithelial cells.
This interaction leads to the production of cytokines and chemokines, and the recruitment
of innate and adaptive immune cells at the site of infection to promote bacterial
clearance204. In chapter 2, we aimed to understand the initial epithelial cell responses
elicited against P. aeruginosa following infection. We showed that the genes whose
products are involved with inflammation such as: MAPK, TNF, and IL-17 signaling
pathways, were upregulated in epithelial cells in response to P. aeruginosa compared to
non-infected control cells (Figure 5C). We observed that most of the differentially
regulated genes at one-hour post-infection were immediate early response genes (IEGs).
Among these IEGs, genes encode EGR1 and FOS transcription factors were the most
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differentially expressed genes (Table S1). These transcription factors are crucial for the
expression of pro-inflammatory response genes that are important for initial host
responses238. We then performed in-depth analysis to determine if bacterial virulence
factors were involved in the changes observed in gene expression. We identified that
some changes in IEGs expression only occurred when bacteria were alive, suggesting
the implication of an active mechanism (Figure 8). Inside the host, P. aeruginosa uses its
secretion systems to manipulate and evade the host immune response227. Using T3SS
and T6SS, P. aeruginosa can inject its exotoxins directly into the host cells209,347. We
found that in the absence T3SS, the host EGR1 and FOS genes are less differentially upregulated compared to wildtype PA14 in epithelial cells (Table 5). Differential expression
of these genes is important for the activation of pro-inflammatory responses, such as
CXCL8 and IL-6, which leads to further activation of innate immune cells in the host
(Figure 28). The study of the host immune response in vitro in immortalized human type
II pneumocytes allowed us to gain insights into the innate acute response of a specific
cell type in the lung. To obtain a bigger picture of the impact of P. aeruginosa on a broader
set of cells and in the context of infection, we used a murine model of acute pneumonia
as described in Chapter 4. We observed that mice infected with P. aeruginosa had lung
edema and a significant amount of neutrophil recruitment in their lungs (Figure 22,24). In
addition, we observed an increase in the number of Th-17 splenocytes upon infection
(Figure 25). We showed that pro-inflammatory cytokines IL-12, TNF-α, IL-17, KC, IL-1β,
and IL-6, and anti-inflammatory cytokines IL-5, IL-10 were significantly increased in lung
supernatants of P. aeruginosa infected mice compared to non-infected control (Figure
23). These results suggest that P. aeruginosa infection causes cytokine storm in the lungs
of infected mice. Some of these cytokines also have a role in recruitment of neutrophils
to the lungs. We showed that a part of this response was due to the induction of epithelial
cells during infection (Figure 28). The cytokine data obtained in our studies correlates
with overproduction of cytokines, such as IL-6, IL-8, TNF-α, and IL-10 observed in
patients with sepsis348, which is one of the clinically observed outcomes in patients with
P. aeruginosa pneumonia349,350. It was previously reported that bacterial exotoxins
secreted by T3SS play a role in epithelial damage, pathogenesis, and acute septic shock
in P. aeruginosa pneumonia in mice209,351. Functional T3SS and its secretory proteins are
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associated with increased mortality and bacterial burden in acutely infected patients352,353.
The exact role of T3SS exotoxins in eliciting pro-inflammatory responses and the
expression of IEGs needs to be further examined. As we observed in Chapter 2, the
presence of T3SS may lead to the activation of transcription factors, such as EGR1, which
leads to the production of pro-inflammatory cytokines TNFα, IL-1β, IL-6, IL-12, and IL-17
in mice245. Egr-1 deficiency in a mouse model leads to protection against acute
pneumonia caused by P. aeruginosa245. Therapeutic interventions targeting early
response genes, such as EGR1 encoding gene or T3SS of P. aeruginosa may be a
potential solution to alleviate the disease burden in acutely infected patients.

Figure 28: Summary of the elicited host response to P. aeruginosa infection
In response to bacterial infection, epithelial cells express immediate early response genes,

such as EGR1 and AP1 transcription factors. These transcription factors lead to the expression
of pro-inflammatory response genes, such as CXCL8 and IL-6. (B) The expression and
secretion of pro-inflammatory cytokines and chemokines lead to innate cell recruitment. The
recruited cells play a role in bacterial removal via phagocytosis. (C) The recruited professional
antigen-presenting cells migrate to secondary lymphoid organs leading to the induction of the

adaptive immune system. Activation of Th17 cells leads to the secretion of IL-17, which plays
a crucial role in neutrophil recruitment. Overall, P. aeruginosa leads to a robust proinflammatory immune response during acute pneumonia. This figure was created with
BioRender.com
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5.2 Vaccine-mediated immune responses
To prevent the disease burden caused by P. aeruginosa, we need to develop both
therapeutic and preventative solutions. A vaccine against this pathogen is the primary
prophylactic option to prevent infections caused by P. aeruginosa. Understanding the
elicited immune responses required for protection against P. aeruginosa can help us to
develop an effective human vaccine against this pathogen. With that purpose, we
characterized the vaccine-mediated immune responses both in whole-cell and subunit P.
aeruginosa vaccines in chapters 3 and 4, respectively.
Mucosal surfaces are one of the initial sites of entry for P. aeruginosa. We hypothesized
that mucosal immunity against this pathogen could potentially be beneficial to prevent
infection and bacterial colonization. Therefore, we performed intranasal immunization
with whole-cell and subunit P. aeruginosa vaccines. We observed that FpvA-KLH
vaccinated mice can elicit IgA antibodies against unconjugated FpvA peptides in lung
supernatants (Figure 26). Similarly, WCV mice had IgA antibody titers against the whole
bacteria in lung supernatants (Figure 14C). However, to understand the exact role IgA
has on protection from this bacterium, additional studies are required using IgA knockout
mice in murine vaccination/challenge model. In our studies, the elicited IgA response
significantly correlated to decreased bacterial burden in WCV mice (Figure 14F, I).
However, we did not observe this correlation in FpvA-KLH vaccinated mice, which may
suggest that the role of elicited IgA response may differ in whole-cell and subunit
vaccines.
Tissue-resident memory T cells have been shown to play an important role in defense
against other Gram-negative bacteria354,355. We have shown the recruitment of CD4+
tissue-resident memory T cells to the lung in response to intranasal FpvA-KLH
vaccination (Figure 27). Our study has been the first study to report that tissue-resident
memory cells may play a potentially important role in protection against P. aeruginosa.
Tissue-resident memory T cells reside in the lungs, and they share many markers with
other types of cells. Therefore, depletion of these cells has many caveats. Fingolimod
(FTY720) immunosuppressive drug was used to study the protective role of CD4+ tissue119

resident T cells354. However, FTY720 blocks both circulating B and T cells356. Therefore,
it may not be ideal for studying the role of CD4+ tissue-resident memory T cells,
specifically. Therefore, performing adoptive transfer of P. aeruginosa specific CD4+
tissue-resident memory T cells might be a better option to understand the role of these
cells in protection against P. aeruginosa.
In our studies, we showed that antibodies play a crucial role in vaccine-mediated
protection against this bacterium. In chapter 3, we observed that in the absence of B cells,
the WCV mediated bacterial clearance was abrogated (Figure 13). In addition, passive
immunization with WCV sera alone was protective against this bacterium (Figure 16). In
line with our study, passive immunization with vaccinated mice sera or monoclonal
antibody therapies specific to virulence factors and outer-membrane proteins were
protective against P. aeruginosa121,143,149,196,277–282. Especially, opsonic antibodies against
this bacterium is crucial for effective P. aeruginosa vaccine20. We observed that both
WCV and FpvA-KLH subunit P. aeruginosa vaccines could generate opsonic antibodies
against this bacterium. However, the antibodies elicited by WCV mediated better
phagocytic killing (Figure 21E). The opsonic antibodies generated by whole-cell P.
aeruginosa

vaccine

were

previously

shown

to

be

directed

partly

against

lipopolysaccharide (LPS)123 The antibodies elicited to highly repetitive structures, such as
LPS can be developed independently of T cells357. We observed that CD4+ T cells were
not required for bacterial clearance induced by WCV during challenge with an LPS
homologous strain, which suggests that P. aeruginosa-specific T-cell independent
antibodies elicited by WCV alone can be protective against this bacterium. The bacterial
structures recognized by these T-cell independent antibodies needs to be further
determined in future studies. While we observed that T-cell independent antibodies might
be sufficient to protect WCV, this might not be the case in the FpvA-KLH P. aeruginosa
subunit vaccine. The FpvA-KLH vaccine does not include any repetitive structures, such
as LPS or flagella. We observed that FpvA-KLH vaccination leads to an FpvA peptide
and protein specific antibody response in mice (Figure 21). , Generally, antibody
responses to protein antigens need additional help from antigen-specific T cells358.
Therefore, we hypothesize that CD4+ T cells may play an essential role in the FpvA-KLH
vaccine. In previous studies, it was reported that in the absence of opsonic antibodies to
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the challenge strain, CD4+ T cells play a primary role in live-attenuated P. aeruginosa
vaccines129,135. , Therefore, the role of CD4+ T cells needs to be further determined for
both subunit and WCV vaccine. Overall, the proposed model of vaccine mediated immune
responses required for protection against P. aeruginosa is shown in Figure 29.

Figure 29: Summary of the proposed model of vaccine-mediated protection
against P. aeruginosa
(A) After intranasal vaccination against P. aeruginosa, antigen-specific antibodies and T cells
are generated in the secondary lymphoid organs, such as the spleen. The elicited response
also includes memory B cells and plasma cells. (B) The antigen-specific T cells, B cells, and
antibodies that are transported via the blood to the mucosal surfaces. (C) In lung alveoli, we
expect to observe antigen-specific antibody responses and tissue-resident memory T cells
upon vaccination. This figure was created with BioRender.com.
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5.3 Developing a subunit vaccine against P. aeruginosa
Vaccine development against P. aeruginosa has been the interest of many researchers
for more than 50 years. However, as of 2020, there is still no P. aeruginosa vaccine
approved for human use. One of the primary long-term goals of this work was to develop
a vaccine against P. aeruginosa. Therefore, we developed a novel peptide-based subunit
vaccine against this pathogen.

5.3.1 Iron acquisition outer-membrane proteins as vaccine candidates
In preclinical efficacy studies, outer membrane proteins (OMPs) of P. aeruginosa have
shown promising results121,164,165,199. During acute pneumonia, genes encoding OMPs
associated with the acquisition of iron are significantly upregulated88. Among these
genes, the expression of the fpvA gene encoding ferripyoverdine receptor (FpvA) was
increased 7.4-fold during acute pneumonia88. FpvA is the iron acquisition receptor that
binds to the siderophore pyoverdine111. We hypothesized that FpvA could be a potential
vaccine antigen to generate a subunit P. aeruginosa vaccine. In Chapter 4, we
demonstrated that a subunit vaccine based on FpvA outer-membrane receptor could
protect mice against P. aeruginosa.
In this work, we used FpvA as an antigen to test our peptide-based vaccine platform and
hypothesis that iron-acquisition receptors can be potential vaccine antigens. However,
other iron-acquisition outer membrane protein-encoding genes are also differentially
upregulated in P. aeruginosa during acute pneumonia88. These include genes encoding
HasR and PhuR receptors that are important heme uptake mechanisms of P.
aeruginosa113. Targeting outer-membrane proteins that play a role in heme acquisition
were shown to be protective in other pathogens, such as Heamophilus ducreyi and
Eschericia coli (UPEC)304,359.
In future studies, investigation of Pseudomonas aeruginosa subunit vaccine targeting
multiple iron acquisition receptors may be beneficial due to potential increases in vaccine
efficacy and decreases in the development of vaccine-escape strains.
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5.3.2 Peptide-based vaccines
Peptide-based vaccines have been developed against both bacterial and viral
pathogens360–364. It was also used as a vaccine strategy against P. aeruginosa363,364. By
using peptide-based vaccines, we can specifically target immunodominant B and T-cell
epitopes to induce desirable immune responses and reduce the risk of unintentional
cross-reactivity and reactogenicity334,365. Also, problems associated with protein
purification and potential LPS contamination can be avoided. Therefore, it is potentially
favorable to use in industrial applications. In Chapter 4, we developed a peptide-based
vaccine based on the iron acquisition receptor, FpvA (Figure 19), and tested this vaccine
in the murine vaccination/challenge model.
One of the caveats of using a peptide-based vaccination approach is the immunogenicity
of the peptides334,336. In our study, the generated FpvA-based synthetic peptides were
poorly immunogenic (Figure 20C). To increase the immunogenicity of the peptides, we
used Keyhole Limpet Hemocyanin (KLH) as our carrier protein. We observed that FpvA
peptides conjugated to KLH were immunogenic (Figure 20D). FpvA-KLH peptide-based
conjugate vaccine decreased the bacterial burden and lung edema compared to adjuvantonly control (Figure 22). While we used KLH as a carrier protein in this study, it is not
approved for human use. Currently, there are only a few FDA approved carrier protein
strategies. Using clinically safe and potent carrier proteins can be a potential future
approach for the development of a peptide-based conjugate vaccine against this
pathogen. One of these potential carrier proteins includes detoxified diphtheria toxin
(CRM197). CRM197 is a non-toxic variant of diphtheria toxin, which has a point mutation
that eliminates toxicity and enzymatic activity of the toxin 366. We observed that FpvA
peptides conjugated to CRM197 carrier protein could elicit higher antibody titers against
FpvA peptides compared to those conjugated to KLH (data not shown). To optimize the
FpvA peptide-based conjugate vaccine, it may be beneficial for future studies to
investigate the vaccine efficacy of FpvA peptides conjugated to various FDA approved
carrier proteins, such as CRM197.
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Another approach to increase the immunogenicity of the peptide-based vaccines can be
to use potent adjuvants. In our studies, we have used curdlan as an adjuvant to
supplement our FpvA peptide-based P. aeruginosa subunit vaccine. Curdlan is a βglucan that has been shown to induce Th1/Th17 immune responses263. In our study, we
observed that curdlan adjuvanted FpvA peptide-based conjugate vaccine-elicited Th17
immune response and antigen-specific IL-17 response (Figure 25C-D). Despite its
advantages, curdlan is not a licensed adjuvant for human use. The potential efficacy and
the elicited immune response of the FpvA peptide-based P. aeruginosa subunit vaccine
with a combination of FDA approved adjuvants, such as alum, CpG, AS04, and MF59
needs to be further examined in future studies.
One of the major challenges of the peptide-based vaccines is the structural conformation
of the designed peptides. The usage of adjuvants and carrier proteins can affect peptide
conformation, which in turn, may affect the elicited antibody responses365,367. Antibodies
can target both linear epitopes and conformational epitopes368. Linear epitopes are
conformation-independent, making them prime candidates for vaccine design365. In our
study, we observed that the antibodies elicited upon vaccination with FpvA-KLH were
able to recognize FpvA peptides, FpvA protein, as well as the whole bacteria (Figure 21).
However, we do not know whether the elicited antibodies are conformation-dependent or
independent. To further optimize the vaccine formulation, the peptide epitope
conformations, and their role in elicited immune response needs to be determined.
Peptide-based vaccines are a good alternative to conventional vaccines regarding the
limitation of side effects and the ease of production of vaccines against pathogens. The
peptide-based FpvA-KLH subunit vaccine developed in this work can be a potential
pioneer of a protective vaccine against P. aeruginosa. However, the developed FpvAKLH subunit vaccine is currently not ready for clinical trials and needs to be further
optimized. This work can be accomplished by 1) optimizing the used adjuvants and carrier
proteins suitable for human use 2) targeting multiple iron acquisition receptors 3) testing
in different murine models, including a CF model.
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5.3.3 Limitations of the mouse model
We performed the vaccination and challenge experiments described in chapters 3 and 4
using outbred CD1 mice to mimic what we could observe in the human population with
genetic variability. However, we used only female mice in our studies. Females generate
stronger immune responses against vaccination369. The observed results in chapters 3
and 4 may not be applicable or differ in male mice models. In future studies, the addition
of male mice to conducted studies could eliminate this concern. Also, the vaccination
studies were performed in 6-weeks old mice. The efficacy of the performed vaccines in
aged and newborn mice needs to be further determined.
In our studies, we used acute pneumonia as a model of infection. This model and the
infection dose we used lead to severe infection in mice leading to high morbidity and
mortality within 24 hours. To prevent potential distress in mice, we determined 14-16
hours post-infection as the endpoint of our mouse studies. Therefore, we could only
examine vaccine protection based on the number of bacteria present in the nares and
lung. Using other models of infection such as chronic P. aeruginosa infection model using
agar beads can help us to further define the vaccine efficacy and protection. In addition,
performing infection/vaccination studies with a transgenic β-ENaC mouse model that
overexpress Na+ channels and create a CF-like phenotype can be beneficial in future
studies.
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5.3.4 Conclusions and outlook for future vaccine development against
P. aeruginosa
Overall, the work performed in this dissertation elucidated the host immune responses
elicited against P. aeruginosa during vaccination and infection. The results obtained in
this dissertation will help to develop novel therapeutic targets and vaccines against P.
aeruginosa.
The primary findings of this work were:
•

Infection with P. aeruginosa leads to the expression of immediate early response
genes and injectosomes of P. aeruginosa affects the differential expression of
these genes in epithelial cells

•

Acute pneumonia caused by P. aeruginosa leads to lung edema, significant
increase in proinflammatory cytokines, and recruitment of neutrophils to the lung.

•

The whole-cell P. aeruginosa vaccine protects P. aeruginosa primarily due to
elicited B cell and antigen-specific antibody response.

•

The peptide-based subunit vaccination approach using extracellular portions of
FpvA can be a potential strategy for the P. aeruginosa vaccine.

This work was the first step to establish the feasibility of a peptide-based subunit vaccine
that uses iron-acquisition receptors as antigens against P. aeruginosa. In future studies,
this vaccine needs to be further optimized for potential use in clinical trials. To achieve
this goal, a future vaccine against this bacterium needs to include multiple vaccine
antigens, clinically approved adjuvants/carrier proteins, and elicit a strong antibody
response.
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Figure S1: Serum antibodies from the FpvA-KLH vaccinated and challenged mice
against individual FpvA peptides.
IgG antibody titers against individual peptides from sera of mice vaccinated with FpvA-KLH (n =
9). (Peptide 2, p = 0.0039). The comparisons were made to the hypothetical value of 1 (no
detectable response), using the Wilcoxon signed ranked test. The asterisks refer to the level of
significance of each group compared to 1: **p ≤ 0.01.
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Figure S2: Total body weight at 16 hours post-challenge.
Total body weight of NVC (n = 8), WCV (n = 10), and FpvA-KLH (n = 8) vaccinated and challenged
mice. The NVNC (n = 10) group was used as a control. Each circle represents data from one
mouse. Data represent two independent experiments. Error bars are mean ± SEM values.
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Figure S3: Total white blood cells and frequency of myeloid cell populations in
blood at 16 hours post-challenge.
Total white blood cells (A), proportion of neutrophils (B), monocytes (C), and eosinophils (D) in
NVNC (n = 6), NVC (n = 8), and FpvA-KLH (n = 9) vaccinated mice. Group comparisons were
analyzed by ANOVA followed by a Tukey’s multiple-comparison test. The asterisks refer to the
level of significance: *p ≤ 0.05; **p ≤ 0.01. Error bars are mean ± SEM values.
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Figure S4: Frequency of myeloid cell populations in lung 16 h post-challenge.
The proportion of eosinophils (A), alveolar macrophages (B), CD11b+ dendritic cells (C), and
interstitial macrophages (D) in NVNC (n = 5), NVC (n = 6) and FpvA-KLH (n=4) vaccinated mice.
Group comparisons were analyzed by ANOVA followed by a Tukey’s multiple-comparison test.
The asterisks refer to the level of significance: *p ≤ 0.05; **p ≤ 0.01; ****p ≤ 0.0001. Error bars are
mean ± SEM values.
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IFN-γ ELISPOT

Figure S5: Antigen-specific IFN-γ response upon FpvA-KLH vaccination.
ELISpot assay to identify IFN-γ specific response of intranasal curdlan only and FpvA-KLH
vaccination with curdlan in the presence or absence of heat-killed P. aeruginosa at day 34 postvaccination (n = 5 in each group). Splenocytes were incubated with heat-killed whole-cell 2x107
CFU/well P. aeruginosa or complete RPMI 1640 media without stimulant for 72 hours. PMA was
used as a positive stimulant control. Group comparisons were analyzed by ANOVA followed by a
Tukey’s multiple-comparison test.
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Table S1: Differentially expressed genes in epithelial cells after one-hour infection
with P. aeruginosa.
Fold changes after one-hour infection with P. aeruginosa PA14 in A549 cells compared
to mock-treated cells.

RNU6-925P
CXCL2
HAS2
CD274
SLAMF7
RP1-130L23.1
GDF15
RNVU1-6
RP1-179P9.3
AC005363.11
RRAGD
PID1
MYPN
AP001505.10
IGF2
IER2
SNORA7B
KCNG1
U1_11
MAFF
CXCL8
TRIB1
DUSP5
FOSL1
PLPP3
PTGS2
NFKBIZ
PHLDA1
AC011933.2
TMEM251
HSD17B14
CTB-33G10.6
SERTAD1
AADACP1
NID2
RP11-134E15.2

Gene symbol Fold change
U1_8
RNU6-1161P
RNU11_1
SNORA57_4
RNU11_2
EGR1
FOS
RNVU1-18
RP11-255A11.4
CTC-250I14.3
FOSB
TET3
RNVU1-15
SCG2
LINC00910
SLC6A15
NR4A2
HAS2-AS1
RP11-411G2.1
CCL20
CRABP2
RP11-465B22.3
ATF3
IL6
RNU4-1
RP11-505D17.1
NR4A1
RN7SKP255
PPP1R15A
DGUOK-AS1
KLF6
CXCL3
APOE
RN7SKP203
PRDM1

83.98
65.67
49.29
35.99
35.57
28.41
17.47
14.23
9.95
7.8
7.39
7.17
6.88
6.17
5.53
4.59
4.39
4.39
4.19
4.15
4.1
3.53
3.51
3.5
3.5
3.43
3.38
3.38
3.32
3.27
3.22
3.2
3.18
3.11
3.1

161

3.05
3.01
3.01
2.98
2.97
2.96
2.92
2.92
2.84
2.8
2.8
2.79
2.76
2.74
2.7
2.68
2.65
2.6
2.58
2.57
2.57
2.52
2.5
2.47
2.47
2.46
2.46
2.44
2.42
2.42
2.41
2.37
2.37
2.36
2.35
2.35

UCN2
DUSP6
ZFP36
RP1-228H13.5
EREG
HIST1H4K
GEM
NPIPB3
IER3
NR0B1
NR4A3
BDNF
EMP1
CYP1B1
RP11-295G20.2
RP11-507K12.1
FAM155B
F2RL1
P2RY11
RNU4-2
KLF4
CITED2
PHLDA2
PTHLH
KCNF1
RP11-392P7.6
IL18R1
LDLR
UPP1
SPARC
NXF1
SYT1
FASN
MDK
HIST1H1D
TAGLN

2.35
2.32
2.32
2.32
2.3
2.3
2.29
2.28
2.26
2.25
2.24
2.21
2.21
2.19
2.19
2.19
2.17
2.16
2.16
2.16
2.15
2.14
2.14
2.14
2.13
2.11
2.1
2.07
2.07
2.06
2.05
2.05
2.04
2.02
-2.02
-2.04

ZNF185
HMGB1P1
SNORD3C
CYP4F11
THAP5
ANXA13
HERPUD1
CRIP1
EEF1A1P11
HIST1H2AB
SLC16A3
UGT1A9
BAAT
RP11-864I4.1
RP4-616B8.4
SNORD3D_1
RP11-442H21.2
IGFBP3
PDGFB
VCAN
ANXA8
RP11-203J24.9
SNORA24_2
FICD
CRELD2
TM4SF4
ASS1
FRMD3
AP000439.3
RN7SL338P
RP11-499O7.7
TC2N
SNORD116-9
FAM25C
RNU6-367P
RNU5D-1
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-2.04
-2.05
-2.05
-2.07
-2.1
-2.13
-2.14
-2.16
-2.17
-2.17
-2.17
-2.2
-2.21
-2.22
-2.24
-2.25
-2.26
-2.27
-2.27
-2.3
-2.32
-2.32
-2.32
-2.34
-2.35
-2.41
-2.48
-2.65
-2.71
-2.76
-3.24
-3.32
-4.09
-4.36
-35.08
-51.17

Table S2: Biological GO Terms significantly enriched in epithelial cells after onehour infection with P. aeruginosa.
Non-redundant biological GO terms in A549 cells upon P. aeruginosa infection
compared to non-infected mock control cells.
GO-term

Description

Associated genes

GO:0033993

Response to lipid

GO:0010243

GO:0048870

Response to
organonitrogen
compound
Cell motility

GO:0034097

Response to cytokine

GO:0009991

Response to
extracellular stimulus

GO:0051384

Response to
glucocorticoid
Regulation of cell
motility

ASS1, CD274, CXCL2, CXCL3, CXCL8, FOS, FOSB,
FOSL1, IL6, KLF4, LDLR, MDK, NR0B1, NR4A1, NR4A2,
NR4A3, PID1, PTGS2, SPARC, TRIB1, ZFP36
APOE, ASS1, EGR1, EREG, FOS, FOSB FOSL1, GDF15,
HERPUD1, IGF2, IL6, KLF4, LDLR, NR4A1, NR4A2,
NR4A3, P2RY11, PID1, PTGS2, RRAGD, SPARC
APOE, CCL20, CD274, CITED2, CXCL2, CXCL3, CXCL8,
CYP1B1, EREG, F2RL1, HAS2, IER2, IGFBP3, IL6, KLF4,
MDK, NR4A1, NR4A2, NR4A3, PDGFB, PLPP3, PTGS2,
SCG2, SLC16A3, SPARC
APOE, CCL20, CD274, CITED2, CXCL2, CXCL3, CXCL8,
CYP1B1, EREG, F2RL1, HAS2, IER2, IGFBP3, IL6, KLF4,
MDK, NR4A1, NR4A2, NR4A3, PDGFB, PLPP3, PTGS2,
SCG2, SLC16A3, SPARC, TRIB1
ASS1, CCL20, CD274, CXCL2, CXCL3, CXCL8, EGR1,
EREG, F2RL1, FASN, FOS, FOSL1, HAS2, IL18R1, IL6,
KLF4, KLF6, PDGFB, PID1, PTGS2, SPARC, ZFP36
APOE, ASS1, ATF3, FOS, FOSL1, GDF15, LDLR, NR4A2,
P2RY11, PTGS2, RRAGD, SPARC, UCN2, UPP1, ZFP36
APOE, CCL20, CD274, CITED2, CXCL8, CYP1B1, EREG,
F2RL1, HAS2, IGFBP3, IL6, KLF4, NR4A3, PDGFB,
PLPP3, PTGS2, SPARC, TRIB1
EREG, IGFBP3, IL6, KLF4, NR4A3, PDGFB, PTGS2,
TRIB1

GO:2000145

GO:0048660

GO:0032496
GO:0001568

GO:0071498
GO:0045893

GO:0048585

Regulation of smooth
muscle cell
proliferation
Response to
lipopolysaccharide
Blood vessel
development
Cellular response to
fluid shear stress
Positive regulation of
transcription, DNAtemplated
Negative regulation of
response to stimulus

ASS1, CD274, CXCL2, CXCL3, CXCL8, FOS, IL6, PTGS2,
SPARC, TRIB1
APOE, CXCL8, CYP1B1, EGR1, EREG, FOSL1, HAS2,
IL6, KLF4, NR4A1, PDGFB, PRDM1, PTGS2, SCG2,
SPARC
ASS1, HAS2, KLF4, PTGS2
APOE, ATF3, CITED2, EGR1, F2RL1, FOS, FOSB,
FOSL1, HIST1H1D, IER2, IGF2, IL6, KLF4, KLF6, MAFF,
MDK, NR4A1, NR4A2, NR4A3, PDGFB, PID1, SERTAD1
APOE, ATF3, CXCL8, DUSP5, DUSP6, EGR1, F2RL1,
GDF15, HERPUD1, IGFBP3, IL6, KLF4, LDLR, NR0B1,
NR4A2, NR4A3, PDGFB, PID1, PPP1R15A, PTGS2,
SCG2, TRIB1
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Table S3: KEGG pathways significantly enriched in epithelial cells after one-hour
infection with P. aeruginosa.
KEGG pathways in A549 cells upon P. aeruginosa infection compared to non-infected
mock-control cells.
Pathway

Description

Associated Genes

hsa04657

IL-17 signaling pathway

hsa04668

TNF signaling pathway

CXCL2, CXCL3, CCL20, CXCL8, PTGS2, IL6,
FOS, FOSB, FOSL1
CXCL2, CXCL3, CCL20, PTGS2, IL6, FOS

hsa05167

Kaposi's sarcoma-associated
herpesvirus infection

CXCL2, CXCL3, CXCL8, PTGS2, IL6, PGDFB,
FOS, ZFP36

hsa05132

Salmonella infection

CXCL2, CXCL3, CXCL8, IL6, FOS

hsa04010

MAPK signaling pathway

hsa05202

Transcriptional misregulation in
cancer

EREG, PDGFB, IGF2, BDNF, NR4A1, FOS,
DUSP5, DUSP6,
CXCL8, IL6, IGFBP3, NFKBIZ, DUSP6, NR4A3

hsa05134

Legionellosis

CXCL3, CXCL2, CXCL8, IL6

hsa05166

HTLV-I infection

ZFP36, FOSL1, ATF3, FOS, EGR1, IL6, PDGFB

hsa04060

Cytokine-cytokine receptor interaction

hsa05323

Rheumatoid arthritis

CXCL2, CXCL3, CCL20, CXCL8, IL6, PDGFB,
IL18R1
CCL20, CXCL8, IL6, FOS

hsa04913

Ovarian steroidogenesis

PTGS2, LDLR, CYP1B1
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Table S4: Immediate early response gene dataset
Gene symbol

Official full name

Function

References

IL6

Interleukin-6

Cytokine/Chemokine

226

TRIB1

Tribbles pseudokinase 1

Enzyme

370

DUSP5

Dual specificity phosphatase 5

Enzyme

226

PTGS2

Prostaglandin-endoperoxide synthase 2

Enzyme

371

DUSP6

Dual specificity phosphatase 6

Enzyme

226

GDF15

Growth differentiation factor 15

Cytokine/Chemokine

372

EREG

Epiregulin

Growth Factor

373

NR4A2

Nuclear receptor subfamily 4 group A member 2

Transcription factor

226

NR4A1

Nuclear receptor subfamily 4 group A member 1

Transcription factor

226

NR4A3

Nuclear receptor subfamily 4 group A member 3

Transcription factor

226

LDLR

Low density lipoprotein receptor

Protein binding

226

PHLDA1

Pleckstrin homology-like domain family A member

Protein binding

374

1
ZFP36

ZFP36 ring finger protein

RNA binding protein

226

GEM

GTP binding protein overexpressed in skeletal

Protein binding

226

muscle
IER3

Immediate early response 3

Protein binding

226,370

BDNF

Brain derived neurotrophic factor

Growth factor

375

EGR1

Early growth response 1

Transcription factor

226,370

FOS

Fos proto-oncogene, AP-1 transcription factor

Transcription factor

226,370

Transcription factor

226,370

subunit
FOSB

FosB proto-oncogene, AP-1 transcription factor
subunit

ATF3

Activating transcription factor 3

Transcription factor

226

KLF6

Kruppel like factor 6

Transcription factor

376

IER2

Immediate early response 2

Transcription factor

370

MAFF

MAF bZIP transcription factor F

Transcription factor

372

FOSL1

FOS like 1, AP-1 transcription factor subunit

Transcription factor

377

KLF4

Kruppel like factor 4

Transcription factor

376

HES1

Hes family bHLH transcription factor 1

Transcription factor

372

KLF2

Kruppel like factor 2

Transcription factor

376

RHOB

Ras homolog family member B

Protein binding

378
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Table S5: Differentially expressed genes in epithelial cells after one-hour
incubation with heat-killed P. aeruginosa
Fold changes in A549 cells incubated for one-hour with heat-killed P. aeruginosa
compared to non-infected mock control cells.

Gene symbol

Fold change

EGR1
FOS
IL6
NR4A1
IER2
KLF6
MIR4737
RP5-882O7.1
RNU6-9
U1_8
RNU6ATAC
HMGN2P6
SUMO2P6
RNVU1-7
RP11-627K11.6
SDS
HAS2-AS1
CTD-2651B20.6
CXCL3
RNVU1-18
ANXA10
FBXO2
CXCL2
HIST1H3A
TAB3-AS2
RP11-301O19.1
RP11-347E10.1
AC011933.2
HAS2
CCL20
CLCF1
REPIN1
AC002116.7
TFF1
RP3-423B22.5

9.08
7.23
3.15
2.36
2.05
2.05
57.02
49.63
43.47
41.99
34.53
9.19
8.62
7.74
6.17
5.22
3.84
3.56
3.49
3.36
3.34
3.14
3.12
3.06
2.98
2.83
2.8
2.79
2.72
2.64
2.54
2.54
2.49
2.49
2.41

PRDM1
ZNF281
GINS4
RP11-497H16.9
CXCL8
ANPEP
CXCL1
TYMSOS
NID2
UBE2C
FAM72C
PCBP1
CRABP2
SMIM6
RP11-542C16.2
PHLDA2
SDSL
NFKBIZ
BSCL2
TPPP3
AHNAK
NMRAL2P
AGAP9
CBWD4P
RP11-499O7.7
TC2N
RSRP1
ZFAS1
NPIPA3
SDHAP3
DST
LYSMD3
RP11-420A23.1
RP11-545J16.1
EIF4A2
NSUN5P1
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2.38
2.33
2.32
2.28
2.26
2.21
2.2
2.19
2.17
2.16
2.12
2.12
2.11
2.11
2.09
2.06
2.04
2.03
2.02
2.02
-2.03
-2.04
-2.05
-2.05
-2.05
-2.05
-2.07
-2.07
-2.08
-2.08
-2.1
-2.12
-2.14
-2.16
-2.17
-2.17

COL4A4
IL18BP
GOLGA8A
CTD-2020K17.1
MAT2A
RNU6-925P
RP11-213G2.3
HERC2P2
RNF103-CHMP3
SPX
CCDC18-AS1
SCARNA13
LENG8
GOLGA8B
CEACAM6
HKDC1
AHSA2
C2orf82
FICD
GABRE
RP11-162P23.2
SMOC1
SYNE1
AL162759.1
ALDH1L2
C6orf48
AC005336.4
RP4-555D20.1
LTB4R
CCDC84
ANKRD1
TBC1D3L

-2.18
-2.18
-2.19
-2.2
-2.22
-2.23
-2.25
-2.26
-2.26
-2.27
-2.3
-2.31
-2.32
-2.33
-2.34
-2.34
-2.37
-2.38
-2.38
-2.4
-2.4
-2.4
-2.4
-2.43
-2.43
-2.45
-2.48
-2.48
-2.49
-2.51
-2.55
-2.55

GAS5
RBAK
HNRNPUL2-BSCL2
RP11-448A19.1
SLN
RP11-241F15.1
HERPUD1
RP11-77H9.2
RP11-274B21.14
DNAJB9
AC003006.7
RP4-555D20.2
SLITRK6
COL4A3
MALAT1_1
PUS3
MIR34AHG
CTD-2587H19.3
BEX2
SENP3-EIF4A1
NEAT1
FAM129A
RP11-498C9.4
DDIT3
RN7SL338P
CTC-573N18.1
DLEU2_6_3
RP11-241F15.10
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-2.58
-2.6
-2.62
-2.62
-2.64
-2.7
-2.71
-2.74
-2.77
-2.82
-2.84
-2.84
-2.89
-3.01
-3.16
-3.18
-3.27
-3.31
-3.52
-3.54
-3.56
-4
-4.41
-4.57
-4.83
-5.73
-7.25
-7.27

Table S6: Differentially expressed genes in epithelial cells after one-hour infection
with P. aeruginosa PA14: pscC transposon mutant.
Fold changes after one-hour infection with PA14: pscC transposon mutant in A549 cells
compared to non-infected mock-control cells.

Gene
symbol
EGR1
FOS
FOSB
FOSL1
NR4A2
BDNF
ATF3
GDF15
DUSP5
PHLDA1
TRIB1
KLF4
KLF6
NR4A1
ZFP36
MAFF
EREG
IER2
DUSP6
RP5882O7.1
RNU6703P
U1_8
CYCSP55
HDGFP1
SCG2
RNVU1-18
RP11349N19.2
RP11175B9.3
AC073046.
25
DGUOKAS1
SNORA7B
SLC6A15
CRABP2
F2RL2
HAS2-AS1

Fold
change
16.64
8.93
5.19
3.32
3.11
2.99
2.95
2.92
2.73
2.7
2.48
2.44
2.43
2.42
2.33
2.18
2.05
2.03
2.02
92.32
66.72
60.44
48.52
45.79
9.65
8.22
7.86
7.35
6.3
6.18
5.24
4.62
4.61
4.18
4.11

SNORA73
A
CBX3P9
RNVU1-15
RP3423B22.5
RP11465B22.3
C9orf43
RP11115J23.1
RP11109P14.9
PRDM1
RP1228H13.5
THNSL1
AC011933.
2
HSD17B14
RRAGD
HMGA2
FAM129A
SYT1
CCL20
KCNG1
MYPN
CXCL2
RP11392P7.6
APOE
RP11670E13.6
HOXA3
RP1164D22.5
IGF2
KCNF1
PPP1R15A
BCAT1
AADACP1
CHGB
BMPER
F2RL1

3.92
3.78
3.74
3.7
3.62
3.58
3.49
3.4
3.23
3.13
3.12
3.11
3.01
2.96
2.95
2.94
2.94
2.92
2.91
2.85
2.83
2.82
2.78
2.78
2.73
2.69
2.64
2.63
2.62
2.6
2.59
2.56
2.55
2.55
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RP1183J16.1
ANP32B
HAS2
RP11282O18.3
PHC1P1
AP000304.
12
RP1138L15.3
TMEM9BAS1
POMGNT2
GREM1
EMP1
NID1
TRIB3
AC108488.
4
KCNE4
PLPP3
URGCPMRPS24
MXD1
RP11134F2.8
CXCL16
SOX9
AKT1S1
OVCA2
SFRP1
RP4639F20.1
CLCF1
MCTP1
PRH1PRR4
CCDC97
NR0B1
PDF
CDCP1
PTHLH
RHBDD1

2.55
2.53
2.48
2.46
2.4
2.39
2.37
2.37
2.35
2.31
2.3
2.29
2.29
2.28
2.26
2.26
2.26
2.23
2.23
2.22
2.22
2.21
2.21
2.21
2.2
2.19
2.19
2.19
2.16
2.16
2.16
2.15
2.15
2.15

RNU1-1
LRFN3
RANGRF
NPTXR
PDCL3
TARDBP
TPP1
FAM127B
PHLDA2
MICALL1
NEFL
AP000275.
65
ATN1
BCL6
IL18R1
C2orf74
SURF2
CXCL8
PAPPA
SNRPF
RP11295G20.2
CXCL3
FAM155B
RP11632K20.2
BRCA2
CDKN2C
RP11158I13.2
CD24
CHMP1BAS1
TRAIP
ZNF724
MAP3K14
GGT3P
HIST1H2A
M
HIST1H4I
IDH2
TOP2A
KNSTRN
MOK
SMTN
C5orf34
EMP2
TBC1D2
MAD2L1
PYCRL
RP1110C24.1
PSRC1
RP11395B7.4

2.14
2.13
2.13
2.12
2.12
2.12
2.12
2.11
2.1
2.09
2.09
2.08
2.08
2.08
2.08
2.07
2.07
2.06
2.06
2.06
2.05
2.04
2.04
2.01
-2.01
-2.02
-2.02
-2.03
-2.03
-2.03
-2.03
-2.04
-2.05
-2.05
-2.05
-2.05
-2.05
-2.06
-2.06
-2.06
-2.08
-2.08
-2.09
-2.1
-2.1
-2.1
-2.12
-2.12

FRMD3
ATAD5
TPX2
BLM
BRIP1
HMGB1P5
LRRC45
HMGB1P1
KIF20B
STMN1

-2.13
-2.14
-2.14
-2.15
-2.15
-2.15
-2.15
-2.16
-2.16
-2.16

ZNF185
HIST2H2A
A4
PLCB3
C6orf99
CCNF
KIF15
RP11203J24.9
KIF14
SYNC
MYBL1
LINC01322
DEPDC1
KIAA1524
CDCA8
EVA1A
RP4555D20.2
ACOX3
COL4A1
GLDC
HIST1H2B
L
CENPF
HIST1H3J
SNORD3C
C6orf47AS1
NDC80
TAGLN
SPIN2B
BAAT
BUB1
RP11184M15.1
CDT1
ANLN
ANXA8L1
SAPCD2
NUSAP1
TTK
SULT1A4
C11orf86

-2.16
-2.17
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-2.17
-2.18
-2.18
-2.18
-2.19
-2.2
-2.2
-2.21
-2.22
-2.25
-2.25
-2.26
-2.26
-2.26
-2.27
-2.27
-2.28
-2.29
-2.3
-2.3
-2.31
-2.32
-2.32
-2.32
-2.33
-2.34
-2.34
-2.37
-2.4
-2.41
-2.41
-2.42
-2.43
-2.43
-2.44
-2.45

CTC246B18.10
ANGPTL4
PTTG1
IQGAP3
KNL1
HMMR
KIF2C
TUBB3
GTSE1
HIST1H2B
J
RP11499O7.7
SCARNA7
UGT1A9
TICRR
FAM111B
RHOQP2
TRIM59
SNORD3B1
HIST1H1D
NUF2
CTB58E17.3
RP11398C13.6
ANKRD2
RP11254F7.4
HIST1H2A
B
PDGFB
SHPK
CCNE2
PALMD
SLC16A3
CENPE
SPC24
NAMPTP1
ASPM
RHOQP3
ANXA8
SNORD3A
RP1198K11.5
SNORA24_
2
AL162759.
1
HIST1H2A
L
CTD2538C1.2
FAM25C

-2.46
-2.47
-2.47
-2.48
-2.48
-2.51
-2.52
-2.53
-2.54
-2.54
-2.54
-2.56
-2.57
-2.58
-2.59
-2.59
-2.6
-2.62
-2.63
-2.64
-2.65
-2.65
-2.66
-2.67
-2.71
-2.72
-2.73
-2.76
-2.77
-2.91
-2.93
-3.05
-3.06
-3.11
-3.14
-3.16
-3.26
-3.3
-3.46
-3.47
-3.48
-3.51
-3.6

RP11241F15.10
KCNJ16
TNFAIP6
TM4SF4
SNORD11
6-9

-3.65
-3.74
-3.77
-3.82
-4.03

RP5875H18.9
AP000439.
3
PDZK1
SLN
RP4616B8.4

-4.61
-4.66
-4.81
-5.17
-5.34
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RP11241F15.9
RNU6367P
RNU6863P

-8.33
-34.08
-43.2

Table S7: Differentially expressed genes in epithelial cells after one-hour infection
with P. aeruginosa PA14 ΔHSI-II: III transposon mutant.
Fold changes after one-hour infection with PA14 ΔHSI-II: III transposon mutant in A549
cells compared to non-infected mock control cells.
Gene symbol

Fold change

RNU11_1
SNORD105B
U1_8
SCARNA18_3
SNORD116-21
RP5-882O7.1
MIR3685
HDGFP1
FOS
RNU6-1161P
EGR1
RNVU1-15
RNVU1-18
FOSB
CTD-3014M21.1
RNU4-1
CH507-513H4.5
U1_11
NR4A2
RP11-707G18.1
CXCL2
RP1-241P17.4
CCL20
CTD-2124B8.2
SNORD3B-2
PPP1R15A
RP3-477M7.5
ATF3
CXCL8
RP11-399J13.2
CXCL3
NR4A1
SNORA7B
KLF2
NFKBIZ
RP1-89D4.1

72.55
58.55
57.08
55.53
37.38
37.27
37.01
36.62
36.46
34.88
31.27
13.53
13.02
6.86
6.53
5.78
5.47
4.73
4.03
4.01
3.99
3.91
3.86
3.83
3.76
3.53
3.45
3.34
3.24
3.22
3.17
3.16
2.96
2.94
2.91
2.82

IER2
PRDM1
CTB-33G10.6
KLF6
IL6
RNU4-2
EEF1E1-BLOC1S5
RP11-507K12.1
CYP1B1
SERTAD1
PCLAF
HES1
ZFP36
IRX5
CTC-326K19.6
CITED2
RP11-468E2.2
RP4-613B23.5
DUSP6
MAFF
PTGS2
ANPEP
RHOB
CTD-3035K23.6
CRABP2
RP11-479G22.8
SYNJ2BP
RNU2-63P
U1_9
TFF1
MRPL12
METTL18
RP11-163E9.2
SNORD3D_1
TAGLN
TMEM136
SLITRK6
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2.78
2.77
2.75
2.73
2.72
2.72
2.71
2.64
2.62
2.56
2.55
2.48
2.37
2.36
2.35
2.33
2.31
2.31
2.29
2.28
2.26
2.25
2.18
2.16
2.09
2.09
2.09
2.04
2.04
2.03
2.01
-2.03
-2.04
-2.04
-2.05
-2.05
-2.13

IL11
FICD
CTD-2066L21.3
RBAK
FAM129A
DNAJB9
RP11-539L10.3
MAT2A
BEX2
C2orf82
C6orf48

-2.15
-2.17
-2.19
-2.2
-2.23
-2.26
-2.28
-2.29
-2.3
-2.37
-2.37

ZSCAN32
MIR34AHG
RN7SL338P
PDGFB
HERPUD1
AC004449.6
GGT3P
CTC-573N18.1
DLEU2_6_3
RNU6-367P
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-2.45
-2.48
-2.48
-2.59
-2.76
-2.85
-3.03
-5.07
-6.79
-36.01

Table S8: The average of cytokines in lung supernatant at 16 hours post-challenge.
Cytokine

NVNC

NVC

FpvA-KLH

IFN-γ

1.3 ± 0.7

181.3 ± 160.7

639.6 ± 631.5

IL-10

3.5 ± 0.7

1289.8 ± 850.9

1071.7 ± 1078.8

IL-12

108.4 ± 8.8

4106.0 ± 1111.4

4932.1 ± 3452.8

TNF-α

18.3 ± 6.0

20931.1 ±

28751.6 ±

10359.3

21773.9

IL-1β

87.4 ± 27.8

18553.3 ± 6976

13220.0 ± 9423.3

KC

17.9 ± 3.6

132435.3 ±

52429.2 ±

80388.1

23586.7

421386.9 ±

332129.2 ± 96537

IL-6

67.3 ± 13.4

205115.9
IL-4

1.7 ± 0.5

13.5 ± 2.8

16.9 ± 6.4

IL-5

2.5 ± 0.2

49.1 ± 19.6

76.7 ± 54.1

IL-2

2.6 ± 0.4

118.6 ± 42.9

762.6 ± 735.1

IL-17

0.9 ± 0.6

797.8 ±770.1

645.9 ± 1087.7

Data in the table represent the mean cytokine response ± standard error of the mean.
Results are shown in pg/ml.
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